HK40050858A

HK40050858A - Methods for lowering blood sugar with a gliflozin sodium-glucose cotransporter 2 inhibitor pharmaceutical composition

Info

Publication number: HK40050858A
Application number: HK62021039485.9A
Authority: HK
Inventors: R·P·普莱伯尔斯基; J·菲罗尔
Original assignee: 阿斯利康(英国)有限公司
Priority date: 2018-06-14
Filing date: 2019-06-13
Publication date: 2021-12-31

Description

Method for lowering blood glucose using gliflozin Sodium (gliflozin Sodium) -glucose co-transporter 2 inhibitor pharmaceutical composition

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims priority from U.S. provisional patent application No. 62/685,202, filed on 14/6/2018, which is incorporated herein by reference in its entirety.

Technical Field

The present disclosure relates generally to methods for reducing blood glucose, e.g., thereby treating type 2 diabetes and/or maintaining sub-diabetic blood glucose levels, by administering an over-the-counter girlizin Sodium (gliflozin Sodium) -glucose co-transporter 2 inhibitor pharmaceutical composition to an individual in need thereof, wherein the individual is eligible for the composition in an over-the-counter manner.

Background

Worldwide, diabetes is a leading cause of death and increased healthcare costs. Non-infectious disease Risk Factor cooperative organization (NCD Risk factory corporation), Lancet (The Lancet), 387: 1513-. Since 1980, the number of diabetic patients worldwide has increased almost three-fold. As above. By 2015, according to CDC, about 12% of all adults in the united states have diabetes and about 35% of all adults in the united states have prediabetes. Disease Control and Prevention center (Centers for Disease Control and preservation), "National Diabetes Statistics Report 2017 in 2017" (2017). In addition, nearly half of diabetics have no control of their blood glucose. Polonsky et al, Patient preference and compliance (Patient preference, reference), 10:1299-1307 (2016). In addition, diabetes poses a significant economic challenge. In the american Diabetes Association (u.s. american Diabetes Association), Diabetes Care (Diabetes Care), 36(4), 1033-46(2013), the american Diabetes Association estimated $ 2450 million in 2012 to be used directly and indirectly for medical costs associated with diagnosed Diabetes.

Fortunately, diabetes can be managed by, for example, the use of gliflozin sodium-glucose co-transporter 2 inhibitors, which are well-established prescription drugs for lowering blood glucose, for example, thereby treating type 2 diabetes and/or maintaining sub-diabetic blood glucose levels. For example, the efficacy of dapagliflozin (dapagliflozin) to reduce blood glucose has been demonstrated in at least 14 double-blind, placebo-controlled, randomized studies, with dapagliflozin first approved in the united states for the treatment of diabetes in 2014. However, there are limitations to the prescription required to obtain the gelistine sodium-glucose co-transporter 2 inhibitor. Unfortunately, long-term trends indicate that many people avoid the use of prescription drugs, including the geisin sodium-glucose co-transporter 2 inhibitor.

One way to make the gliflozin sodium-glucose co-transporter 2 inhibitor more readily available is to make it available without prescription, such as over the counter ("OTC"). Converting a drug from prescription to OTC has a number of Health benefits, including, but not limited to, producing broader therapeutic effectiveness, providing more treatment methods, providing direct and rapid treatment pathways, enabling patients to play an active role in their own Health care and enabling patients to Self-prevent and alleviate minor symptoms or conditions (World Health Organization), Guidelines for Regulatory evaluation of drugs for Self-administered drugs (Guidelines for the Regulatory Assessment of medical Products for use in Self-care), 2000. In view of the large number of individuals with uncontrolled hyperglycemia, the provision of OTC gyricon sodium-glucose co-transporter 2 inhibitors may provide significant social health benefits.

However, converting the medical classification from prescription-only to OTC poses significant risks, and the patient population will not be able to properly self-select for safe use in medicine and subsequent autonomous administration in a responsible manner. Phenomena embodied in these problems include erroneous self-diagnosis, erroneous drug identification, unidentified drug-drug interactions (DDI), unintended adverse drug reactions and/or side effects, improper drug administration and/or dosing, masked illness, addiction, improper drug dependence, substance abuse, and patient's delayed pursuit of necessary medical care. Ruiz et al, Current Drug Safety, 5(4), 315 (2010).

Since the gegliflozin sodium-glucose co-transporter 2 inhibitor can cause side effects in some patients, the drug-receiving population should be carefully selected and monitored. To ensure the safety of the OTC classification of the geijing sodium-glucose co-transporter 2 inhibitor, potential patients must effectively self-select for the drug. However, recent studies have found that many potential patients do not continue to focus on guidelines printed on OTC drug packaging to ensure safe and responsible use. American society (PR New wire Association) who, According to New surveys, Should Pay More Attention to Over-the-counter (OTC) drug labeling (american cover paper move Attention to Over-the-counter (OTC) medicine labeling to New Survey) on day 10, 15 (2015) (quote research on macneil Consumer health care). According to these studies, 40% of potential patients view the instructions only as a guideline and 80% do not read their label again for the OTC agent that was previously used. More disturbingly, only 58% of the men examined find it important to focus on the limitations on the OTC label.

Currently, there are two regulatory approaches in the united states for the legitimate sale of OTC drugs. In the first approach, sales were made in accordance with OTC Drug monographs that set regulatory standards for over-the-counter drugs not covered by human Drug applications, such as New Drug Applications (NDA) or simplified New Drug applications (Abbrevised New Drug applications; ANDA). OTC monographs were generated as a result of a three-stage OTC drug audit by the FDA. In the first phase of the audit, an audit panel is consulted to determine whether the ingredients of the proposed OTC composition can be generally considered safe and effective for self-treatment. In the second approach, sales are made under the authority of an approved New Drug Application (NDA) or simplified new drug application (ANDA) for a particular product. To support over-the-counter labeling of drugs that are being sought regulatory approval by NDA, consumer research is required to evaluate the ability of consumers to select and not select themselves as appropriate drug users based on the proposed drug label. Oliver, A., (Regulatory Rapporteur), 10(3):4-9(2013), which is incorporated herein by reference.

However, attempts to convert the classification of drugs with potentially long-term benefits to social health from prescription-only to OTC-type have often failed, primarily due to improper patient selection and medication. The best documented situation may be associated with statins (statins) for the treatment of high cholesterol.

For example, Merck applied for sale of over-the-counter lovastatin (lovastatin) at least three times in 2000, 2005 and 2007, but all were rejected by the FDA. In 2005, an expert counseling group of the FDA rejected Merck's proposal for allowing sale of over-the-counter lovastatin in 2005. The panel focused on a market survey in support of this proposal, in which about one third of the 3316 consumers offered the drug over the counter decided that they would purchase the drug. After reviewing the data, the expert group concluded that: 45% of purchases are inappropriate for a variety of reasons, including the age of the individual, the lack of knowledge of the individual's contraindications for, and association with, their pathology. Dyer O., British journal of medicine (BMJ), 330(7484), 164 (2005). In 2007, the committee concluded again: not proven to be adequate for long term self-selection and adequate adherence by consumers without intervention of a doctor The ability to be treated. Division of Metabolic and Endocrine Drug Products, 2005, NDA 21-213 over-the-counter20mg Joint counseling Committee conference (NDA 21-213 Non-description)20mg Joint Advisory Committee Meeting)》。

Similarly, Pfizer announced in 2011 that it is intended to beFrom prescription only to OTC state. See OTC bulletin, 11/16/2011, page 7. However, when aiming to simulate 10mgWhen the phase 3 "actual use" trial of OTC use of atorvastatin calcium failed to reach its primary goal, it was no longer tried in 2014 because satisfactory results were not reached in terms of patients checking their low density lipoprotein cholesterol (LDL-C) levels following the instructions and taking appropriate action based on their test results after checking their LDL-C levels. Pfizer inc., Pfizer Reports Second Quarter Results-Quarter 2015Results in Pfizer Reports 2015, (2015).

In fact, from Bristol-Myers Squibb and Merck&Co respectively toAnd the first failure of lovastatin to OTC, in nearly two decades, no statins have ever been granted the OTC state in the united states. Nevertheless, according to current guidelines, nearly 1/6 adults eligible for cholesterol-lowering drugs are left untreated in the united states.

The information disclosed in this background section is only for enhancement of understanding of the general background of the invention and should not be taken as an acknowledgement or any form of suggestion that this information forms the prior art that is known to a person skilled in the art.

Disclosure of Invention

In view of the foregoing background, there is a need in the art for systems and methods for identifying human subjects to whom over-the-counter gliflozin sodium-glucose co-transporter 2 inhibitor pharmaceutical compositions may be delivered to lower blood pressure, e.g., to thereby treat type 2 diabetes and/or maintain sub-diabetic blood glucose levels.

The present disclosure addresses a need in the art for systems and methods configured for identifying human subjects to whom a geragliflozin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition (e.g., dapagliflozin) may be delivered over-the-counter to treat type 2 diabetes, for example, by lowering blood pressure. In the present disclosure, systems and methods are provided for delivering a gerlabel sodium-glucose co-transporter 2 inhibitor pharmaceutical composition to an individual in an over-the-counter manner. The survey results from the individual are run against a first plurality of filters. When a filter of the first plurality of filters is activated, it is deemed inappropriate to deliver a gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition to the individual. The survey results are also run against a second plurality of filters. Providing a corresponding alert to the individual when a respective filter of the second plurality of filters is activated. When none of the first plurality of filters is activated and the individual has confirmed each alert associated with each activated filter of the second plurality of filters, the method proceeds to fulfillment. Fulfilling the process storage composition order, communicating the drug fact label for the gerlabel sodium-glucose co-transporter 2 inhibitor pharmaceutical composition to the individual and authorizing the individual to be provided with the gerlabel 2 inhibitor pharmaceutical composition after the individual confirms that the label has been read.

Accordingly, one aspect of the present disclosure provides a method for identifying an individual suitable for over-the-counter delivery of a gelistine sodium-glucose co-transporter 2 inhibitor pharmaceutical composition in order to lower the blood glucose of the individual, e.g., thereby treating type 2 diabetes and/or maintaining sub-diabetic blood glucose levels. The method includes conducting a first survey of an individual to obtain a plurality of survey results. In some embodiments, the survey results indicate one or more of the following: whether the individual is pregnant, nursing, or scheduled to become pregnant; a type 1 diabetes status of the individual; ketoacidosis status of the subject; renal status of the subject; the age of the individual; the blood glucose level of the individual; whether an individual has liver problems; whether the individual has a history of urinary problems; the surgical status of the individual; the dietary status of the individual; whether an individual has had pancreatic problems; the alcohol consumption status of the individual; and whether the subject is using diabetes drugs.

The method also includes running all or a portion of the findings against a first plurality of filters of a first category. The filters in the first category correspond to contraindications. When a respective filter of the first plurality of filters is activated, it is deemed inappropriate to deliver a gerlabel sodium-glucose co-transporter 2 inhibitor pharmaceutical composition to an individual. The method is then terminated accordingly without delivering the gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition to the subject. In some embodiments, the first plurality of filters comprises one or more of: a first pregnancy filter, a type 1 diabetes filter, a ketoacidosis filter, a nephropathy filter, an age filter, and a blood glucose filter.

The method also includes running all or a portion of the findings against a second plurality of filters of a second category. The filters in the second category correspond to risk factors. Providing an alert to the individual corresponding to a respective filter of the second plurality of filters when the respective filter is activated. In some embodiments, the second plurality of filters comprises one or more of: liver disease filters, urinary problem filters, surgical filters, dietary filters, pancreatic disease, alcohol consumption filters, and diabetes drug filters. However, unlike the filters in the first plurality of filters, the filters in the second plurality of filters do not automatically terminate the process without delivering the geremin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition to the individual.

The method continues by obtaining confirmation from the individual of the alert issued to the individual by any of the second plurality of filters. In some embodiments, the confirmation of the individual is a written confirmation, a verbal confirmation, or an electronic confirmation, such as an electronic signature.

The method continues by: fulfillment processes occur when none of the first plurality of filters are activated and the individual has confirmed each alert associated with each activated filter of the second plurality of filters.

In some embodiments, the fulfillment process includes storing in the profile of the individual an indication of an initial order for a gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition, an over-the-counter drug label conveying the gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition, and authorizing provision of the gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition to the individual after confirming that the individual has received and read the over-the-counter drug label.

In some embodiments, the geriflozin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition has the following structure:

wherein the content of the first and second substances,

R¹、R²and R^2aIndependently hydrogen, OH, OR⁵Alkyl, CF₃、OCHF₂、OCF₃、SR⁵ⁱOr halogen, or R¹、R²And R^2aMay together form a cyclic five-, six-or seven-membered carbocyclic or heterocyclic ring which may contain from 1 to 4 heteroatoms in the ring, which heteroatoms are N, O, S, SO and/or SO₂；

R₃And R₄Independently hydrogen, OH, OR^5aO aryl, OCH₂Aryl, alkyl, cycloalkyl, CF₃、-OCHF₂、-OCF₃Halogen, -CN, -CO₂R^5b、-CO₂H、COR^6b、-CH(OH)R^6c、-CH(OR^5h)R^6d、-CONR⁶R^6a、-NHCOR^5c、-NHSO₂R^5d、-NHSO₂Aryl, -SR^5e、-SOR^5f、-SO₂R^5g、-SO₂Aryl or a five-, six-or seven-membered heterocyclic ring which may contain 1 to 4 heteroatoms in the ring, which heteroatoms are N, O, S, SO and/or SO ₂Or R is³And R⁴Together with the carbon to which they are attached form a cyclic five-, six-or seven-membered carbocyclic or heterocyclic ring which may contain from 1 to 4 heteroatoms in the ring, which heteroatoms are N, O, S, SO and/or SO₂；

R⁵、R^5a、R^5b、R^5c、R^5d、R^5e、R^5f、R^5g、R^5hAnd R⁵ⁱIndependently is an alkyl group;

R⁶、R^6a、R^6b、R^6cand R^6dIndependently is hydrogen, alkyl, aryl, alkylaryl or cycloalkyl, or R⁶And R^6aTogether with the nitrogen to which they are attached form a cyclic five-, six-or seven-membered heterocyclic ring which may contain from 1 to 4 heteroatoms in the ring, which heteroatoms are N, O, S, SO and/or SO₂；

A is O, S, NH or (CH)₂)_nWherein n is 0-3, or a pharmaceutically acceptable salt, stereoisomer, or prodrug ester thereof;

with the proviso that when A is (CH)₂)_nWherein n is 0, 1, 2 or 3 or A is O and R¹、R²And R^2aAt least one of which is OH OR OR⁵Then R¹、R²And R^2aIs CF₃、OCF₃Or OCHF₂And/or R³And R⁴Is CF₃、-OCHF₂、-OCF₃、-CN、-CO₂R^5b、CH(OR^5h)R^6d、CH(OH)R^6c、COR^6b、-NHCOR^5c、-NHSO₂R^5d、-NHSO₂Aryl, -SR^5e、-SOR^5f、-SO₂R^5gor-SO₂And (4) an aryl group.

In some embodiments, the gegliflozin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition comprises dapagliflozin or a pharmaceutically acceptable salt thereof. In some embodiments, the gegliflozin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition comprises dapagliflozin propylene glycol. In some embodiments, the gerlabel sodium-glucose co-transporter 2 inhibitor pharmaceutical composition comprises empagliflozin (empagliflozin), canagliflozin (canagliflozin), or eggliflozin (ertugliflozin).

In one aspect, the present disclosure provides methods for identifying an individual (e.g., an individual previously qualified to receive a supply of a gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition) for eligibility for a re-order of a gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition (e.g., optionally together with methods for identifying an individual's initial eligibility for a subscription of a gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition). The method includes a re-fulfillment routine. The re-fulfillment program includes conducting a second survey of the individual to obtain a second plurality of survey results. In some embodiments, the second survey result indicates one or more of: whether the individual is pregnant, nursing, or scheduled to become pregnant; whether the subject has developed ketoacidosis after receiving its last supply of the pharmaceutical composition of geilizin sodium-glucose co-transporter 2 inhibitor; whether an individual has a renal problem after receiving their last supply of a pharmaceutical composition of a geilizin sodium-glucose co-transporter 2 inhibitor; whether the individual has experienced symptoms of urinary problems after receiving its last supply of the pharmaceutical composition of the geilezine sodium-glucose co-transporter 2 inhibitor; whether an individual has a liver problem after receiving their last supply of a pharmaceutical composition of geletam sodium-glucose co-transporter 2 inhibitor; the surgical status of the individual; the dietary status of the individual; whether an individual has a pancreatic problem after receiving their last supply of a pharmaceutical composition of geletam sodium-glucose co-transporter 2 inhibitor; the alcohol consumption status of the individual; whether the individual has experienced a yeast infection after receiving its last supply of a pharmaceutical composition of geletam sodium-glucose co-transporter 2 inhibitor; whether an individual has developed symptoms of hypoglycemia after receiving its last supply of a pharmaceutical composition of the geilizin sodium-glucose co-transporter 2 inhibitor; whether the individual is experiencing physical stress; and whether the subject began to take diabetes medication after receiving their last supply of the pharmaceutical composition of geilizin sodium-glucose co-transporter 2 inhibitor.

The method also includes running all or a portion of the second plurality of findings against a third plurality of filters of the first category. The filters in the first category of filters correspond to contraindications. When a respective filter of the third plurality of filters is activated, the individual is deemed not eligible for a pharmaceutical composition of a geqizin sodium-glucose co-transporter 2 inhibitor. Thus, the restocking process is terminated without delivering the gerlabel sodium-glucose co-transporter 2 inhibitor pharmaceutical composition to the individual. In some embodiments, the third plurality of filters comprises one or more of: pregnancy filters, ketoacidosis filters, kidney problem filters, urinary problem filters, body pressure filters, and diabetes drug filters.

The method also includes running all or a portion of the second plurality of findings against a fourth plurality of filters of the second category. The filters in the second category of filters correspond to risk factors. Providing an alert to the individual corresponding to a respective filter of the fourth plurality of filters when the respective filter is activated. In some embodiments, the fourth plurality of filters comprises one or more of: liver disease filters, surgical filters, dietary filters, pancreatic disease filters, alcohol consumption filters, yeast infection filters, and hypoglycemia symptom filters.

The method continues by obtaining confirmation from the individual of the alert issued to the individual by any filter of the fourth plurality of filters. The method continues with the fulfillment process when the fulfillment process has not terminated by activation of a filter of the third plurality of filters and the individual has confirmed each alert associated with each activated filter of the fourth plurality of filters.

In some embodiments, the fulfillment process includes storing in the profile of the individual an indication to reorder a geilezin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition, communicating to the individual an over-the-counter drug fact label for the geilezin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition, and authorizing the individual for a reorder supply of the geilezin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition after confirming that the individual has received and read the over-the-counter drug fact label.

In some embodiments, when the individual profile of the individual does not include the current glycemic state of the individual, the method includes obtaining the glycemic state of the individual in the second plurality of findings and including the glycemic filter in the third plurality of filters of the first category.

In some embodiments, the method includes obtaining the glycemic state of the individual in a second plurality of findings and including a glycemic filter in a third plurality of filters of the first category.

In some embodiments, for example, when the geragliflozin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition comprises canagliflozin, the first plurality of findings further comprises one or more of: a history of heart failure in the subject; a history of resection of the subject; a history of leg neuropathy in the subject; a history of diabetic foot ulcers in the subject; and a history of hyperkalemia in the subject. Thus, the second plurality of filters comprises one or more filters corresponding to additional findings, e.g. selected from a heart failure filter, an ablation, a leg neuropathy filter, a diabetic foot ulcer filter (which is triggered at least when the first plurality of findings indicate an individual), and a hyperkalemia filter.

In some embodiments, for example when the gerliptin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition comprises eggliflozin, the first plurality of findings further comprises one or more of: a history of resection of the subject; a history of leg neuropathy in the subject; and a history of diabetic foot ulcers in the subject. Thus, the second plurality of filters includes one or more filters corresponding to other findings, for example selected from an resection filter, a leg neuropathy filter, and a diabetic foot ulcer filter.

In some embodiments, for example when the geragliflozin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition comprises dapagliflozin, the first plurality of findings further comprises whether the individual has had bladder cancer, and the first plurality of filters comprises a first bladder cancer filter.

In some embodiments, the alert corresponding to the respective filter of the second plurality of filters includes prompting the individual to indicate whether the individual has discussed the potential risk factor of the activated respective filter of the second plurality of filters with a healthcare professional. The method further includes obtaining confirmation from the individual when the individual indicates that the individual has discussed the potential risk factors for the activated respective filter of the second plurality of filters with a healthcare professional.

In some embodiments, for example when the geragliflozin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition comprises dapagliflozin, the second plurality of findings further comprises the bladder cancer status of the individual, and the third plurality of filters further comprises a bladder cancer filter.

Drawings

Fig. 1 illustrates an exemplary system topology according to an embodiment of the present disclosure, including an over-the-counter (OTC) dispensing device for identifying a human individual suitable for over-the-counter delivery of a germlining sodium-glucose co-transporter 2 inhibitor pharmaceutical composition to lower blood glucose (e.g., thereby treating type 2 diabetes and/or maintaining sub-diabetic blood glucose levels), a data collection device for collecting data from the individual, one or more user devices associated with the human individual, and one or more dispensing devices for dispensing an over-the-counter germlining sodium-glucose co-transporter 2 inhibitor pharmaceutical composition, wherein the above-identified components are optionally interconnected by a communication network.

Fig. 2 illustrates an example device for identifying a human subject suitable for delivering an over-the-counter gliflozin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition to lower blood glucose (e.g., thereby treating type 2 diabetes and/or maintaining sub-diabetic blood glucose levels), according to various embodiments of the present disclosure.

Fig. 3 illustrates an example device associated with a human subject for identifying a human subject suitable for over-the-counter delivery of a gerlabel sodium-glucose co-transporter 2 inhibitor pharmaceutical composition for lowering blood glucose (e.g., thereby treating type 2 diabetes and/or maintaining sub-diabetic blood glucose levels) according to an embodiment of the present disclosure, wherein it is to be understood that in some embodiments the example device of fig. 3 works with the device of fig. 2 to perform the methods illustrated in fig. 4-8 by, for example, providing the device of fig. 2 with findings and/or the results of the priming filter of the present disclosure for such findings, but in alternative embodiments the device of fig. 2 performs all of the methods of the present disclosure and does not use the device of fig. 3. In other alternative embodiments, the apparatus of fig. 3 performs the method of the present disclosure and does not use the apparatus of fig. 2.

Figures 4A, 4B, 4C, 4D, 4E, 4F, 4G, 4H, 4I, 4J, and 4K collectively provide a flow diagram for identifying a human subject suitable for over-the-counter delivery of a gerlabel sodium-glucose co-transporter 2 inhibitor pharmaceutical composition for lowering blood glucose (e.g., thereby treating type 2 diabetes and/or maintaining sub-diabetic blood glucose levels), wherein elements in the dashed box are optional, according to various embodiments of the present disclosure.

Fig. 5A, 5B, 5C, and 5D collectively illustrate a first survey of individuals for obtaining a first plurality of survey results according to an embodiment of the present disclosure.

Fig. 6 illustrates feedback from the first survey according to an embodiment of the disclosure.

Figures 7A, 7B, and 7C collectively illustrate an example method for identifying an individual suitable for over-the-counter supply of a geremide sodium-glucose co-transporter 2 inhibitor pharmaceutical composition, according to an embodiment of the present disclosure.

Figures 8A, 8B, 8C, and 8D collectively illustrate an example method for identifying an individual suitable for re-prescribing an over-the-counter supply of a geiletin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition, in accordance with embodiments of the present disclosure.

In the drawings, reference numerals refer to the same or equivalent parts throughout the several views of the drawings.

Detailed Description

Diabetes is an increasingly serious health problem in the united states and throughout the world. Although diabetes can be effectively treated using existing pharmaceutical compositions, these drugs require prescription to be available because many individuals do not have adequate access and/or avoid the medical system for a variety of reasons. As a result, many people do not properly manage their diabetic conditions. While over-the-counter alternatives to these prescription drugs will increase the access to these compositions, improving the population management of diabetes worldwide, patients often have difficulty in self-selecting for the appropriate over-the-counter medication. Because improper use of these drugs can cause ineffective treatment and/or serious side effects, there is a need for better methods for selecting over-the-counter diabetes drugs and treating patients with over-the-counter diabetes drugs. The present disclosure provides, among other things, methods, systems, and computer-readable media that can address these issues.

Reference will now be made in detail to embodiments, examples of which are illustrated in the accompanying drawings. In the following detailed description of the embodiments, numerous specific details are set forth in order to provide a thorough understanding of the invention. However, it will be understood by those skilled in the art that the present invention may be practiced without these specific details.

It will also be understood that, although the terms first, second, etc. may be used herein to describe various elements, these elements should not be limited by these terms. These terms are only used to distinguish one element from another. For example, a first filter may be referred to as a second filter, and similarly, a second filter may be referred to as a first filter, without departing from the scope of the present disclosure. The first filter and the second filter are both filters, but are not identical filters.

The terminology used in the present disclosure is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. As used in the description of the invention and the appended claims, the singular forms "a", "an", and "the" are intended to include the plural forms as well, unless the context clearly indicates otherwise. It is also to be understood that the term "and/or" as used herein refers to and encompasses any and all possible combinations of one or more of the associated listed items. It will be further understood that the terms "comprises" and/or "comprising," when used in this specification, specify the presence of stated features, integers, steps, operations, elements, and/or components, but do not preclude the presence or addition of one or more other features, integers, steps, operations, elements, components, and/or groups thereof.

As used herein, the term "if" may be interpreted to mean "when … …" or "at … …" or "in response to a determination" or "in response to a detection", depending on the context. Similarly, depending on the context, the phrase "if it is determined" or "if [ stated condition or event ] is detected" may be interpreted to mean "at the time of the determination … …" or "in response to the determination" or "upon detection of [ stated condition or event ] or" in response to the detection of [ stated condition or event ] ".

As used herein, the term "over-the-counter" means in accordance with the limitations disclosed herein, but is provided by retail purchase without a prescription or license from a doctor or healthcare practitioner.

As used herein, the term "pharmaceutical compound" refers to any physical state of a substance. Pharmaceutical compounds include capsules, tablets, liquids, topical formulations and inhalation formulations.

As used herein, the term "contraindication" refers to conditions that render treatment (e.g., over-the-counter use of a gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition) inappropriate. Contraindications include physical characteristics of the individual, such as pregnancy or renal disease, and concomitant medication use, such as the use of a pharmaceutical composition of the geist sodium-glucose co-transporter 2 inhibitor. In this context, according to some embodiments of the methods, systems, and software disclosed herein, identifying a contraindication activates a first class of filters that prevents authorization to provide a gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition.

As used herein, the term "risk factor" refers to a condition that renders treatment (e.g., over-the-counter use of a geqin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition) inappropriate. Risk factors include physical characteristics of the subject, such as blood glucose readings, and contemporaneous drug use, such as use of diabetes drugs. In this context, according to some embodiments of the methods, systems, and software disclosed herein, identifying a risk factor activates a second class of filter that prevents authorization to provide a geist sodium-glucose co-transporter 2 inhibitor pharmaceutical composition without confirming that the individual has discussed the risk factor with a medical professional.

As used herein, "drug interaction," e.g., drug interaction with a geqizin sodium-glucose co-transporter 2 inhibitor, includes pharmacokinetic and pharmacodynamic drug interactions. In general, a pharmacokinetic drug interaction is an interaction between two drugs (e.g., a gelistine sodium-glucose co-transporter 2 inhibitor and a second drug) that causes a change in the absorption, transport, distribution, metabolism, and/or excretion of either drug. In general, a pharmacokinetic drug interaction is an interaction between two drugs (e.g., a gelistine sodium-glucose co-transporter 2 inhibitor and a second drug) that causes a direct change in the effect of either drug. For a more complete overview of pharmacokinetic and pharmacodynamic drug interactions, see Cascorbi, I, J.International medicine Germany (Dtsch Arztebl Int.), 109(33-34):546-55(2012), the contents of which are incorporated herein by reference.

In the context of the present disclosure, a condition is classified as contraindicated or a risk factor is the specific identity and dosage of the gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition that is specific for authorized over-the-counter use. The classification of the particular conditions of different gerlabel sodium-glucose co-transporter 2 inhibitor pharmaceutical compositions (e.g., use of a contemporary gerlabel sodium-glucose co-transporter 2 inhibitor pharmaceutical composition) may differ (e.g., it may be classified as a contraindication for the first gerlabel sodium-glucose co-transporter 2 inhibitor, a risk factor for the second gerlabel sodium-glucose co-transporter 2 inhibitor, and/or not having both of the above-described effects on the third gerlabel sodium-glucose co-transporter 2 inhibitor). Similarly, a particular condition may be classified as a contraindication to use a particular gerlabel sodium-glucose co-transporter 2 inhibitor at a first over-the-counter dose, as a risk factor for the same particular gerlabel sodium-glucose co-transporter 2 inhibitor at a second (e.g., lower) over-the-counter dose, and/or as not having the above-mentioned two effects on the same particular gerlabel sodium-glucose co-transporter 2 inhibitor at a third (e.g., lowest) over-the-counter dose.

As used herein, whether an individual "develops" a condition after receiving its last supply of geqin sodium-glucose co-transporter 2 inhibitor refers to a condition that is newly present to the individual, i.e., a condition that the individual does not have when receiving its last supply of geqin sodium-glucose co-transporter 2 inhibitor, and a newly diagnosed condition, independent of whether the condition is present when the individual receives its last supply of geqin sodium-glucose co-transporter 2 inhibitor, i.e., a condition that the individual is not aware of when receiving its last supply of geqin sodium-glucose co-transporter 2 inhibitor.

Unless otherwise specified, the term "alkyl", alone or as part of another substituent, means a straight or branched chain or cyclic hydrocarbon group, or combinations thereof, which may be fully saturated, mono-unsaturated, or polyunsaturated and may include those having the indicated number of carbon atoms (e.g., C)₁-C₁₀Meaning one to ten carbons) of divalent, trivalent, and polyvalent groups. Examples of saturated hydrocarbon groups include the following groups: such as methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, isobutyl, sec-butyl, cyclohexyl, (cyclohexyl) methyl, cyclopropylmethyl, homologs and isomers of, for example, n-pentyl, n-hexyl, n-heptyl, n-octyl and the like. Unsaturated alkyl is alkyl having one or more double or triple bonds. Examples of unsaturated alkyl groups include ethenyl, 2-propenyl, crotyl (crotyl), 2-isopentenyl, 2- (butadienyl), 2, 4-pentadienyl, 3- (1, 4-pentadienyl), ethynyl, 1-and 3-propynyl, 3-butynyl, and higher homologs and isomers. Unless otherwise indicated, the term "alkyl group "also means derivatives that optionally include alkyl groups as defined in more detail below, such as" heteroalkyl groups ". Alkyl groups limited to hydrocarbyl groups are referred to as "homoalkyl groups". Exemplary alkyl groups include monounsaturated C_9-10Oleoyl chain or di-unsaturated C_9-10、_12-13A linolenyl chain.

The term "alkylene" alone or as part of another substituent means a divalent radical derived from an alkane, by way of example (but not limitation), from-CH₂CH₂CH₂CH₂-derivatised, and further including groups described below as "heteroalkylene". Typically, the alkyl (or alkylene) group will have 1 to 24 carbon atoms, with groups having 10 or fewer carbon atoms being preferred in the present invention. "lower alkyl" or "lower alkylene" is a short chain alkyl or alkylene group typically having eight or fewer carbon atoms.

Unless otherwise indicated, the terms "cycloalkyl" and "heterocycloalkyl", alone or in combination with other terms, denote the cyclic forms of "alkyl" and "heteroalkyl", respectively. Further, for heterocycloalkyl, a heteroatom may occupy the position of the heterocycle's attachment to the rest of the molecule. Examples of cycloalkyl groups include cyclopentyl, cyclohexyl, 1-cyclohexenyl, 3-cyclohexenyl, cycloheptyl, and the like. Other exemplary cycloalkyl groups include steroids such as cholesterol and derivatives thereof. Examples of heterocycloalkyl include 1- (1,2,5, 6-tetrahydropyridinyl), 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-morpholinyl, 3-morpholinyl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydrothiophen-2-yl, tetrahydrothiophen-3-yl, 1-piperazinyl, 2-piperazinyl, and the like.

The terms "halo" or "halogen", alone or as part of another substituent, mean, unless otherwise stated, a fluorine, chlorine, bromine or iodine atom. Furthermore, terms such as "haloalkyl" are intended to include both monohaloalkyl and polyhaloalkyl. For example, the term "halo (C)₁-C₄) Alkyl "is intended to include, but is not limited to, trifluoromethyl, 2,2, 2-trifluoroethyl, 4-chlorobutyl, 3-bromopropyl, and the like.

Unless otherwise indicated, the term "aryl" means a polyunsaturated aromatic substituent which can be a single ring or multiple rings (preferably 1 to 3 rings) which are fused together or linked covalently. The term "heteroaryl" refers to an aryl substituent (or ring) containing one to four heteroatoms selected from N, O, S, Si and B, wherein the nitrogen and sulfur atoms are optionally oxidized, and the nitrogen atoms are optionally quaternized. Exemplary heteroaryl groups are six-membered azines, such as pyridyl, diazinyl, and triazinyl. The heteroaryl group may be attached to the rest of the molecule through a heteroatom. Non-limiting examples of aryl and heteroaryl groups include phenyl, 1-naphthyl, 2-naphthyl, 4-biphenyl, 1-pyrrolyl, 2-pyrrolyl, 3-pyrazolyl, 2-imidazolyl, 4-imidazolyl, pyrazinyl, 2-oxazolyl, 4-oxazolyl, 2-phenyl-4-oxazolyl, 5-oxazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-benzothiazolyl, purinyl, 2-benzimidazolyl, 5-indolyl, 1-isoquinolyl, 5-isoquinolyl, 2-quinoxalyl, 5-quinoxalyl, 3-quinolyl and 6-quinolyl. The substituents for each of the above-indicated aryl and heteroaryl ring systems are selected from the group of acceptable substituents described below.

For simplicity, the term "aryl" when used in combination with other terms (e.g., aryloxy, arylsulfenoxy, arylalkyl) includes aryl, heteroaryl, and heteroarene rings as defined above. Thus, the term "arylalkyl" is intended to include groups in which the aryl group is attached to an alkyl group (e.g., benzyl, phenethyl, pyridylmethyl, and the like), including alkyl groups in which a carbon atom (e.g., methylene) has been replaced by, for example, an oxygen atom (e.g., phenoxymethyl, 2-pyridyloxymethyl, 3- (1-naphthyloxy) propyl, and the like).

Each of the above terms (e.g., "alkyl," "heteroalkyl," "aryl," and "heteroaryl") is meant to optionally include substituted and unsubstituted forms of the indicated species. Exemplary substituents for these materials are provided below.

Alkyl and heteroalkyl (including generallyGroups referred to as alkylene, alkenyl, heteroalkylene, heteroalkenyl, alkynyl, cycloalkyl, heterocycloalkyl, cycloalkenyl, and heterocycloalkenyl) are commonly referred to as "alkyl substituents" and may be one or more of a variety of groups selected from (but not limited to) the following: H. substituted OR unsubstituted aryl, substituted OR unsubstituted heteroaryl, substituted OR unsubstituted heterocycloalkyl, -OR ', -O, ═ NR ', -N-OR ', -NR ' R ", -SR ', halo, -SiR ' R" R ' ", -oc (O) R ', -c (O) R ', -CO ₂R'、-CONR'R”、-OC(O)NR'R”、-NR”C(O)R'、-NR'-C(O)NR”R”'、-NR”C(O)₂R'、-NR-C(NR'R”R”')＝NR””、NRC(NR'R”)＝NR”'、-S(O)R'、-S(O)₂R'、-S(O)₂NR'R”、NRSO₂R', -CN and-NO₂The number of which ranges from zero to (2m '+1), where m' is the total number of carbon atoms in such groups. R ', R ", R'" and R "" each preferably independently mean hydrogen, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl (e.g., aryl substituted with 1-3 halogens), substituted or unsubstituted alkyl, alkoxy or thioalkoxy or arylalkyl. For example, when a compound of the invention includes more than one R group, each R group is independently selected, and when more than one R ', R ", R'" and R "" groups are present, each of these groups is also the same. When R' and R "are attached to the same nitrogen atom, they may combine with the nitrogen atom to form a 5, 6 or 7 membered ring. For example, -NR' R "is intended to include, but is not limited to, 1-pyrrolidinyl and 4-morpholinyl. From the above discussion of substituents, it will be understood by those skilled in the art that the term "alkyl" is intended to include groups having a carbon atom bonded to a group other than a hydrogen radical, such as haloalkyl (e.g., -CF)₃and-CH₂CF₃) And acyl (e.g., -C (O) CH)₃、-C(O)CF₃、-C(O)CH₂OCH₃Etc.). These terms encompass groups that are considered exemplary "alkyl substituents" which are components of exemplary "substituted alkyl" and "substituted heteroalkyl" moieties.

Arylheteroaryl radicals, analogous to the substituents described for alkyl radicalsAnd substituents of heteroaromatic hydrocarbon groups are commonly referred to as "aryl substituents". Substituents are selected from, for example: groups attached to the heteroaryl OR heteroarene core through a carbon OR heteroatom (e.g., P, N, O, S, Si OR B) include, but are not limited to, substituted OR unsubstituted alkyl, substituted OR unsubstituted aryl, substituted OR unsubstituted heteroaryl, substituted OR unsubstituted heterocycloalkyl, -OR ', -O, ═ NR ', -N-OR ', -NR ' R ", -SR ', -halo, -SiR ' R" R ' ", -oc- (O) R ', -c (O) R ', -CO₂R'、-CONR'R”、-OC(O)NR'R”、-NR”C(O)R'、NR'C(O)NR”R”'、-NR”C(O)₂R'、NR-C(NR'R”R”')＝NR””、NRC(NR'R”)＝NR”'、-S(O)R'、-S(O)₂R ', -S (O)2NR' R ', NRSO2R', -CN and-NO₂、-R'、-N₃、-CH(Ph)₂Fluorine (C)₁-C₄) Alkoxy and fluorine (C)₁-C₄) Alkyl groups ranging in number from zero to the total number of open valences on the aromatic ring system. Each of the above named groups is attached to the heteroarene or heteroaryl nucleus, either directly or through a heteroatom (e.g. P, N, O, S, Si or B); and wherein R ', R ", R'" and R "" are preferably independently selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl. For example, when a compound of the invention includes more than one R group, each R group is independently selected, and when more than one R ', R ", R'" and R "" groups are present, each of these groups is also the same.

As used herein, the term "heteroatom" includes oxygen (O), nitrogen (N), sulfur (S), and silicon (Si), boron (B), and phosphorus (P).

The symbol "R" is a general abbreviation representing a substituent selected from the group consisting of H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, and substituted or unsubstituted heterocycloalkyl.

The term "salt" includes salts of the compounds prepared by neutralizing an acid or base, depending on the particular ligand or substituent found on the compounds described herein. When the compounds of the present invention contain relatively acidic functional groups, base addition salts can be obtained by contacting the neutral forms of such compounds with a sufficient amount of the desired base, either neat or in a suitable inert solvent. Examples of base addition salts include sodium, potassium, calcium, ammonium, organic amino or magnesium salts or the like. Examples of the acid addition salts include acid addition salts derived from inorganic acids such as hydrochloric acid, hydrobromic acid, nitric acid, carbonic acid, monohydrogencarbonic acid, phosphoric acid, monohydrogenphosphoric acid, dihydrogenphosphoric acid, sulfuric acid, monohydrogensulfuric acid, hydroiodic acid, or phosphorous acid, etc.; and salts derived from relatively nontoxic organic acids such as acetic, propionic, isobutyric, butyric, maleic, malic, malonic, benzoic, succinic, suberic, fumaric, lactic, mandelic, phthalic, benzenesulfonic, p-tolylsulfonic, citric, tartaric, methanesulfonic, and the like. Certain specific compounds of the invention contain both basic and acidic functional groups that allow the compounds to be converted into base or acid addition salts. Also included are hydrates of the salts.

It is to be understood that in any compound described herein having one or more chiral centers, each center may independently have the R-configuration or the S-configuration or mixtures thereof if absolute stereochemistry is not explicitly indicated. Thus, the compounds provided herein can be enantiomerically pure or stereoisomeric mixtures. Further, it is understood that in any compound described herein having one or more double bonds (resulting in a geometric isomer that may be defined as E or Z), each double bond may be independently E or Z or a mixture thereof. Similarly, it will be understood that in any compound described, all tautomeric forms are also intended to be included.

In one aspect of the disclosure, a survey of individuals is conducted to obtain survey results in order to determine whether an individual qualifies for obtaining an over-the-counter (OTC) gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition for lowering blood glucose (e.g., thereby treating type 2 diabetes and/or maintaining sub-diabetic blood glucose levels). The results of the survey are used as a basis for running a first category of filter. If any of the first class of filter triggering conditions is initiated, then the individual is not eligible for a pharmaceutical composition of an OTC gyricon sodium-glucose co-transporter 2 inhibitor. The results of the survey are also used as a basis for running a second category of filters. If the trigger condition of any of the second category of filters is activated, a warning message is provided to the individual relating to the respective filter of the second category that has been activated. If a filter of the first category is not activated and the individual successfully resolves the warning message associated with the corresponding filter of the second category that has been activated, then a fulfillment process for OTC delivery of the gesicam sodium-glucose co-transporter 2 inhibitor pharmaceutical composition is initiated.

Fig. 1 illustrates an example of an integrated system 48 for conducting one or more individual surveys to identify individuals eligible for OTC delivery of a gelidine sodium-glucose co-transporter 2 inhibitor pharmaceutical composition. The integrated system 48 includes one or more connected user devices 102. The user device 102 is configured for inputting survey data and generating a request for a geremin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition. The system 48 also includes one or more dispensing devices 104 configured to receive instructions to provide a eligible individual with a gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition. In addition, the system 48 includes a gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition Over The Counter (OTC) dispensing device 250 and one or more data collection devices 200 configured to collect individual data.

Throughout this disclosure, for clarity, the data collection device 200 and the gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition OTC dispensing device 250 will be represented as separate devices. That is, the disclosed functionality of the data collection device 200 and the disclosed functionality of the gyragliflozin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition OTC dispensing device 250 are contained in separate devices, as illustrated in fig. 1. It will be appreciated, however, that in fact, in some embodiments, the disclosed functionality of the data collection device 200 and the disclosed functionality of the gyragliflozin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition OTC dispensing device 250 are contained in a single device.

With the aid of integration system 48, the individual's survey results are run against a first plurality of filters (e.g., filter 216-1, filter 216-2, filter 216-4, etc.). When a filter (e.g., filter 216) in the first plurality of filters is activated by a respective individual, the respective individual is deemed not eligible for a pharmaceutical composition of a geist sodium-glucose co-transporter 2 inhibitor. The survey results are also run against a second plurality of filters (e.g., filter 222-1, filter 222-2, filter 222-6, etc.). When a respective filter of the second plurality of filters is activated by a respective individual, an alert (e.g., filter alert 226) associated with the respective filter is provided to the respective individual. In some embodiments, the survey results are run for the first plurality of filters and the second plurality of filters simultaneously. In some embodiments, the survey results are run against a first plurality of filters and then against a second plurality of filters. When none of the filters of the first plurality of filters are activated and the individual has confirmed or otherwise successfully addressed each alert associated with each activated filter of the second plurality of filters, the method implemented by the integration system 48 proceeds to a fulfillment process. As part of the fulfillment process, a composition order is stored (e.g., in an individual profile 232 associated with the individual receiving the drug), and a drug fact label for the gesicam sodium-glucose co-transporter 2 inhibitor (e.g., drug fact label 230) is communicated to the eligible individual. After the individual confirms that the tag has been read, the dispensing of the gerzin sodium-glucose co-transporter 2 inhibitor is authorized.

Referring to fig. 1, an OTC dispensing device 250 for a pharmaceutical composition of geiletin sodium-glucose co-transporter 2 inhibitor identifies an individual as eligible for over-the-counter delivery of a pharmaceutical composition of geiletin sodium-glucose co-transporter 2 inhibitor for use in lowering blood glucose, e.g., to thereby treat type 2 diabetes and/or maintain sub-diabetic blood glucose levels. To this end, a data collection device 200, which is in electrical communication with a gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition OTC dispensing device 250, receives findings derived from one or more user devices 102 associated with respective individuals. In some embodiments, the data collection device 200 receives such survey results directly from the user device 102. For example, in some embodiments, the data collection device 200 receives this data wirelessly through radio frequency signals. In some embodiments, such signals conform to the 802.11(Wi-Fi), Bluetooth, or ZigBee standards. In some embodiments, the data collection device 200 receives such data directly, analyzes the data, and sends the analyzed data to the gyragliflozin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition OTC dispensing device 250.

In some embodiments, the data collection device 200 and/or the gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition OTC dispensing device 250 are not proximate to the individual and/or do not have wireless functionality, or such wireless functionality is not used for the purpose of obtaining survey results. In such embodiments, the communication network 106 may be used to communicate survey questions (e.g., survey questions 208, 212) from the gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition OTC dispensing device 250 to the user device 102 and to communicate answers to such survey questions from the user device 102 to the data collection device 200 and/or the gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition OTC dispensing device 250. Further, in some embodiments, the communication network 106 is used to communicate authorization from the gelliflozin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition OTC dispensing device 250 to dispense gelliflozin sodium-glucose co-transporter 2 inhibitor survey questions to the dispensing device 104.

Examples of network 106 include the World Wide Web (WWW), intranets and/or wireless networks (e.g., cellular telephone networks), wireless Local Area Networks (LANs) and/or Metropolitan Area Networks (MANs), and other devices that communicate via wireless. The wireless communication optionally uses any of a number of communication standards, protocols, and technologies, including, but not limited to, global system for mobile communications (GSM), Enhanced Data GSM Environment (EDGE), High Speed Downlink Packet Access (HSDPA), High Speed Uplink Packet Access (HSUPA), evolution-data only (EV-DO), HSPA +, dual cell HSPA (DC-HSPDA), Long Term Evolution (LTE), Near Field Communication (NFC), wideband code division multiple access (W-CDMA), Code Division Multiple Access (CDMA), Time Division Multiple Access (TDMA), bluetooth, wireless fidelity (Wi-Fi) (e.g., IEEE 802.11a, IEEE 802.11ac, IEEE 802.11ax, IEEE 802.11b, IEEE 802.11g, and/or IEEE 802.11n), voice over internet protocol (VoIP), Wi-MAX, email protocols (e.g., Internet Message Access Protocol (IMAP), and/or Post Office Protocol (POP)))) Real-time messaging (e.g., extensible messaging and presence protocol (XMPP), session initiation protocol for real-time messaging and presence support extensions (SIMPLE), real-time messaging and presence service (IMPS)), and/or Short Message Service (SMS), or any other suitable communication protocol, including communication protocols that have not been developed as of the filing date of this disclosure.

Of course, other topologies for system 48 are possible. For example, one or more user devices 102 and one or more dispensing devices 104 may communicate directly with the data collection device 200 and/or the gyricon sodium-glucose co-transporter 2 inhibitor pharmaceutical composition OTC dispensing device 250 without relying on the communication network 106. Further, the data collection device 200 and/or the gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition OTC dispensing device 250 may constitute a portable electronic device, a server computer, or indeed several computers linked together in a network, or may be a virtual machine in a cloud computing environment, a container in a cloud computer environment, or a combination thereof. Thus, the exemplary topology shown in fig. 1 is only used to describe features of embodiments of the present disclosure in a manner that is readily understood by those of skill in the art.

In view of the foregoing, turning to fig. 2, an exemplary gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition OTC dispensing device 250 configured for determining whether an individual qualifies for OTC delivery of a gerzin sodium-glucose co-transporter 2 inhibitor is depicted. Referring to fig. 2, in an exemplary embodiment, the gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition OTC dispensing device 250 includes one or more computers. For purposes of illustration, in fig. 2, the gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition OTC dispensing device 250 is represented as a single computer that includes all the functionality for identifying a human subject as eligible for over-the-counter delivery of a gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition for lowering blood glucose, e.g., thereby treating type 2 diabetes and/or maintaining sub-diabetic blood glucose levels. However, the present disclosure is not limited thereto. In some embodiments, the functionality for qualifying a human individual for over-the-counter delivery of a gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition for lowering blood glucose (e.g., thereby treating type 2 diabetes and/or maintaining sub-diabetic blood glucose levels) is spread over any number of networked computers and/or resides on each of several networked computers, hosted on one or more virtual machines at a remote location that are accessible through the communication network 106, and/or hosted on one or more containers at a remote location that are accessible through the communication network 106. Those skilled in the art will appreciate that any of a number of different computer topologies are useful for the application and that all such topologies are within the scope of the present disclosure.

The girlistine sodium-glucose co-transporter 2 inhibitor pharmaceutical composition OTC dispensing device 250 of fig. 2 is configured to conduct a first survey (e.g., an initial identification of a supply of an individual's girlistine sodium-glucose co-transporter 2 inhibitor pharmaceutical composition using the assessment module 252) and/or a second survey (e.g., a re-identification of a supply of an individual's girlistine sodium-glucose co-transporter 2 inhibitor pharmaceutical composition using the re-assessment module 254). The first survey (e.g., evaluation) includes various survey questions 208-1, 212-1 related to filters 216, 222 within the plurality of filters of the first filter category 214-1 and the plurality of filters of the second filter category 220-1, respectively. Answers to questions in the first survey received by the device are run against a first category 214-1 of filters and a second category 220-1 of filters within the first and second pluralities of filters 214-1, 216-1, respectively. Similarly, the second survey (e.g., re-evaluation) also includes various questions related to filters 216, 222 within the plurality of filters of the first category 214-2 and the plurality of filters of the second category 220-2, respectively. Answers to questions in the second survey received by the device are run against, for example, a first category 216-2 of filters and a second category 220-2 of filters within the first and second pluralities of filters, respectively. The filters 216 of the first filter class 214 are configured to terminate the authentication process when initiated. The filters 222 of the second filter category 220 are configured to provide alerts to individuals related to the respective survey questions. In other words, the device of fig. 2 is configured to collect results from a survey (e.g., survey questions 208 and survey questions 212) and run the results against corresponding filters (e.g., filter 216 and filter 222, respectively) to determine whether an individual is eligible for OTC delivery of a geiletin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition.

In this disclosure, a plurality of filters refers to a series or set or filters in a first filter category or a second category. For example, in some embodiments, the plurality of filters of the first filter category 214 may include any subset of the filters 216 of the first filter category. As an example, in some embodiments, the first category of the plurality of filters includes filters 216-1, 216-2, 216-3, … …, 216-i, or any combination thereof. Similarly, the plurality of filters of the second filter category 220 may include any set of filters 222 of the second filter category. Further, in some embodiments, the second category of the plurality of filters includes filters 222-1, 222-2, 222-3, … …, 222-i, or any combination thereof.

With continued reference to fig. 2, in some embodiments, the distribution device 250 includes one or more processing units (CPUs) 274, a network or other communication interface 284, a memory 192 (e.g., random access memory), one or more disk storage and/or permanent devices 290 optionally accessed by one or more controllers 288, one or more communication buses 213 for interconnecting the above components, a user interface 278 (the user interface 278 including a display 282 and an input 280 (e.g., keyboard, keypad, touch screen)), and a power supply 276 for powering the above components. In some embodiments, data in memory 192 is seamlessly shared with non-volatile memory 290 using known computing techniques such as caching. In some embodiments, memory 192 and/or memory 290 comprise mass storage devices that are remotely located with respect to the one or more central processing units 274. In other words, some of the data stored in memory 192 and/or memory 290 may actually be hosted on a computer that is located external to the gyricon sodium-glucose co-transporter 2 inhibitor pharmaceutical composition OTC dispensing device 250, but may be electronically accessed by the gyricon sodium-glucose co-transporter 2 inhibitor pharmaceutical composition OTC dispensing device 250 through the internet, an intranet, or other form of network or electronic cable (illustrated as element 106 in fig. 2) using network interface 284.

In some embodiments, the reservoir 192 of the gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition OTC dispensing device 250 stores one or more of:

an operating system 202, which includes programs for handling various basic system services;

an assessment module 252 for identifying an individual eligible for initial over-the-counter delivery of a pharmaceutical composition for reducing blood glucose, e.g., thereby treating type 2 diabetes and/or maintaining sub-diabetic blood glucose levels, a gyragliflozin sodium-glucose co-transporter 2 inhibitor, by communicating survey questions, obtaining results thereof, and applying the results to an identification filter, the assessment module comprising:

a first filter class 214-1, including filters 216 (e.g., a first plurality of filters), each respective filter 216 of the first filter class 214-1 being associated with one or more survey questions 208 and one or more trigger conditions 218;

a second filter category 220-1, including filters 222 (e.g., a second plurality of filters), each respective filter 222 in the second filter category 220-1 being associated with one or more survey questions 212, trigger conditions 224, and alerts 226;

a fulfillment module 228-1 for performing a fulfillment process when the filter 216 in the first filter category 214-1 is not activated by the individual and the individual has confirmed each alert 226 associated with each filter 222 in the second filter category 220-1 that is activated by the individual's answer to the survey question 212, wherein the fulfillment process comprises communicating to the individual an over-the-counter drug fact label 230 of a gesicyn sodium-glucose co-transporter 2 inhibitor pharmaceutical composition and receiving confirmation from the individual that the over-the-counter drug fact label has been received and read;

A reevaluation module 254 for qualifying an individual for subsequent over-the-counter delivery of a gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition for reducing blood glucose, e.g., thereby treating type 2 diabetes and/or maintaining sub-diabetic blood glucose levels, by communicating survey questions, obtaining results thereof, and applying the results to an identification filter, the evaluation module comprising:

a first filter class 214-2 including a filter 216 (e.g., a third plurality of filters), each respective filter 216 of the first filter class 214-2 being associated with one or more survey questions 208 and one or more trigger conditions 218;

a second filter category 220-2 including filters 222 (e.g., a second plurality of filters), each respective filter 222 in the second filter category 220-2 being associated with one or more survey questions 212, trigger conditions 224, and alerts 226;

a redemption module 228-2 for performing a redemption process when the filter 216 in the first filter category 214-2 is not activated by the individual and the individual has confirmed each alert 226 associated with each filter 222 in the second filter category 220-2 that is activated by the individual's answer to the survey question 212, wherein the redemption process comprises communicating an over-the-counter drug fact label 230 of a geisin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition to the individual and receiving confirmation from the individual that the over-the-counter drug fact label has been received and read;

An individual profile data store 232 containing individual profiles 232 for each of a plurality of individuals, each respective individual profile 232 including information (e.g., transportation information, billing information, biometric information, etc.) relating to a respective individual of the plurality of individuals, a date and place of initial ordering 236 and any subsequent dates and places of ordering 238 of a gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition by the respective individual using a gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition OTC dispensing device 250;

an adverse events module 242 for identifying and aggregating records of adverse events related to multiple individuals, e.g., corresponding to the activation of a filter 216 in the first filter category 214-2 during a re-fulfillment process;

a reimbursement module 240 for determining eligibility and/or communicating insurance claims related to delivery of the gyricon sodium-glucose co-transporter 2 inhibitor, e.g., based on insurance information stored in the respective individual profile 232.

In some embodiments, evaluation module 252, re-evaluation module 254, and/or fulfillment module 228 may be accessible within any browser (e.g., a phone, a tablet computer, a laptop/desktop computer, or a smart watch). In some embodiments, the evaluation module 252, reevaluation module 254, and/or fulfillment module 228 run on the local device framework and may be downloaded to the user device 102 running an operating system 202 such as Android, iOS, or WINDOWS.

In some embodiments, one or more of the above-identified data elements or modules (e.g., the evaluation module 252, the fulfillment module 228-1, etc.) of the gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition OTC dispensing device 250 for identifying a human subject for over-the-counter delivery of a gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition for reducing blood glucose (e.g., thereby treating type 2 diabetes and/or maintaining sub-diabetic blood glucose levels) are stored in one or more of the memory devices previously described and correspond to a set of instructions for performing the functions described above. The above-identified data, modules, or programs (e.g., sets of instructions) need not be implemented as separate software programs, procedures, or modules, and thus various subsets of these modules may be combined or otherwise re-arranged in various embodiments. In some embodiments, memories 192 and/or 290 optionally store a subset of the modules and data structures identified above. Further, in some embodiments, memories 192 and/or 290 store other modules and data structures not described above.

In some embodiments, the gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition OTC dispensing device 250 for identifying a human subject as eligible for over-the-counter delivery of a gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition for reducing blood glucose (e.g., thereby treating type 2 diabetes and/or maintaining sub-diabetic blood glucose levels) is a smartphone (e.g., iPhone, Blackberry (Blackberry), etc.), laptop computer, tablet computer, desktop computer, smart watch, or another form of electronic device (e.g., a game console). In some embodiments, the gyragliflozin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition OTC dispensing device 250 is non-movable. In some embodiments, the gyragliflozin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition OTC dispensing device 250 is mobile.

In some embodiments, the gyricon sodium-glucose co-transporter 2 inhibitor pharmaceutical composition OTC dispensing device 250 is not a smartphone, but is a tablet computer, desktop computer, emergency vehicle computer, or other form or wired or wireless networking device. For the sake of brevity and clarity, only a few of the possible components of the gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition OTC dispensing device 250 are shown in fig. 2 in order to better emphasize the additional software modules installed on the gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition OTC dispensing device 250.

Fig. 3 provides an illustration of a user device 102 that may be used with the present disclosure. The user device 102 illustrated in figure 3 has one or more processing units (CPU)374, peripheral interfaces 370, a memory controller 368, a network or other communication interface 384, a memory 392 (e.g., random access memory), a user interface 378 (user interface 378 includes a display 382 and an input 380 (e.g., keyboard, keypad, touch screen)), an optional accelerometer 317, an optional GPS 319, optional audio circuitry 372, optional speaker 360, optional microphone 362, one or more optional intensity sensors 364 (e.g., a touch-sensitive surface such as a touch-sensitive display system 382 of user device 102) for detecting intensity of contacts on user device 102, optional input/output (I/O) subsystem 366, one or more optional optical sensors 373, one or more communication buses 313 for interconnecting the above components, and a power supply 376 for powering the above components.

In some embodiments, input 380 is a touch-sensitive display, such as a touch-sensitive surface. In some embodiments, the user interface 378 includes one or more soft keyboard embodiments. The soft keyboard embodiment may include standard (e.g., QWERTY) and/or non-standard symbol configurations on the displayed icons.

In addition to the one or more accelerometers 317, the user device 102 illustrated in fig. 3 optionally includes a magnetometer (not shown) and a GPS 319 (or GLONASS or other global navigation system) receiver for obtaining information about the location and orientation (e.g., portrait or landscape) of the user device 102 and/or for determining the amount of physical exertion by the individual.

It should be appreciated that the user device 102 illustrated in fig. 3 is merely one example of a multifunctional device that may be used to conduct a survey (e.g., the first survey 206) to identify eligibility for over-the-counter delivery of a geiletin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition for lowering blood glucose (e.g., thereby treating type 2 diabetes and/or maintaining sub-diabetic blood glucose levels), and that the user device 102 optionally has more or fewer components than shown, optionally combines two or more components, or optionally has a different configuration or arrangement of components. The various components shown in fig. 3 are implemented in hardware, software, firmware, or a combination thereof, including one or more signal processing and/or application specific integrated circuits.

The memory 392 of the user device 102 illustrated in fig. 3 optionally includes high-speed random access memory, and optionally also includes non-volatile memory, such as one or more magnetic disk storage devices, flash memory devices, or other non-volatile solid-state memory devices. Access to memory 392 by other components of the gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition OTC dispensing device 250 (e.g., the one or more CPUs 374) is optionally controlled by memory controller 368. In some embodiments, memory 392 of user device 102 illustrated in fig. 3 optionally comprises:

an operating system 302, which includes programs for handling various basic system services;

an assessment module 252 as described above in combination with a gelliflozin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition OTC dispensing device 250;

the first category 214 described above in combination with the gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition OTC dispensing device 250, further comprising a pregnancy filter 216-1, a type 1 diabetes filter 216-2, a ketoacidosis filter 216-3, a first nephropathy filter 216-4, an age filter 216-5, and a first glycaemic filter 216-6; and

A second class 220 described above comprising a first liver disease filter 222-1, a first urinary problem filter 222-2, a surgical filter 222-3, a first diet filter 222-4, a first pancreatic disease filter 222-5, an alcohol consumption filter 222-6, and a first diabetic drug filter 222-7 in combination with a gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition OTC dispensing device 250;

in some embodiments, optional accelerometer 317, optional GPS 319, and/or magnetometer (not shown), or such components of user device 102 are used to recommend one or more suitable pharmaceutical locations for delivery of over-the-counter gyricon sodium-glucose co-transporter 2 inhibitor pharmaceutical compositions to a qualified individual. In some embodiments, GPS 319 is used to determine whether OTC delivery of the individual's geletam sodium-glucose co-transporter 2 inhibitor pharmaceutical composition is geographically limited. Geographic restrictions include individuals living outside of the delivery or transportation area, sales restrictions, and/or government regulations.

Peripheral interface 370 may be used to couple the input and output peripherals of the apparatus to CPU 374 and memory 392. The one or more processors 374 run or execute various software programs and/or sets of instructions stored in memory 392, such as the survey module 204, to perform various functions and process data for the user device 102.

In some embodiments, peripherals interface 370, CPU 374, and memory controller 368 are optionally implemented on a single chip. In some other embodiments, it is implemented on a separate chip.

The RF (radio frequency) circuitry of network interface 384 receives and transmits RF signals, also referred to as electromagnetic signals. In some embodiments, the answers to the survey module 204, the survey questions 208/212, the survey questions 208/212, and/or the over-the-counter pharmaceutical fact tag 230 are communicated to the individual device 102 using this RF circuitry. In some embodiments, the RF circuitry 384 converts electrical signals to or from electromagnetic signals and communicates with the communication network and other communication devices and/or the data collection device 200 and/or the gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition OTC dispensing device 250 via electromagnetic signals. The RF circuitry 384 optionally includes well-known circuitry for performing these functions, including but not limited to an antenna system, an RF transceiver, one or more amplifiers, a tuner, one or more oscillators, a digital signal processor, a CODEC chipset, a Subscriber Identity Module (SIM) card, memory, and so forth. The RF circuitry 384 optionally communicates with the communication network 106. In some embodiments, circuitry 384 does not include RF circuitry, and is actually connected to network 106 by one or more hard-wired lines (e.g., fiber optic cable, coaxial cable, etc.).

In some embodiments, audio circuitry 372, optional speaker 360, and optional microphone 362 provide an audio interface between the individual and user device 102. Audio circuitry 372 receives audio data from peripheral interface 370, converts the audio data to electrical signals, and transmits the electrical signals to speaker 360. The speaker 360 converts the electrical signals into human audible sound waves. In some embodiments, speaker 360 converts electrical signals into sound waves that are not audible to humans. Audio circuitry 372 also receives electrical signals converted from sound waves by microphone 362. The audio circuit 372 converts the electrical signals to audio data and transmits the audio data to the peripheral interface 370 for processing. Audio data is optionally retrieved from and/or transmitted to memory 392 and/or RF circuitry 384 by peripheral interface 370.

In some embodiments, power supply 376 optionally includes a power management system, one or more power sources (e.g., battery, Alternating Current (AC)), a recharging system, a power failure detection circuit, a power converter or inverter, a power status indicator (e.g., a Light Emitting Diode (LED)), and any other components related to the generation, management, and distribution of power in a portable device.

In some embodiments, user device 102 optionally also includes one or more optical sensors 373. The one or more optical sensors 373 optionally include a Charge Coupled Device (CCD) or a Complementary Metal Oxide Semiconductor (CMOS) phototransistor. The one or more optical sensors 373 receive light from the environment projected through the one or more lenses and convert the light into data representing an image. The one or more optical sensors 373 optionally capture still images and/or video. In some embodiments, the optical sensor is located on the back of user device 102, as opposed to display 382 on the front of user device 102, so that input 380 can be used as a viewfinder for taking still and/or video images. In some embodiments, another optical sensor 373 is located on the front side of the user device 102 such that an image of the individual is obtained (e.g., in order to verify the health, pathology, or identity of the individual, which is part of identifying the individual's eligibility for over-the-counter delivery of a geist sodium-glucose co-transporter 2 inhibitor pharmaceutical composition for lowering blood glucose, e.g., to thereby treat type 2 diabetes and/or maintain sub-diabetic blood glucose levels, in order to aid in remote diagnosis of the pathology of the individual or in order to obtain visual physiological measurements of the individual, etc.).

As illustrated in FIG. 3, user device 102 preferably includes an operating system 302 that includes programs for handling various basic system services. The operating system 302 (e.g., iOS, DARWIN, RTXC, LINUX, UNIX, OS X, WINDOWS, or an embedded operating system such as VxWorks) includes various software components and/or drivers for controlling and managing general system tasks (e.g., memory management, storage device control, power management, etc.) and facilitates communication between various hardware and software components.

In some embodiments, user device 102 is a smartphone or a smartwatch. In other embodiments, the user device 102 is not a smartphone or smart watch, but is a tablet computer, desktop computer, emergency vehicle computer, or other form of or wired or wireless networking device. For the sake of brevity and clarity, only a few of the possible components of user device 102 are shown in fig. 3 to better emphasize additional software modules installed on user device 102.

Although the system 48 disclosed in fig. 1 may operate independently, in some embodiments it may also be linked with an electronic medical record system to exchange information in any manner.

Having now disclosed details of a system 48 for identifying a human subject's eligibility for over-the-counter delivery of a gerlabel sodium-glucose co-transporter 2 inhibitor pharmaceutical composition for lowering blood glucose (e.g., thereby treating type 2 diabetes and/or maintaining sub-diabetic blood glucose levels), details regarding methods (400) (including processes and features) performed by a system according to embodiments of the present disclosure are disclosed with reference to fig. 4A-4K. In some embodiments, such processes and features of the system are performed by evaluation module 252, re-evaluation module 254, fulfillment module 228-1, and/or re-fulfillment module 228-2 illustrated in FIGS. 2 and 3. In some embodiments, evaluation module 252, re-evaluation module 254, fulfillment module 228-1, and/or re-fulfillment module 228-1 are a single software module. In the flow chart, elements in the dashed box are considered optional.

Block 402-. The gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition OTC dispensing device (e.g., device 250) comprises one or more processors (e.g., processor 274) and memory (e.g., memory 192). The memory stores non-transitory instructions that, when executed by the one or more processors, perform a method.

Referring to block 403, in some embodiments, a gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition, the gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition has a structure of structure (I):

wherein:

R₃And R₄Independently hydrogen, OH, OR^5aO aryl, OCH₂Aryl, alkyl, cycloalkyl, CF₃、-OCHF₂、-OCF₃Halogen, -CN, -CO₂R^5b、-CO₂H、COR^6b、-CH(OH)R^6c、-CH(OR^5h)R^6d、-CONR⁶R^6a、-NHCOR^5c、-NHSO₂R^5d、-NHSO₂Aryl, -SR^5e、-SOR^5f、-SO₂R^5g、-SO₂Aryl or a five-, six-or seven-membered heterocyclic ring which may contain 1 to 4 heteroatoms in the ring, which heteroatoms are N, O, S, SO and/or SO₂Or R is³And R⁴Together with the carbon to which they are attached form a cyclic five-, six-or seven-membered carbocyclic or heterocyclic ring which may contain from 1 to 4 heteroatoms in the ring, which heteroatoms are N, O, S, SO and/or SO₂；

R⁶、R^6a、R^6b、R^6cand R^6dIndependently is hydrogen, alkyl, aryl, alkylaryl or cycloalkyl, or R⁶And R^6aCo-forming with the nitrogen to which it is attached A cyclic five-, six-or seven-membered heterocyclic ring which may contain 1 to 4 heteroatoms in the ring, which heteroatoms are N, O, S, SO and/or SO₂；

Referring to block 404-406, in some embodiments, the geragliflozin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition comprises dapagliflozin. In some embodiments, the gegliflozin sodium-glucose co-transporter 2 inhibitor is a pharmaceutically acceptable salt of dapagliflozin. In some embodiments, the gegliflozin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition comprises dapagliflozin propylene glycol.

In some embodiments, the geriflozin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition comprises one of: dapagliflozin (e.g. (2S,3R,4R,5S,6R) -2- [ 4-chloro-3- [ (4-ethoxyphenyl) methyl ] phenyl ] -6- (hydroxymethyl) dioxane-3, 4, 5-triol), eprazidol (e.g. (2S,3R,4R,5S,6R) -2- [ 4-chloro-3- [ [4- [ (3S) -oxocyclopent-3-yl ] oxyphenyl ] methyl ] phenyl ] -6- (hydroxymethyl) dioxane-3, 4, 5-triol), canagliflozin (e.g. (2S,3R,4R,5S,6R) -2- [3- [ [5- (4-fluorophenyl) thiophen-2-yl ] methyl ] -4-methylphenyl ] -6- (hydroxymethyl) oxane Yl) dioxane-3, 4, 5-triol) and/or eggliflozin (e.g. (1S,2S,3S,4R,5S) -5- [ 4-chloro-3- [ (4-ethoxyphenyl) methyl ] phenyl ] -1- (hydroxymethyl) -6, 8-dioxabicyclo [3.2.1] octane-2, 3, 4-triol). These and other gerbil sodium-glucose co-transporter 2 inhibitors are described, for example, in Dekkers et al, Current diabetes Reports (Curr. diabetes Reports), 18:27(2018), the contents of which are incorporated herein by reference.

In some embodiments, the gerzin sodium-glucose co-transporter 2inhibitor Pharmaceutical composition includes any of the compounds disclosed in U.S. patent No. 7,851,502, entitled Pharmaceutical formulations containing SGLT2inhibitor (Pharmaceutical formulations a SGLT2 inhibitor), which is incorporated herein by reference. In some embodiments, the gerzin sodium-glucose co-transporter 2inhibitor pharmaceutical composition comprises any of the compounds disclosed in U.S. patent No. 9,834,533, entitled Process for preparing SGLT2inhibitors and intermediates thereof, which is incorporated herein by reference. In some embodiments, the geragliflozin sodium-glucose co-transporter 2inhibitor pharmaceutical composition comprises any compound disclosed in U.S. patent No. 9,845,303, entitled Process for the preparation of dapagliflozin, which is incorporated herein by reference.

In some embodiments, the germacrozin sodium-glucose co-transporter 2inhibitor pharmaceutical composition comprises any of the compounds disclosed in U.S. patent No. 8.853,412, entitled pyrrolidone derivatives as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders, which is incorporated herein by reference.

In some embodiments, the gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition includes any of the compounds disclosed in U.S. patent No. 8,999,941 entitled Crystalline and non-Crystalline forms of SGLT2 inhibitors (crystalloid and non-crystalloid forms of SGLT2 inhibitors), which is incorporated herein by reference. In some embodiments, the geragliflozin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition comprises any compound disclosed in U.S. patent No. 9,695,159, entitled "Process for the preparation of dapagliflozin," which is incorporated herein by reference.

In some embodiments, the gerzin sodium-glucose co-transporter 2 inhibitor Pharmaceutical composition includes any of the compounds disclosed in U.S. patent No. 9,192,617, entitled Pharmaceutical compositions, methods for treating, and uses thereof (Pharmaceutical compositions, methods for treating, and the uses of thermoof), which is incorporated herein by reference. In some embodiments, the gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition includes any of the compounds disclosed in U.S. patent No. 9,902,751, entitled Process for the preparation of empagliflozin, which is incorporated herein by reference.

Referring to block 407, in some embodiments, the lowering of blood glucose is for the treatment of type 2 diabetes. Typically, this is achieved by reducing blood sugar levels or absorption.

In some embodiments, in response to receiving a first request from an individual to be identified as eligible to receive a supply of a gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition, the system generates a corresponding individual profile, e.g., containing biographical information about the individual, e.g., one or more of: individual name, date of birth, residence, shipping address, social security number, medical record number, insurance information, user name, identification password, and the like. In some embodiments, the system registers as a new user of a gerlabel sodium-glucose co-transporter 2 inhibitor pharmaceutical composition an individual who has not previously received an over-the-counter supply of a gerlabel sodium-glucose co-transporter 2 inhibitor pharmaceutical composition, and the device will perform a preliminary assessment method to identify the eligibility of the individual to receive a supply of a gerlabel sodium-glucose co-transporter 2 inhibitor pharmaceutical composition, e.g., whether or not the individual has previously received a supply of a gerlabel sodium-glucose co-transporter 2 inhibitor pharmaceutical composition by prescription.

In some embodiments, the system registers an individual who has previously been prescribed a supply of a geletam sodium-glucose co-transporter 2 inhibitor pharmaceutical composition as a previous user of the geletam sodium-glucose co-transporter 2 inhibitor pharmaceutical composition, and the device will perform a re-assessment method to re-qualify the individual for a supply of a geletam sodium-glucose co-transporter 2 inhibitor pharmaceutical composition.

In some embodiments, the system is to perform a method for identifying an individual's eligibility for receiving a supply of a gemiflozin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition that is modified to account for the contraindications and differences in risk factors for the two gemiflozin sodium-glucose co-transporter 2 inhibitor pharmaceutical compositions when the individual has previously received a supply of a different gemiflozin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition by prescription. For example, in response to receiving a request to qualify a user who has previously received a supply of a pharmaceutical composition containing eggliflozin by prescription for acceptance of an over-the-counter supply of dapagliflozin, the system performs a method modified for re-qualifying (e.g., re-evaluating) the individual for eligibility for a sodium-glucose co-transporter 2 inhibitor pharmaceutical composition of gyflozin, the method including an investigation question and corresponding filter related to whether the individual has undergone a body part resection (e.g., unrelated to whether the re-evaluation for the pharmaceutical composition containing eggliflozin would normally consider the individual's resection history) because the factors will not be considered when the individual receives a prescription for the composition containing dapagliflozin.

In some embodiments, in response to receiving a second or subsequent request from the user to qualify for supply of the geiletin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition, the system registers the individual as returned to the customer, for example when the individual previously received an over-the-counter supply of geiletin sodium-glucose co-transporter 2 inhibitor and a corresponding individual profile 232 of an already existing individual.

In some embodiments, prior to conducting the authentication or re-authentication method, the device prompts (702, 704) the user to confirm that they have sufficient privacy to provide sensitive medical information (e.g., prompt 704 in fig. 7A) and/or that they have medical information needed to complete the authentication process (e.g., in fig. 7A, prompt 702 to confirm that they have knowledge of their blood glucose level).

Block 408-411 referring to block 408 of fig. 4A, the method includes conducting a first survey of individuals, thereby obtaining a first plurality of survey results (e.g., in response to the survey questions 208, 212, such as one or more of the survey questions set forth in table 1). In some embodiments, the device communicates one or more survey questions to the individual, prompts for answers, and then receives answers to the one or more survey questions from the individual. In some embodiments, the first survey result indicates some or all of the features listed in table 1. For example, in some embodiments, the first plurality of survey results indicate 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or all 20 of the features listed in table 1. In one embodiment, the first survey questions 208, 212 and results are indicative of at least features 1-13 as provided in Table 1.

Referring to block 409, such as illustrated in fig. 7A-7C, in some embodiments, the first survey result indicates whether the individual is pregnant, nursing, or an individual who plans to become pregnant (e.g., an answer to survey questions 208 (such as questions 502 illustrated in fig. 5A), such as relating to and/or applying to a first category of pregnancy filter 216) (706)); whether the individual has type 1 diabetes (e.g., an answer to the survey question 208 that is associated with and/or applied to the type 1 diabetes filter 216 of the first category) (708); a ketoacidosis status of the individual (e.g., an answer to survey questions 208 related to and/or applied to a first category of ketoacidosis filters 216) (710); a renal disease status of the individual (e.g., an answer to the survey question 208 that is related to and/or applied to the first category of renal disease filter 216 (712)); an age of the individual (e.g., an answer to the survey question 208 that is related to and/or applied to the age filter of the first category 216 (716)); a blood glucose level of the individual (e.g., an answer to the survey question 208 that is associated with and/or applied to the first category of blood glucose filters 216 (718)); whether the individual has a liver question (e.g., an answer to the survey question 212 that is related to and/or applied to the liver disease filter of the second filter category 222 (720)); whether the individual has a history of urinary questions (e.g., answers to survey questions 212 related to and/or applied to the second category of urinary question filter 222 (722)); a surgical status of the individual (e.g., an answer to the survey question 212, which is related to and/or applied to the second category of surgical filters 222 (724)); a dietary status of the individual (e.g., an answer to the survey question 212 that is related to and/or applied to the second category of dietary filter 222 (726)); whether the individual has had a pancreatic question (e.g., an answer to the survey question 212, which is associated with and/or applied to the pancreatic disease filter of the second category 222 (728)); the alcohol consumption status of the subject (e.g., the answer to the survey question 212, which is associated with and/or applied to the second category of alcohol consumption filter 222 (730)) and whether the subject is using diabetes medication (e.g., the answer to the survey question 212, which is associated with and/or applied to the second category of diabetes medication filter 222 (732)).

In some embodiments, such as when the geragliflozin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition comprises dapagliflozin, the first plurality of findings further comprises whether the individual has had bladder cancer (e.g., an answer to the survey question 208 that is associated with and/or applied to the first category of bladder cancer filter 216) (714).

In some embodiments, such as when the giragliflozin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition comprises canagliflozin, the first plurality of findings further comprises the subject's history of heart failure, the subject's history of resection, the subject's history of leg neuropathy, the subject's history of diabetic foot ulcers, and the subject's history of hyperkalemia (e.g., answers to survey questions 210 related to and/or applied to a second category of heart failure, resection, leg neuropathy, diabetic foot ulcer, and/or hyperkalemia filter 220).

In some embodiments, such as when the geragliflozin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition comprises egagliflozin, the first plurality of findings further comprises the subject's history of resection, the subject's history of leg neuropathy, and the subject's history of diabetic foot ulcers (e.g., answers to survey questions 210 related to and/or applied to the second category of resection, leg neuropathy, and/or diabetic foot ulcer filters 220).

In some embodiments, the first survey comprises a question that elicits an answer that provides some or all of the features listed in table 1. In some embodiments, the survey includes questions corresponding to each of the survey results required by the methods described herein. In other embodiments, the survey includes questions corresponding to only a subset of the survey results required by the methods described herein. In some such embodiments, other survey results required by the methods described herein are obtained by other means (e.g., from medical professionals, previous surveys, pharmacy-related data, electronic health records related to individuals, individual profile data store 232, etc., when registering/ordering services related to qualifying individuals for over-the-counter medications). For example, in some embodiments, an individual provides a personal medical identification associated with an insurance company, hospital, or other medical professional, and obtains information about the individual, such as one or more findings, required by the methods described herein from a pre-existing database associated with the personal medical identification (e.g., the individual's most recently determined blood glucose measurement).

TABLE 1 example characteristics for identifying an individual's eligibility to receive an over-the-counter supply of a geqizin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition

Results	Example features
		1	Whether the individual is pregnant, lactating or scheduled to become pregnant
2	Type 1 diabetes status in an individual
		3	Ketoacidosis status of a subject
4	Renal status of an individual
		5	Age of the individual
6	Blood glucose levels of an individual
		7	Whether an individual has liver problems
8	Whether or not the individual has ever had a urinary problem
		9	IndividualsSurgical status of
10	Individual dietary status
		11	Whether an individual has had a pancreatic problem
12	Alcohol consumption status of an individual
		13	Whether a subject is taking diabetes medication
14	History of heart failure in an individual
		15	History of resection of an individual
16	History of leg neuropathy in an individual
		17	History of diabetic foot ulcers in an individual
18	History of hyperkalemia in individuals
		19	Whether an individual is allergic to a pharmaceutical composition of a Gelidine sodium-glucose co-transporter 2 inhibitor
20	Whether or not the individual has ever suffered from bladder cancer

It is contemplated that in some embodiments, the first survey will not include any one or more of the survey questions 208, 212 provided in table 1, e.g., will not be used for evaluation. For example, in some embodiments, when an individual is identified for one particular gyragliflozin sodium-glucose co-transporter 2 inhibitor but not another gyragliflozin sodium-glucose co-transporter 2 inhibitor, the characteristics associated with the particular survey question will be informative. For example, in one embodiment, the method for identifying an individual for a pharmaceutical composition containing dapagliflozin comprises an investigative question as to whether the individual has ever suffered from bladder cancer, whereas the method for identifying an individual for a pharmaceutical composition containing egagliflozin does not have such a question, as prior bladder cancer is not an angagliflozin contraindication. One skilled in the art will recognize that different gliflozin sodium-glucose co-transporter 2 inhibitors have different risks, contraindications and drug interaction profiles. Thus, the survey information required to qualify an individual for use of one geletam sodium-glucose co-transporter 2 inhibitor with a known adverse drug interaction may not be necessary to qualify the same individual for use of a second geletam sodium-glucose co-transporter 2 inhibitor.

Thus, it is contemplated that first survey question 208 comprises any subset of the survey results provided in Table 1. For the sake of brevity, all possible combinations of the survey questions 208, 212 provided in table 1 are not specifically described herein. However, one of ordinary skill in the art will be able to contemplate any particular subset of the survey questions 208, 212 provided in table 1. Similarly, one skilled in the art may be aware of other survey questions not provided in table 1, which may be combined with any subset of the survey questions provided in table 1 to form the first survey question used in the methods described herein.

In some embodiments, the first and/or second survey is conducted by sending a plurality of questions to an individual (e.g., some or all of the survey questions) and receiving answers to the plurality of survey questions, then applying any answers to the respective filters. For example, referring to the workflow in fig. 7, the device sends questions related to all filters of the first category, all filters of the second category, or all filters in the workflow (e.g., in the form of a virtual survey where all questions are displayed in a single user interface, or in the form of a series of questions displayed in a continuous user interface). After receiving answers to all survey questions, the device then applies the answers to all filters (e.g., sequentially or simultaneously) to determine whether the individual is eligible to receive a supply of the geqin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition. In an alternative embodiment, the device sends questions (e.g., in the form of a virtual survey where such unanswered questions are all displayed in a single user interface, or in the form of a series of questions displayed in a continuous user interface) that are only related to the first category of filters (because the device is unable to obtain answers to the questions, such as an electronic health record for the individual, from an electronic database associated with the individual) and only related to the second category of filters (the device is unable to obtain answers to the questions from an electronic database associated with the individual). After receiving answers to all survey questions, the device then applies the answers to all filters (e.g., sequentially or simultaneously) to determine whether the individual is eligible to receive a supply of the geqin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition.

In some embodiments, the first and/or second survey is conducted in a continuous manner, such as by sending a first question or a first set of survey questions (e.g., associated with a single filter) to an individual, receiving answers to the single survey question or a small set of survey questions, and applying the one or more answers to the filter, followed by sending the second question or second set of questions to the individual. For example, referring to the workflow in fig. 7, in some embodiments, the apparatus sends a first question related to the individual's pregnancy and/or lactation status to the individual (e.g., question 502' of fig. 5A if do you are pregnant or plan to be pregnant. After receiving an answer (e.g., 'yes or no') to the survey question, the apparatus applies the answer to a first pregnancy filter (704). If the first pregnancy filter is activated (e.g., in response to the answer "yes"), the device terminates (703) the process and optionally provides a message to the user as to why he was denied the provision of the gyricon sodium-glucose co-transporter 2 inhibitor pharmaceutical composition (e.g., as illustrated in fig. 5B, a message 504 prompting the individual that use of the gyricon sodium-glucose co-transporter 2 inhibitor pharmaceutical composition will pose a risk to the fetus/infant).

In some embodiments, the first survey comprises a question that elicits an answer that provides some or all of the features listed in table 1. In some embodiments, the survey includes questions corresponding to each of the survey results required by the methods described herein. In other embodiments, the survey includes questions corresponding to only a subset of the survey results required by the methods described herein. In some embodiments, other survey results required by the methods described herein are obtained by other means (e.g., from medical professionals, previous surveys, databases associated with pharmacies, etc., when registering/ordering services related to qualifying individuals for over-the-counter medications). For example, in some embodiments, an individual provides a personal medical identification associated with an insurance company, hospital, or other medical professional, and obtains information about the individual, such as one or more findings, required by the methods described herein from a pre-existing database associated with the personal medical identification (e.g., the individual's most recently determined blood glucose measurement). The same applies to the second survey 210 and the corresponding results to the first survey 206.

Referring to block 410, in some embodiments, the first plurality of findings further includes whether the individual is allergic to a gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition. In some embodiments, and the first plurality of filters further comprises an adverse reaction filter that is activated when the first plurality of findings indicate that the individual is allergic to a gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition.

Referring to block 411, in some embodiments, the first plurality of findings further includes whether the individual has had bladder cancer (e.g., filter 7a in table 2). In some embodiments, and the first plurality of filters further comprises a bladder cancer filter that is activated when the first plurality of findings indicate that the individual has had bladder cancer.

Block 412-422 referring to block 412 of FIGS. 4B-4C, all or a portion of the first survey results are run against the first plurality of filters of the first category 214. As previously described, the first plurality of filters includes a subset of the filters 216 of the first filter category 214. When a respective filter of the first plurality of filters is activated (e.g., when the survey results indicate that the trigger condition 218 is satisfied), the individual is deemed not eligible for delivery of the gerlabel sodium-glucose co-transporter 2 inhibitor pharmaceutical composition and the method is terminated without delivery of the gerlabel sodium-glucose co-transporter 2 inhibitor pharmaceutical composition.

In some embodiments, when the method is terminated without delivering the gerlabel sodium-glucose co-transporter 2 inhibitor pharmaceutical composition, the individual is prevented from attempting to re-qualify for use the gerlabel sodium-glucose co-transporter 2 inhibitor pharmaceutical composition for a predetermined period of time (e.g., at least one day, at least one week, at least one month, etc.). This prevents individuals from abusing the systems and methods of the present disclosure.

With reference to blocks 413-422, a particular filter 216 of the first plurality of filters and the exemplary trigger condition 218 that caused the corresponding filter to be activated are described in detail.

In some embodiments, the first plurality of filters of first category 214 includes some or all of filters 216 listed in table 2. For example, in some embodiments, the first plurality of filter results indicates 2, 3, 4, 5, 6, or all 7 of the filters listed in table 2. In one embodiment, the first plurality of filters includes at least filters 1-6 as provided in table 2.

TABLE 2 example filters for contraindications related to identification of eligibility of an individual to receive over-the-counter supply of a Gelidine sodium-glucose co-transporter 2 inhibitor pharmaceutical composition

Filter	Example guidelines
		1a	First pregnancy filter
2a	Type 1 diabetes filter
		3a	First ketoacidosis filter
4a	Kidney disease filter
		5a	Age filter
6a	First blood sugar filter
		7a	Bladder cancer filter

It is contemplated that, in some embodiments, the first plurality of filters will not include any one or more of the filters 216 provided in table 2. For example, in some embodiments, when an individual is identified for one particular gyragliflozin sodium-glucose co-transporter 2 inhibitor but not another gyragliflozin sodium-glucose co-transporter 2 inhibitor, the characteristics associated with the particular finding will be informative. For example, when an individual is identified for a composition containing eggliflozin, it is informative whether the individual has a history of diabetic foot ulcers, but not when an individual is identified for a composition containing dapagliflozin.

Accordingly, it is contemplated that the first plurality of filters includes any subset of the filters 216 provided in table 2. Similarly, one of ordinary skill in the art may be aware of other filters 216 not provided in table 2, which may be combined with any subset of the filters 216 provided in table 2 to form the first plurality of filter results used in the methods described herein. For the sake of brevity, all possible combinations of the filters 216 provided in table 2 are not specifically described herein.

Referring to block 413 and 414 of FIG. 4B, in some embodiments, the first plurality of filters includes a first pregnancy filter (e.g., the first pregnancy filter 216-1 of FIG. 3 and/or the filter 1a of Table 2). In some embodiments, the first pregnancy filter is configured to be activated at least when the first plurality of findings indicate that the individual is pregnant or that the individual is nursing. In some embodiments, the first pregnancy filter is further configured to be activated when the individual plans to become pregnant within a predetermined time period. When the first pregnancy filter is initiated, the individual is not permitted to obtain the over-the-counter germline sodium-glucose co-transporter 2 inhibitor pharmaceutical composition (e.g., the method is terminated without authorizing provision of the germline sodium-glucose co-transporter 2 inhibitor pharmaceutical composition to the individual). For example, the device sends a prompt 502 to the individual, as illustrated in fig. 5A, and the device applies the individual's answer to the first pregnancy filter. If the individual's answer indicates that they are pregnant, that they are scheduled to be pregnant, that they are nursing or that they are scheduled to be nursing, a pregnancy filter is initiated and the method is terminated without authorizing the provision of the pharmaceutical composition of the geist sodium-glucose co-transporter 2 inhibitor to the individual. In some embodiments, the device sends a message explaining why authorization is denied, such as message 504 illustrated in fig. 5B.

Referring to block 415 of fig. 4B, in some embodiments, the first plurality of filters includes a type 1 diabetes filter (e.g., type 1 diabetes 216-2 in fig. 3 and/or filter 2a in table 2). The type 1 diabetes filter is configured to be activated at least when the first plurality of findings indicate that the individual has type 1 diabetes. If the type 1 diabetes filter is activated, the individual is not permitted to obtain the over-the-counter germline sodium-glucose co-transporter 2 inhibitor pharmaceutical composition (e.g., the method is terminated without authorizing the individual to be provided with the germline sodium-glucose co-transporter 2 inhibitor pharmaceutical composition).

Referring to block 416 of fig. 4B, in some embodiments, the first plurality of filters includes a first ketoacidosis filter (e.g., first ketoacidosis filter 216-3 in fig. 3 and/or filter 3a in table 2). The first ketoacidosis filter is configured to be activated at least when the first plurality of findings indicates that the individual has ketoacidosis. If the ketoacidosis filter is activated, the individual is not permitted to obtain the over-the-counter geridon sodium-glucose co-transporter 2 inhibitor pharmaceutical composition (e.g., the method is terminated without authorizing the individual to be provided with a geridon sodium-glucose co-transporter 2 inhibitor pharmaceutical composition).

Referring to block 417 of fig. 4B, in some embodiments, the first plurality of filters includes a kidney disease filter (e.g., kidney disease filter 216-4 in fig. 3 and/or filter 4a in table 2). In some embodiments, the renal disease filter is activated when the first plurality of findings indicate that the individual has renal disease. If the renal disease filter is activated, the individual is not permitted to obtain the over-the-counter germline sodium-glucose co-transporter 2 inhibitor pharmaceutical composition (e.g., the method is terminated without authorizing the individual to be provided with a germline sodium-glucose co-transporter 2 inhibitor pharmaceutical composition).

Referring to block 418-419 of fig. 4B, in some embodiments, the first plurality of filters includes an age filter (e.g., age filter 216-5 of fig. 3 and/or filter 5a of table 2). In some embodiments, the age filter is activated when the first plurality of findings indicates that the individual is less than eighteen years of age. If the age filter is activated, the individual is not permitted to obtain the over-the-counter germline sodium-glucose co-transporter 2 inhibitor pharmaceutical composition (e.g., the method is terminated without authorizing the individual to be provided with a germline sodium-glucose co-transporter 2 inhibitor pharmaceutical composition).

Referring to block 420-422 of FIG. 4B, in some embodiments, the first plurality of filters includes a first glucose filter (e.g., the first glucose filter 216-6 of FIG. 3 and/or the filter 6a of Table 2). In some embodiments, the first blood glucose filter is activated when the first plurality of findings indicates that the subject's blood glucose level is below a first baseline blood glucose level or above a maximum blood glucose level. If the first glycemic filter is activated, the individual is not permitted to obtain the over-the-counter germline sodium-glucose co-transporter 2 inhibitor pharmaceutical composition (e.g., the method is terminated without authorizing provision of the germline sodium-glucose co-transporter 2 inhibitor pharmaceutical composition to the individual). In some embodiments, the first baseline blood glucose level used in the first blood glucose filter is 6.5% glycated hemoglobin. In some embodiments, the maximum blood glucose level used in the first blood glucose filter is 7.5% glycated hemoglobin to 8% glycated hemoglobin.

Blocks 423 and 434 and 476 and 481 referring to blocks 423 of fig. 4C-4D, the method further includes running all or a portion of the first survey results for the second plurality of filters of the second category 220. When a respective filter of the second plurality of filters is activated, an alert 226 corresponding to the respective filter (e.g., filter alert 226-4 corresponding to filter 222-4) is provided to the individual. In some embodiments, the alert 226 is provided as a next step after the corresponding filter is activated, e.g., before applying the survey results to any subsequent filters. For example, with respect to fig. 7B-7C, in some embodiments, when the liver disease filter is triggered at 720, the device will provide a warning to the individual before proceeding to the drug interaction filter at 711, e.g., requiring the individual to confirm that they have discussed their liver disease history with a healthcare professional, e.g., and the healthcare professional still advises to use the gesicin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition. In some embodiments, the alert 226 is provided after the survey results are applied to all subsequent filters. For example, as illustrated in fig. 7B, in some embodiments, when the liver disease filter is triggered at 770, the device will proceed to the urinary problem filter at 722 before sending the alert to the individual, and then after applying the survey results to all subsequent filters, send all alerts corresponding to the second category of filters at 736, as illustrated in fig. 7C.

In some embodiments, the second plurality of filters 222 of the second category 220 includes some or all of the filters listed in table 3. For example, in some embodiments, the first plurality of filters includes 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or all 13 of the filters listed in table 3. In one embodiment, the first plurality of filters includes at least filters 1-7 as provided in table 3.

TABLE 3 example filters for risk factors associated with identifying an individual's eligibility to receive an over-the-counter supply of a geqizin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition

Referring to block 425, in some embodiments, the second plurality of filters includes a first liver disease filter (e.g., first liver disease filter 222-1 in fig. 3 and/or filter 1a in table 3). The first liver disease filter is configured to be activated at least when the first plurality of findings indicate that the individual has liver problems. In some embodiments, liver problems that can trigger the first liver disease filter include impaired liver function, acute liver failure, and cholestasis. When the first liver disease filter is activated, the device sends an alert corresponding to the first liver disease filter and requires the user to confirm the alert before authorizing the provision of the gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition.

Referring to block 426 and 427, in some embodiments, the second plurality of filters includes a first urinary problem filter (e.g., the first urinary problem filter 222-2 of FIG. 3 and/or the filter 2a of Table 3). The first urinary problem filter is configured to be activated at least when the first plurality of findings indicate that the individual has a history of urinary problems. When the first urinary problem filter is activated, the device sends an alert corresponding to the first urinary problem filter and requires the user to confirm the alert before authorizing the provision of the gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition. In some embodiments, the first urinary problem filter is also activated when the first plurality of findings indicate that the individual has a history of urinary tract infections or urination problems.

Referring to block 428, in some embodiments, the second plurality of filters includes a first surgical filter (e.g., first surgical filter 222-3 in fig. 3 and/or filter 3a in table 3). The first surgical filter is configured to be activated at least when the first plurality of findings indicate that the individual is planning to perform a surgery. When the first surgical filter is activated, the device sends an alert corresponding to the first surgical filter and requires the user to confirm the alert before authorizing the provision of the gerlabel sodium-glucose co-transporter 2 inhibitor pharmaceutical composition.

Referring to block 429-430 of fig. 4D, in some embodiments, the second plurality of filters includes a first diet filter (e.g., first diet filter 222-4 of fig. 3 and/or filter 4a of table 3). The first diet filter is configured to be activated at least when the first plurality of findings indicate a decrease in food intake of the individual. When the first dietary filter is activated, the device sends an alert corresponding to the first dietary filter and requires the user to confirm the alert before authorizing the provision of the gyragliflozin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition. In some embodiments, the first dietary filter is activated when the first plurality of findings indicate that the individual's food intake is decreasing due to disease, surgery, or recent dietary changes.

Referring to block 431, in some embodiments, the second plurality of filters includes a first pancreatic disease filter (e.g., first pancreatic disease filter 222-5 in fig. 3 and/or filter 5a in table 3). The first pancreatic disorder filter is configured to be activated at least when the first plurality of findings indicate that the individual has a pancreatic problem. When the first pancreatic disorder filter is activated, the device sends an alert corresponding to the first pancreatic disorder filter and requires the user to confirm the alert before authorizing the provision of the gerlabel sodium-glucose co-transporter 2 inhibitor pharmaceutical composition.

Referring to block 432-433, in some embodiments, the second plurality of filters includes a first alcohol consuming filter (e.g., first alcohol consuming filter 222-6 in FIG. 3 and/or filter 6a in Table 3). When the first alcohol consumption filter is activated, the device sends an alert corresponding to the first alcohol consumption filter and requires the user to confirm the alert before authorizing the provision of the gyragliflozin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition. In some embodiments, the first alcohol-consuming filter is activated when the first plurality of findings indicate that the individual consumes, on average, at least the predetermined number of alcoholic beverages over the predetermined time period.

Referring to block 434, in some embodiments, the second plurality of filters includes a first diabetes drug filter (e.g., first diabetes drug filter 222-7 in fig. 3 and/or filter 7a in table 3). The first diabetes drug filter is configured to be activated at least when the first plurality of findings indicate that the subject is using diabetes drug. When the first diabetic drug filter is activated, the device sends an alert corresponding to the first diabetic drug filter and requires the user to confirm the alert before authorizing the provision of the gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition.

Referring to block 476-478 of FIG. 4K, in some embodiments, the geragliflozin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition comprises canagliflozin. When the giragliflozin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition comprises canagliflozin, the second plurality of filters further comprises a heart failure filter (e.g., filter 9a in table 3), an ablation filter (e.g., filter 10a in table 3), a leg neuropathy filter (e.g., filter 11a in table 3), a diabetic foot ulcer filter (e.g., filter 12a in table 3), and a hyperkalemia filter (e.g., filter 13a in table 3). In some embodiments, the heart failure filter is activated when the first plurality of findings indicates that the individual has a history of heart failure. In some embodiments, the resection filter is triggered at least when the first plurality of findings indicate that the individual has undergone a body part resection. In some embodiments, the leg neuropathy filter is triggered at least when the first plurality of findings indicate that the individual has leg neuropathy. In some embodiments, the diabetic foot ulcer filter is triggered at least when the first plurality of findings indicate that the individual has a diabetic foot ulcer. In some embodiments, the hyperkalemia filter is triggered at least when the first plurality of findings indicate that the individual has hyperkalemia.

Referring to blocks 479-481 of figure 4K, in some embodiments, the geragliflozin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition comprises egagliflozin. When the gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition comprises eggliflozin, the second plurality of filters further comprises an amputation filter (e.g., filter 10a in table 3), a leg neuropathy filter (e.g., filter 11a in table 3), and a diabetic foot ulcer filter (e.g., filter 12a in table 3). In some embodiments, the resection filter is triggered at least when the first plurality of findings indicate that the individual has undergone a body part resection. In some embodiments, the leg neuropathy filter is triggered at least when the first plurality of findings indicate that the individual has leg neuropathy. In some embodiments, the diabetic foot ulcer filter is triggered at least when the first plurality of findings indicate that the individual has a diabetic foot ulcer.

It is contemplated that, in some embodiments, the second plurality of filters will not include any one or more of the filters provided in table 3. For example, in some embodiments, when an individual is identified for one particular germyl sodium-glucose co-transporter 2 inhibitor pharmaceutical composition but not another germyl sodium-glucose co-transporter 2 inhibitor pharmaceutical composition, the characteristics associated with the particular finding will be informative. Accordingly, it is contemplated that the second plurality of filters includes any subset of the filters provided in table 3. Similarly, one skilled in the art may be aware of other filters not provided in table 3 that may be combined with any subset of the filters provided in table 3 to form a second plurality of filter results used in the methods described herein.

The contraindications and risk factors described in this disclosure are not exhaustive. One skilled in the art may know other contraindications for a particular gerlabel sodium-glucose co-transporter 2 inhibitor pharmaceutical composition and/or consider risk factors as contraindications depending on the intended use of the gerlabel sodium-glucose co-transporter 2 inhibitor pharmaceutical composition. In some embodiments, when an individual is qualified for lower dose OTC use of a geiin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition, contraindications for use of a prescription strength medicament are considered only as risk factors, or not at all.

Thus, it should be appreciated that the survey questions 208, 212 and the filters 216, 222 applied to their survey answers may vary depending on the assigned geremin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition. This is due to differences in contraindication profiles of the various geiletin sodium-glucose co-transporter 2 inhibitor pharmaceutical compositions, e.g. due to different drug-drug interactions, drug clearance pathways, etc. of different geiletin sodium-glucose co-transporter 2 inhibitor pharmaceutical compositions. For example, administration of canagliflozin to patients with moderate renal insufficiency causes a higher incidence of hyperkalemia. Mikhail, "Current Security," 9: 127-. However, administration of dapagliflozin is not associated with an increased risk of hyperkalemia. Thus, in some embodiments, an investigation qualifying an individual for OTC use of canagliflozin may ask whether the individual has a history of hyperkalemia, while an investigation qualifying an individual for OTC use of dapagliflozin may not ask the question.

Referring to block 435 of fig. 4D, the method includes obtaining confirmation from the individual of any alerts 226 sent to the individual by any of the second plurality of filters 222.

Referring to block 424, in some embodiments, the alert 226 corresponding to the respective filter 222 of the second plurality of filters includes a prompt for the individual to indicate, for example, whether it discusses the potential risk factor of the activated respective filter of the second plurality of filters with a healthcare practitioner (e.g., a healthcare practitioner holding the practitioner), and whether the healthcare practitioner indicates that the individual should use the giridol sodium-glucose co-transporter 2 inhibitor pharmaceutical composition in view of the potential risk factor. Thus, confirmation is obtained from the individual when the individual indicates that he has discussed the potential risk factors for the activated respective filter of the second plurality of filters with the healthcare professional. For example, message 602 in FIG. 6 illustrates an alert generic to any filter that is activated. In some embodiments, the alert is specific to a particular filter (e.g., filter alert 226 in FIG. 2), informing the user why the filter was activated.

In some embodiments, the confirmation from the user is verified by the healthcare practitioner (e.g., the method requires verification in order to authorize the provision of the geremin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition), for example to verify the accuracy of the individual's survey results. In some embodiments, the individual is considered a trusted individual when the confirmation is verified by the healthcare practitioner, and therefore there is no need to verify future results.

Block 436-. In some embodiments, the fulfillment process comprises storing in the individual profile 232 an indication of the date of the initial order and/or the location of the dose of the gerlabel sodium-glucose co-transporter 2 inhibitor pharmaceutical composition. For example, the status of the re-supply of the gerzin sodium-glucose co-transporter 2 inhibitor is at least verified using the initial order date. For example, the date of the initial subscription is also used to verify at least the time period elapsed between the initial subscription and future re-subscriptions. Such verification is required to ensure that certain tests (e.g., blood glucose tests) are performed regularly.

The fulfillment process further includes communicating to the individual an over-the-counter drug fact label 230 for a gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition. In some embodiments, the medication fact tag is communicated to the individual in real-time, e.g., within the same user interface as used for the authentication process. In some embodiments, over-the-counter drug fact label 230 specifies the use of the gerlabel sodium-glucose co-transporter 2 inhibitor pharmaceutical composition (e.g., lowering blood glucose, treating diabetes, etc.) and any risks associated with the use of the gerlabel sodium-glucose co-transporter 2 inhibitor pharmaceutical composition (e.g., drug-drug interactions, pharmacokinetic interactions, adverse reactions, etc.). For example, in some embodiments, the over-the-counter drug fact label 230 specifies that the individual use the geremin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition at a daily predetermined dose of 5mg to 10mg per day (block 438). In another example embodiment, the over-the-counter drug fact label 230 specifies that the individual use the gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition at a daily pre-determined dose of 5mg per day (block 439).

Referring to block 440-441 of FIG. 4E, in some embodiments, fulfillment further comprises authorizing provision of the gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition to the individual. Authorization occurs after the individual confirms that the individual has received and read the over-the-counter medication fact label 230. In some embodiments, the authorization includes a pharmacy associated with the individual. In some embodiments, the medication dispense locations associated with an individual are stored in an individual profile 232. In some embodiments, the pharmacy associated with the individual is a physical address, including a street address, a post office box, a pharmacy associated with the individual, a healthcare professional associated with the individual, and/or one or more coordinates (e.g., longitude, latitude, altitude). In some embodiments, providing the subject with the gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition includes transporting the gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition to a physical address associated with the subject (block 441). In some embodiments, providing the individual with a gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition comprises transporting the gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition to a pharmacy and/or location associated with a healthcare professional of the individual and/or an office of a medical practitioner associated with the individual.

Block 442-475 with reference to block 442-475 of FIGS. 4E-4K, the re-fulfillment process is described below. In some embodiments, the present disclosure provides methods for identifying an individual as eligible for a re-supplementation of a geqizin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition. In some embodiments, the identification of a re-supplement to a gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition is performed after an initial identification of the individual, as described herein. In some embodiments, the identifying of the re-supplementation of the gerlabel sodium-glucose co-transporter 2 inhibitor pharmaceutical composition is performed after the prescribing of the gerlabel sodium-glucose co-transporter 2 inhibitor pharmaceutical composition to the individual. For example, in some embodiments, the individual who first undergoes the identification process is asked whether it has previously received a prescription for a geigelean sodium-glucose co-transporter 2 inhibitor pharmaceutical composition and if the individual indicates that it has not previously received a prescription, an initial identification method is used for the individual and if the individual indicates that it has previously received a prescription, a re-supplemental identification method is used for the individual, such as described below.

Referring to block 442 of fig. 4E, in some embodiments, a re-fulfillment process is performed. The re-fulfillment process is in response to receiving a re-order request from the individual for a gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition. In some embodiments, a prompt to initiate a re-fulfillment procedure is sent to the user device 102 associated with the individual after a predetermined amount of time associated with the duration of the dose previously delivered to the individual, such as to remind the user to fulfill an order for their gesicin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition immediately before the user will be scheduled to run out of the previously delivered supply or after the user is scheduled to run out of the previously delivered supply.

Referring to blocks 443-444 of FIG. 4F, in some embodiments, the re-fulfillment process includes conducting a second survey of the individual. The second survey is configured to obtain a second plurality of survey results. These results are derived from respective survey questions (e.g., the device sends one or more survey questions to the user, prompts for answers, and then receives answers to the one or more survey questions from the individual). In some embodiments, the second plurality of survey results indicate some or all of the features listed in table 4. For example, in some embodiments, the second plurality of survey results indicate 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or all 21 of the features listed in table 4. In one embodiment, the second survey question and result is indicative of at least features 1-11 as provided in Table 4.

In some embodiments, the second survey result comprises at least one of: whether the individual is pregnant, nursing, or an individual who is scheduled to become pregnant (e.g., an answer to an investigational question associated with and/or applied to a second pregnancy filter of the first category 214-2 (812)); whether the subject has developed ketoacidosis (e.g., an answer to a survey question associated with and/or applied to a ketoacidosis filter of the first category 214-2) after receiving its last supply of a geletam sodium-glucose co-transporter 2 inhibitor pharmaceutical composition (814)); whether an individual has developed a renal question (e.g., an answer to a survey question associated with and/or applied to a renal question filter of the first category 214-2) after receiving its last supply of a germlined sodium-glucose co-transporter 2 inhibitor pharmaceutical composition (816)); whether or not the individual has developed a urinary tract infection (e.g., an answer to a survey question associated with and/or applied to a second urinary problem filter of the first category 214-2) after receiving its last supply of a geqin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition (818)); whether the individual is experiencing physical stress (e.g., an answer to a survey question related to and/or applied to a physical stress filter of the first category 214-2) (838); whether the subject is using diabetes medication (e.g., an answer to a survey question associated with and/or applied to a second diabetes medication filter of the first category 214-2 (840)); whether an individual has developed a liver question (e.g., an answer to a survey question related to and/or applied to a second liver disease filter of a second category 220-2) after receiving their last supply of a germlined sodium-glucose co-transporter 2 inhibitor pharmaceutical composition (824)); whether the individual is planning to perform surgery (e.g., an answer to a survey question related to and/or applied to a second surgical filter of a second category 220-2 (826)); whether the subject has a reduced food intake after receiving their last supply of the gerlabel sodium-glucose co-transporter 2 inhibitor pharmaceutical composition (e.g., an answer to a survey question associated with and/or applied to a second dietary filter of a second class 220-2 (828)); whether the individual has developed a pancreatic question (e.g., an answer to a survey question associated with and/or applied to a second pancreatic disease filter of a second category 220-2) after receiving its last supply of a germling sodium-glucose co-transporter 2 inhibitor pharmaceutical composition (830)); an alcohol consumption status of the individual (e.g., an answer to a survey question related to and/or applied to a second alcohol consumption filter of a second category 220-2 (832)); whether the individual experienced a yeast infection after receiving its last supply of the geilezine sodium-glucose co-transporter 2 inhibitor pharmaceutical composition (e.g., an answer to a survey question associated with and/or applied to a yeast infection filter of the second class 220-2) and whether the individual experienced hypoglycemia after receiving its last supply of the geilezine sodium-glucose co-transporter 2 inhibitor pharmaceutical composition (e.g., an answer to a survey question associated with and/or applied to a hypoglycemic symptoms filter of the second class 220-2) (836).

In some embodiments, for example, when the geragliflozin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition comprises canagliflozin, the second plurality of findings further comprises one or more of: whether or not an individual has experienced heart failure after receiving its last supply of a pharmaceutical composition of geilizin sodium-glucose co-transporter 2 inhibitor; whether the individual has undergone a body site excision after receiving its last supply of a pharmaceutical composition of a geletam sodium-glucose co-transporter 2 inhibitor; whether an individual has developed leg neuropathy after receiving their last supply of a pharmaceutical composition of a geilizin sodium-glucose co-transporter 2 inhibitor; whether or not an individual has developed a diabetic foot ulcer after receiving its last supply of a pharmaceutical composition of a geilizin sodium-glucose co-transporter 2 inhibitor; and whether the subject develops hyperkalemia after receiving its last supply of a pharmaceutical composition of a gelidine sodium-glucose co-transporter 2 inhibitor.

In some embodiments, for example when the gerliptin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition comprises eggliflozin, the second plurality of findings further comprises one or more of: whether the individual has undergone a body site excision after receiving its last supply of a pharmaceutical composition of a geletam sodium-glucose co-transporter 2 inhibitor; whether an individual has developed leg neuropathy after receiving their last supply of a pharmaceutical composition of a geilizin sodium-glucose co-transporter 2 inhibitor; whether or not an individual has developed a diabetic foot ulcer after receiving its last supply of a pharmaceutical composition of geilizin sodium-glucose co-transporter 2 inhibitor.

In some embodiments, for example when the gemiflozin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition comprises dapagliflozin, the first plurality of findings further comprises whether the individual has developed bladder cancer after receiving its last supply of the gemiflozin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition.

In some embodiments, the second survey comprises questions that elicit responses that provide some or all of the features listed in table 4. In some embodiments, the second survey includes questions corresponding to each of the survey results required by the methods described herein. In other embodiments, the second survey comprises questions corresponding to only a subset of the survey results required by the methods described herein. In such embodiments, other survey results required by the methods described herein are obtained by other means (e.g., from healthcare professionals, previous surveys, databases associated with pharmacies, etc., when registering/ordering services related to qualifying individuals for over-the-counter medications). For example, in some embodiments, an individual provides a personal medical identification associated with an insurance company, hospital, or other healthcare professional, and obtains information about the individual, such as one or more findings, required by the methods described herein from a pre-existing database associated with the personal medical identification (e.g., the individual's most recently determined blood glucose measurement).

TABLE 4 example characteristics for identifying an individual's eligibility to receive an over-the-counter supply of a gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition

It is contemplated that in some embodiments, the second survey will not include any one or more of the survey questions provided in table 4 (e.g., will not be used for re-evaluation). For example, in some embodiments, when an individual is identified for one particular gyragliflozin sodium-glucose co-transporter 2 inhibitor but not another gyragliflozin sodium-glucose co-transporter 2 inhibitor, the characteristics associated with the particular survey question will be informative. For example, a survey question for canagliflozin qualification surveys, rather than anggliflozin qualification surveys, is asked. One skilled in the art will recognize that different gliflozin sodium-glucose co-transporter 2 inhibitors have different risks and drug interaction profiles. Thus, the survey information required to qualify an individual for use of one geletam sodium-glucose co-transporter 2 inhibitor with a known adverse drug interaction may not be necessary to qualify the same individual for use of a second geletam sodium-glucose co-transporter 2 inhibitor.

Thus, it is contemplated that the second survey question elicits a response to any subset of the survey results provided in table 4. For the sake of brevity, all possible combinations of the features provided in table 4 are not specifically described herein. However, one of ordinary skill in the art will be readily able to envision any specific subset of survey questions designed to elicit a response to any subset of the features provided in table 4. Similarly, other survey questions not provided in table 4 may be known to one of ordinary skill in the art, which may be combined with any subset of the survey questions provided in table 4 to form a second survey question used in the methods described herein.

Referring to block 445 of FIG. 4F, all or a portion of the results are run for the third plurality of filters of the first class. When a respective filter of the third plurality of filters is activated (e.g., when the survey results indicate that the trigger condition 218 is satisfied), the individual is deemed not eligible for a gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition and the method is terminated without delivery of the gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition.

Specific filters of the third plurality of filters and exemplary trigger conditions that cause the corresponding filters to be activated are described in detail with reference to blocks 445-456 of FIGS. 4F-4H.

In some embodiments, the third plurality of filters of first category 214 includes some or all of filters 216 listed in table 5. For example, in some embodiments, the first plurality of filters includes 2, 3, 4, 5, 6, or all 7 of the filters listed in table 5. In one embodiment, the first plurality of filters includes at least filters 1-6 as provided in table 5.

TABLE 5 example filters for contraindications related to re-qualification of an individual to receive over-the-counter supply of a Gerostine sodium-glucose co-transporter 2 inhibitor pharmaceutical composition

Filter	Example guidelines
		1a	Pregnant filter
2a	Ketoacidosis filter
		3a	Kidney filter
4a	Urinary problem filter
		5a	Body pressure filter
6a	Diabetes medicine filter
		7a	Blood sugar state filter

In one embodiment, the third plurality of filters includes at least filters 1a-6a as provided in Table 5. In another embodiment, the third plurality of filters includes at least filters 1a-7a as provided in Table 5.

It is contemplated that, in some embodiments, the third plurality of filters will not include any one or more of the filters provided in table 5. For example, in some embodiments, when an individual is identified for one particular gyragliflozin sodium-glucose co-transporter 2 inhibitor but not another gyragliflozin sodium-glucose co-transporter 2 inhibitor, the characteristics associated with the particular finding will be informative. Similarly, other filters not provided in table 5 may be known to those of skill in the art, which may be combined with any subset of the filters provided in table 5 to form a third plurality of filter results for use in the methods described herein. For the sake of brevity, all possible combinations of the filters provided in table 5 are not specifically described herein.

Referring to blocks 446 and 447, in some embodiments, the third plurality of filters includes a pregnancy filter, such as described above with respect to the first pregnancy filter 216-1. In some embodiments, the second pregnancy filter is configured to be activated at least when the first plurality of findings indicate that the individual is pregnant or that the individual is nursing. In some embodiments, the second pregnancy filter is further configured to be activated when the individual plans to become pregnant within a predetermined time period. When the second pregnancy filter is activated, the individual is not permitted to obtain the over-the-counter germline sodium-glucose co-transporter 2 inhibitor pharmaceutical composition (e.g., the method is terminated without authorizing a further supply of the germline sodium-glucose co-transporter 2 inhibitor pharmaceutical composition to the individual).

Referring to blocks 448- _ 449, in some embodiments, the third plurality of filters includes ketoacidosis filters. In some embodiments, the ketoacidosis filter is configured to be activated at least when the second plurality of findings indicate that the individual has developed ketoacidosis after receiving its last supply of the geist sodium-glucose co-transporter 2 inhibitor pharmaceutical composition. In some embodiments, the second plurality of findings indicates that the individual has developed ketoacidosis when the second plurality of findings indicates that the individual has been diagnosed with ketoacidosis after receiving its last supply of the geist sodium-glucose co-transporter 2 inhibitor pharmaceutical composition. In some embodiments, when the second plurality of findings indicate that the individual experienced symptoms of ketoacidosis (e.g., new and/or worsening symptoms) after receiving its last supply of the geist sodium-glucose co-transporter 2 inhibitor pharmaceutical composition, the second plurality of findings indicate that the individual developed ketoacidosis, such as an increase in ketone in the blood of the individual, an increase in ketone in the urine of the individual, nausea, fatigue, vomiting, dyspnea, and/or abdominal pain.

Referring to block 450-451, in some embodiments, the third plurality of filters includes a renal problem filter. In some embodiments, the renal problem filter is configured to be activated at least when the second plurality of findings indicate that the individual has a renal problem following receipt of their last supply of the gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition. In some embodiments, when the findings indicate that the individual was diagnosed with a renal problem after receiving its last supply of the pharmaceutical composition of geqizin sodium-glucose co-transporter 2 inhibitor, the second plurality of findings indicates that the individual has a renal problem. In some embodiments, when the findings indicate that the individual experiences symptoms of renal problems (e.g., new and/or worsening symptoms), the second plurality of findings indicate that the individual has suffered renal problems, such as a decrease in the individual's food intake, a decrease in the individual's water intake, vomiting, diarrhea, and/or dehydration.

Referring to block 452 and 453, in some embodiments, the third plurality of filters includes a second urinary problem filter, such as described above with respect to the first urinary problem filter 222-2. In some embodiments, the second urinary problem filter is configured to be activated at least when the second plurality of findings indicate that the individual experienced symptoms of a urinary tract infection problem after receiving its last supply of the geqizin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition. In some embodiments, the symptom of the urinary problem capable of activating the urinary problem filter is selected from the group consisting of: burning sensation during urination, increased urge to urinate, pelvic pain, hematuria, fever, back pain, nausea and vomiting. In some embodiments, when the findings indicate that the individual was diagnosed with a urinary tract infection after receiving its last supply of the gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition, the second plurality of findings indicates that the individual experienced symptoms of the urinary tract infection.

Referring to block 454 and 455, in some embodiments, the third plurality of filters includes a body pressure filter. In some embodiments, the physical stress filter is configured to be activated at least when the second plurality of findings indicate that the individual is experiencing physical stress. In some embodiments, the body pressure capable of activating the body pressure filter is selected from the group consisting of: fever, recent trauma, infection, and recent surgery.

Referring to block 456 of fig. 4H, in some embodiments, the third plurality of filters includes a second diabetes drug filter, such as described above with respect to the first diabetes drug filter 222-7. In some embodiments, the second diabetes drug filter is configured to be activated at least when the second plurality of findings indicate that the subject is using diabetes drug.

Referring to block 457-466 of FIGS. 4H-4I, the method further includes running all or a portion of the second survey against a fourth plurality of filters of the second category 220-2. Providing an alert to the individual corresponding to a respective filter of the fourth plurality of filters when the respective filter is activated. In some embodiments, after the respective filter is activated, an alert is provided as a next step, e.g., before applying the survey results to any subsequent filters. For example, with respect to fig. 8A-8D, in some embodiments, when the bladder cancer filter is triggered at 818, the device will send an alert to the individual before proceeding to the renal problem filter at 820, e.g., requiring the individual to confirm that he is discussing his bladder cancer with a healthcare professional at 803 and the healthcare professional still advises to use the gliflozin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition. In some embodiments, the alert is provided after the survey results are applied to all subsequent filters. For example, in some embodiments, when the alcohol consumption filter is triggered at 832, the device will proceed to the urinary problem filter at 834 before sending an alert to the individual, and then after applying the survey results to all subsequent filters, all alerts corresponding to the second category of filters occur at 844.

In some embodiments, the fourth plurality of filters of the second category 220-2 includes some or all of the filters listed in table 6. For example, in some embodiments, the fourth plurality of filters comprises 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or all 13 of the filters listed in table 6.

TABLE 6 example filters for risk factors associated with re-qualifying an individual to receive an over-the-counter supply of a geqizin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition

In one embodiment, the fourth plurality of filters includes at least filters 1a-6a as provided in table 6. It is contemplated that, in some embodiments, the fourth plurality of filters will not include any one or more of the filters provided in table 6. For example, in some embodiments, when an individual is identified for one particular germyl sodium-glucose co-transporter 2 inhibitor pharmaceutical composition but not another germyl sodium-glucose co-transporter 2 inhibitor pharmaceutical composition, the characteristics associated with the particular finding will be informative. Accordingly, it is contemplated that the fourth plurality of filters includes any subset of the filters provided in table 6. Similarly, one skilled in the art may be aware of other filters not provided in table 6 that may be combined with any subset of filters 222 provided in table 6 to form a fourth plurality of filter results used in the methods described herein.

Referring to block 458 of fig. 4H, in some embodiments, the fourth plurality of filters includes a second liver disease filter, such as described above with respect to the first liver disease filter 222-1. In some embodiments, the second liver disease filter is configured to be activated at least when the second plurality of findings indicate that the individual has a liver problem after receiving its last supply of the gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition. In some embodiments, the second plurality of findings indicates that the individual has a liver problem when the second plurality of findings indicates that the individual has been diagnosed with a liver problem after receiving its last supply of the geqizin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition.

Referring to block 459, in some embodiments, the fourth plurality of filters includes a second surgical filter, such as described above with respect to first surgical filter 222-3. In some embodiments, the second surgical filter is configured to be activated at least when the second plurality of findings indicate that the individual is planning to perform surgery.

Referring to block 460, in some embodiments, the fourth plurality of filters includes a second diet filter, such as described above with respect to first diet filter 222-4. In some embodiments, the second dietary filter is configured to be activated at least when the second plurality of findings indicate that the individual has a lesser amount of food intake after receiving their last supply of the geqin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition.

Referring to block 461, in some embodiments, the fourth plurality of filters includes a second pancreatic disease filter, such as described above with respect to the first pancreatic disease filter 222-5. In some embodiments, the second pancreatic disorder filter is configured to be activated at least when the second plurality of findings indicate that the individual has a pancreatic problem after receiving its last supply of the gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition. In some embodiments, when the findings indicate that the individual was diagnosed with a pancreatic problem after receiving their last supply of the geqizin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition, the second plurality of findings indicates that the individual has a pancreatic problem. In some embodiments, when the findings indicate that the individual experiences symptoms of pancreatic problems (e.g., new and/or worsening symptoms), the second plurality of findings indicate that the individual has developed pancreatic problems, such as abdominal tenderness and swelling, nausea and vomiting, and/or epigastric pain, including pain radiating to the back of the individual.

Referring to block 462, in some embodiments, the fourth plurality of filters includes a second alcohol-consuming filter, such as described above with respect to the first alcohol-consuming filter 222-6. In some embodiments, the second alcohol consumption filter is configured to be activated at least when the second plurality of findings indicate that the individual consumes at least the predetermined number of alcoholic beverages, on average, over a predetermined time period. In some embodiments, the second alcohol consumption filter is configured to be activated at least when the second plurality of findings indicate that the individual abuses alcohol.

Referring to block 463-464 of fig. 4I, in some embodiments, the fourth plurality of filters comprises a yeast infection filter configured to be activated at least when the second plurality of findings indicate that the individual experienced a yeast infection after receiving its last supply of the gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition. In some embodiments, when the findings indicate that the individual was diagnosed with a yeast infection problem after receiving its last supply of the geqizin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition, the second plurality of findings indicates that the individual experienced a yeast infection. In some embodiments, when the findings indicate that the individual experiences a symptom of yeast infection (e.g., a new and/or worsening symptom), the second plurality of findings indicate that the individual experiences a yeast infection, the symptom being, for example, a sore throat, an increase in urge to urinate, an increase in urine volume, and/or an increase in urge to urinate during the night.

Referring to block 465-466, in some embodiments, the fourth plurality of filters comprises a hypoglycemic symptoms filter configured to be activated at least when the second plurality of findings indicate that the individual experienced hypoglycemia after receiving its last supply of the sodium-glucose co-transporter 2 inhibitor pharmaceutical composition. In some embodiments, when the findings indicate that the individual experiences symptoms of hypoglycemia (e.g., new and/or worsening symptoms), the second plurality of findings indicate that the individual is experiencing hypoglycemia, the symptoms being, for example, shivering, sweating, increased heartbeat, change in vision, increased hunger, headache, and/or changes in mood.

Referring to block 467, in some embodiments, the method further comprises obtaining a confirmation from the individual of each alert sent to the individual by any of the fourth plurality of filters. As described with respect to the alert sent in conjunction with the second plurality of filters of the second category, in some embodiments, the alert includes a potential risk factor prompting the individual to indicate whether they have discussed the activated respective filter of the second plurality of filters with a healthcare practitioner (e.g., a healthcare practitioner) that, for example, and in view of the potential risk factor, the healthcare practitioner indicates that the individual should continue to use the gyragliflozin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition. Thus, confirmation is obtained from the individual when the individual indicates that he has discussed the potential risk factors for the activated respective filter of the fourth plurality of filters with the healthcare professional.

In some embodiments, when a respective filter of the third plurality of filters or the fourth plurality of filters is activated, a record is created relating to the activation of the respective filter (e.g., to record an adverse event that needs to be reported to a regulatory agency). This record is stored in an adverse event module 242 that includes a record of filter initiation events associated with a plurality of individuals (e.g., a set of adverse events associated with a gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition in an entire population of individuals using an over-the-counter gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition). In some embodiments, an indication of an adverse event is communicated to a third party (e.g., a medical practitioner associated with the individual, a healthcare professional of the individual, and/or a manufacturer/promoter of the gemiflozin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition). In some embodiments, the indication is automatically stored in the adverse events module 242 when submitted by the individual as part of the second survey.

Referring to block 468 of fig. 4J, in some embodiments, the process further includes conducting a restocking process when the restocking process has not terminated due to the start of a filter of the third plurality of filters (e.g., the second pregnant filter). To complete the re-fulfillment process, the individual is asked to confirm each alert associated with each activated filter 222 in the fourth plurality of filters.

Referring to block 469, in some embodiments, the fulfillment process further includes storing in the individual profile 232 of the individual an indication of a reordering of the gesicyn sodium-glucose co-transporter 2 inhibitor pharmaceutical composition. The fulfillment process further includes communicating to the individual an over-the-counter drug fact label 230 for a gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition. As previously described, communication of over-the-counter medication fact label 230 may be made in a variety of ways. After the individual confirms that the over-the-counter medication fact label 230 has been received and read, the method includes authorizing the individual to reorder a supply of the gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition. In some embodiments, this reorder includes the individual's pharmacy.

Referring to block 470-. In some embodiments, the second blood glucose state is configured to be initiated at least when the second plurality of findings indicate that the blood glucose level of the individual is at least the second highest blood glucose level. In some embodiments, the second highest blood glucose level used in the second blood glucose filter is a value selected from 6.5% to 7.5% glycated hemoglobin. In some embodiments, the second highest blood glucose level used in the second blood glucose filter is 7% glycated hemoglobin.

Referring to block 472-473, in some embodiments, the reiteration process further includes obtaining the glycemic status of the individual in a second plurality of findings and further includes a second glycemic filter in a third plurality of filters, such as described above with respect to the first glycemic status of the individual 216-6. In some embodiments, the second blood glucose state is configured to be initiated at least when the second plurality of findings indicate that the blood glucose level of the individual is at least the second highest blood glucose level. In some embodiments, the second highest blood glucose level used in the second blood glucose filter is a value selected from 6.5% to 7.5% glycated hemoglobin. In some embodiments, the second highest blood glucose level used in the second blood glucose filter is 7% glycated hemoglobin.

Referring to block 474, in some embodiments, the second plurality of findings further comprises whether the individual experienced dehydration symptoms after receiving their last supply of the gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition. In some embodiments, the fourth plurality of filters further comprises a dehydration filter that is activated at least when the second plurality of findings indicate that the individual experienced dehydration symptoms after receiving their last supply of the gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition. In some embodiments, the dehydration symptom capable of initiating a dehydration filter is selected from the group consisting of: dizziness, fainting, dizziness, and asthenia.

Referring to block 475 of fig. 4K, in some embodiments, such as when the geragliflozin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition comprises dapagliflozin, the second plurality of findings further comprises a bladder cancer status of the individual and, as such, the third plurality of filters further comprises a second bladder cancer filter that is initiated at least when the second plurality of findings indicate that the individual has developed bladder cancer after receiving its last supply of the geragliflozin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition.

Fig. 7 illustrates an example method (700) (e.g., with an electronic device) for identifying an individual's eligibility for an over-the-counter gyricon sodium-glucose co-transporter 2 inhibitor pharmaceutical composition. In some embodiments, the method of fig. 7 is used when the individual has not previously been identified for a drug. In some embodiments, the method of fig. 7 is used when the individual has previously been identified for a gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition, but a predetermined period of time has elapsed since the previous identification (e.g., the individual's last identification was more than one year ago).

Referring to FIG. 7, the device prompts (702) the individual to confirm the privacy notification. Because the present disclosure requires that the individual know and enter sensitive medical information (e.g., information that is accessible only to the individual and the medical practitioner), the privacy of this information is important. After the individual confirms that they have the privacy rights necessary to proceed, the device prompts (704) the user to confirm that they know their blood glucose level (e.g., because the individual must know their blood value to complete the identification process). If the individual indicates that he is not aware of his blood glucose level, the process terminates 701 without authorizing the provision of the gerzin sodium-glucose co-transporter 2 inhibitor agent, and optionally sends a recommendation to the user to return later, for example after he knows his blood glucose level. In some embodiments, the device does not prompt the user to confirm that they are known to be aware of their values, but includes an option to indicate that they are not aware of the values when querying the individual for a particular value. If the individual indicates that he or she knows his or her blood glucose level, the process continues.

The device prompts the individual to provide information about their pregnancy status and then applies (706) the answers received from the individual to the pregnancy filter. When the pregnancy filter is activated (e.g., when the answer indicates that the individual is pregnant, nursing, or scheduled to be pregnant), the device terminates (703) the identification process without authorizing the provision of the gyricon sodium-glucose co-transporter 2 inhibitor agent and optionally, sends a recommendation to the user as to how the gyricon sodium-glucose co-transporter 2 inhibitor agent should not be used.

When the pregnancy filter is not activated, the device performs an identification process, prompts the individual to indicate whether they have type 1 diabetes and then applies (708) the answer received from the individual to the type 1 diabetes filter. When the type 1 diabetes filter is activated (e.g., when the answer indicates that the individual has type 1 diabetes), the device terminates (703) the identification process without authorizing the provision of the gyragliflozin sodium-glucose co-transporter 2 inhibitor agent and, optionally, sends a recommendation to the user as to how the user should not use the gyragliflozin sodium-glucose co-transporter 2 inhibitor agent.

When the type 1 diabetes filter is not activated, the device performs an identification process, prompting the individual to provide their ketoacidosis status and then applies (710) the answers received from the individual to the ketoacidosis filter. When the ketoacidosis filter is activated (e.g., when the answer indicates that the individual has ketoacidosis), the device terminates (703) the identification process without authorizing the provision of the gyragliflozin sodium-glucose co-transporter 2 inhibitor agent and, optionally, sends a recommendation to the user as to how the gyragliflozin sodium-glucose co-transporter 2 inhibitor agent should not be used.

When the ketoacidosis filter is not activated, the device performs an identification procedure that prompts the individual to indicate whether they have a renal disease (712). When the renal disease filter is activated (e.g., when the answer to the prompt indicates that the individual has renal disease), the device terminates (703) the identification process without authorizing the provision of the gyragliflozin sodium-glucose co-transporter 2 inhibitor agent and, optionally, sends a recommendation to the user as to how the user should not use the gyragliflozin sodium-glucose co-transporter 2 inhibitor agent.

When the kidney disease filter is not activated, the device performs an identification process, prompts the individual to indicate whether they have bladder cancer and then applies (714) the answer received from the individual to the bladder cancer filter. When the bladder cancer filter is activated (e.g., when the answer to the prompt indicates that the individual has bladder cancer), the device terminates (703) the identification process without authorizing the provision of the gyricon sodium-glucose co-transporter 2 inhibitor agent and optionally sends a recommendation to the user as to how the user should not use the gyricon sodium-glucose co-transporter 2 inhibitor agent.

When the bladder cancer filter is not activated, the device performs an identification process, prompts the individual to indicate their age and then applies (716) the answers received from the individual to the age filter. When the age filter is activated (e.g., when the answer indicates that the individual's age is less than eighteen years), the device terminates (703) the identification process without authorizing the provision of the gyragliflozin sodium-glucose co-transporter 2 inhibitor medicament and optionally sends a recommendation to the user as to how the gyragliflozin sodium-glucose co-transporter 2 inhibitor medicament should not be used and/or returned when it reaches an age suitable for use of the gyragliflozin sodium-glucose co-transporter 2 inhibitor medicament.

The device performs an authentication process, prompts the individual to provide information about their blood glucose level and then applies (718) the answer received from the individual to the blood glucose filter. When the glucose filter is activated (e.g., when the answer indicates that the individual's blood glucose level is below a minimum blood glucose level or above a first maximum blood glucose level), the method terminates without authorizing the provision of the gyragliflozin sodium-glucose co-transporter 2 inhibitor medicament (701) and optionally sends a recommendation to the user to return later when its blood glucose level is within the minimum and maximum levels.

The device performs an authentication process that prompts the individual to indicate whether they have a liver disease and then applies (720) the answers received from the individual to the first liver disease filter. When the first liver disease filter is activated (e.g., when the answer indicates that the individual has a liver disease), an override procedure is initiated (711-1) (e.g., the device generates a record indicating that the user must confirm that he or she has been discussed with a healthcare professional in connection with using the geletam sodium-glucose co-transporter 2 inhibitor pharmaceutical composition).

The device performs an authentication process that prompts the individual to indicate whether they have a urinary problem and then applies (722) the answer received from the individual to the first urinary problem filter. When the first urinary problem filter is activated (e.g., when the answer indicates that the individual has a urinary problem), an override procedure is initiated (711-2) (e.g., the device generates a record indicating that the user must confirm that he or she has been discussed with a healthcare professional using the gesicam sodium-glucose co-transporter 2 inhibitor pharmaceutical composition).

The device performs an authentication process, prompts the individual to indicate their surgical status and then applies (724) the answers received from the individual to the first surgical filter. When the first surgical filter is activated (e.g., when the answer indicates that the individual is planning to perform a surgery), an override procedure is initiated (711-3) (e.g., the device generates a record indicating that the user must confirm that he or she has been discussed with a healthcare professional regarding the use of the gyricon sodium-glucose co-transporter 2 inhibitor pharmaceutical composition).

The device performs an authentication process that prompts the individual to indicate their dietary status and then applies (726) the answers received from the individual to the first dietary filter. When the first dietary filter is activated (e.g., when the answer indicates that the individual has recently reduced food intake due to illness, surgery, or dietary changes), an override procedure is initiated (711-4) (e.g., the device generates a record indicating that the user must confirm that he or she has discussed with the healthcare professional in terms of using the gesicine sodium-glucose co-transporter 2 inhibitor pharmaceutical composition).

The device performs an identification process that prompts the individual to indicate whether they have had a pancreatic question and then applies 728 the answer received from the individual to the first pancreatic disease filter. When the first pancreatic disorder filter is activated (e.g., when the answer indicates that the individual has a pancreatic question), an override procedure is initiated (711-5) (e.g., the device generates a record indicating that the user must confirm that he or she has been discussed with a healthcare professional in terms of using the gesicin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition).

The device performs an authentication process, prompts the individual to indicate their alcohol consumption status and then applies 730 the answer received from the individual to the first alcohol consumption filter. When the first alcohol consuming disease filter is activated (e.g., when the answer indicates that the individual is abusing alcohol), an override procedure is initiated (711-6) (e.g., the device generates a record indicating that the user must confirm that he or she has discussed with a healthcare professional regarding the use of the gesicin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition).

The device performs an identification process that prompts the subject to indicate whether it is using diabetes medication and then applies (732) the answer received from the subject to the first diabetes medication filter. When the first diabetes drug filter is activated (e.g., when the answer indicates that the subject is using diabetes drug), an override procedure is initiated (711-7) (e.g., the device generates a record indicating that the user must confirm that he is discussed with a healthcare professional in connection with using the geist sodium-glucose co-transporter 2 inhibitor pharmaceutical composition).

The device performs an identification process to determine (734) whether an override procedure has been triggered (e.g., by initiation of any of a first liver disease filter, a first urinary problem filter, a first surgical filter, a first diet filter, a first pancreatic disease filter, a first alcohol consumption filter, or a first diabetes drug filter). If an override procedure has been triggered, the device prompts (717) the user to confirm that they have been discussed with the medical professional with respect to using the gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition (e.g., in view of potential risk factors triggering the first liver disease filter, the first urinary problem filter, the first surgical filter, the first dietary filter, the first pancreatic disease filter, the first alcohol consumption filter, and/or the first diabetic drug filter) and the medical professional recommends use of the gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition. If the user's answer indicates that they have not been discussed with a medical professional or that the medical professional does not advise to use the gerlabel sodium-glucose co-transporter 2 inhibitor pharmaceutical composition, the device terminates (705) the procedure and optionally sends an advice to the individual to consult the medical professional.

If the override procedure is not triggered or the override procedure is triggered and the individual's answer (717) indicates to the medical professional that they recommend their use of the gyricon sodium-glucose co-transporter 2 inhibitor pharmaceutical composition (e.g., in view of the potential risk factor for triggering the override procedure), then the device performs an identification procedure prompting (736) the individual to confirm his answer. If the user confirms his answer, the device sends (738) a drug fact label for the gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition and prompts the user to read the drug fact label. If the individual confirms that he or she has read the drug fact label (e.g., the individual scrolls through the drug fact label), the device proceeds to authorize (740) the purchase of the gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition.

Fig. 8 illustrates an example method (800) for identifying an individual as eligible to re-supplement an over-the-counter gyricon sodium-glucose co-transporter 2 inhibitor pharmaceutical composition (e.g., according to a prescription of a medical professional or an initial identification by a method described herein). Referring to FIG. 8, the device prompts (802) the individual to confirm the privacy notification. After the individual confirms that it has the requisite privacy to proceed, the device determines (806) whether the user (e.g., the individual) has previously re-ordered the over-the-counter gyragliflozin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition up to three times. When the device determines that the individual has previously re-ordered the over-the-counter giriflozin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition three times, the device prompts (808) the user to confirm that he is aware of his blood glucose level (e.g., because the individual must know his blood value to complete the re-identification process). If the individual indicates that he is not aware of his blood glucose level, the process terminates 801 without authorizing the provision of the gerzin sodium-glucose co-transporter 2 inhibitor agent, and optionally sends a recommendation to the user to return later, for example after he knows his blood glucose level.

If the device determines that the individual has not previously re-ordered the over-the-counter girlistine sodium-glucose co-transporter 2 inhibitor pharmaceutical composition three times or if the individual indicates that he or she knows his or her blood glucose level, the device determines whether the blood glucose level has been verified within a predetermined period of time (e.g., within three months of the initial order or within six months thereafter). When a new blood glucose input is required (e.g., when the profile of the individual does not include a record of the individual's blood glucose taken over the past three months (and every six months thereafter, such as for a subsequent reordering process), the device performs the process, prompts the user to indicate whether their blood glucose is below a threshold target level (e.g., 7% glycated hemoglobin) and applies (805) the answer received from the individual to the blood glucose filter. When the glycemic filter is activated (e.g., when the answer indicates that the subject's blood glucose is not below a target level, e.g., 7% glycated hemoglobin), the device terminates (803) the identification process, optionally sending the subject a recommendation to discuss use of a prescribed strength of a geiletin sodium-glucose co-transporter 2 inhibitor agent with a medical professional.

When the glycemic filter is not activated, the device prompts the individual to provide information about their pregnancy status and then applies (812) the answers received from the individual to the pregnancy filter. When the pregnancy filter is activated (e.g., when the answer indicates that the individual is pregnant, nursing or scheduled to be pregnant), the device generates (821-1) a record of the adverse event (e.g., aggregated in an adverse event data store with records of adverse events from multiple users), terminates (801) the identification process and optionally sends advice to the user as to how the gelistine sodium-glucose co-transporter 2 inhibitor pharmaceutical composition should not be used and/or returned when the user is not pregnant, nursing or scheduled to be pregnant.

When the pregnancy filter is not activated, the device performs an identification procedure, prompts the individual to provide information indicating whether ketoacidosis has occurred and applies (814) the answer to the ketoacidosis symptom filter. When the ketoacidosis symptom filter is activated (e.g., when the individual's answer indicates that the individual has developed ketoacidosis after receiving their last supply of the geletam sodium-glucose co-transporter 2 inhibitor pharmaceutical composition), the device generates (821-2) a record of adverse events (e.g., aggregated in an adverse event data store with records of adverse events from multiple users) and the device terminates (803) the identification process, optionally sending the individual a recommendation to discuss use of the geletam sodium-glucose co-transporter 2 inhibitor medicament with a medical professional.

When the ketoacidosis symptom filter is not activated, the device performs an identification process, prompts the individual to provide information indicating whether or not they are presenting renal problems and applies (816) an answer to the renal problem filter. When the renal problem filter is activated (e.g., when the individual's answer indicates that the individual has symptoms of a renal problem after receiving their last supply of the geiletin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition), the device generates (821-3) a record of adverse events (e.g., aggregated in an adverse event data store with records of adverse events from multiple users) and the device terminates (803) the identification process, optionally sending the individual a recommendation to discuss use of the geiletin sodium-glucose co-transporter 2 inhibitor medicament with a medical professional.

When the kidney question filter is not activated, the device performs an authentication process, prompts the individual to provide information indicating whether they have presented a urinary problem and applies 818 the answer to a second urinary question filter. When the second urinary problem filter is activated (e.g., when the individual's answer indicates that the individual has symptoms of a urinary problem after receiving their last supply of the geist sodium-glucose co-transporter 2 inhibitor pharmaceutical composition), the device generates (821-4) a record of adverse events (e.g., aggregated in an adverse event data store with records of adverse events from multiple users) and the device terminates (803) the identification process, optionally sending the individual a recommendation to discuss use of the geist sodium-glucose co-transporter 2 inhibitor agent with a medical professional.

When the second urinary problem filter is not activated, the device performs an identification process, prompts the individual to provide information indicating whether or not they are developing bladder cancer and applies (822) the answer to the bladder cancer filter. When the bladder cancer filter is activated (e.g., when the individual's answer indicates that the individual has developed bladder cancer after receiving their last supply of the geiletin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition), the device generates (821-5) a record of adverse events (e.g., aggregated in an adverse event data store with records of adverse events from multiple users) and the device terminates (803) the identification process, optionally sending the individual a recommendation to discuss use of the geiletin sodium-glucose co-transporter 2 inhibitor medicament with a medical professional.

When the bladder cancer filter is not activated, the device performs an identification process, prompts the individual to provide information indicating whether they have a liver problem and applies (824) the answer received from the individual to a second liver disease filter. When the second liver disease filter is activated (e.g., when the answer indicates that the individual has a liver problem after receiving their last supply of the germline sodium-glucose co-transporter 2 inhibitor pharmaceutical composition), the device generates (821-6) a record of the adverse event (e.g., aggregated in an adverse event data store with records of adverse events from multiple users) and initiates (811-1) an override procedure (e.g., generates a record indicating that the user must confirm that they have discussed their use of the germline sodium-glucose co-transporter 2 inhibitor medicament with a healthcare professional).

The device performs an authentication process, prompts the individual to indicate whether they plan surgery and then applies 826 the answer received from the individual to a second surgical filter. When a second surgical filter is activated (e.g., when the answer indicates that the individual is planning to perform a surgery), the device generates (821-7) a record of the adverse event (e.g., aggregated in an adverse event data store with records of adverse events from multiple users) and initiates (811-2) an override procedure (e.g., generates a record indicating that the user must confirm that he has discussed use of a gyricon sodium-glucose co-transporter 2 inhibitor agent with a healthcare professional).

The device performs an identification process, prompts the individual to indicate whether their food intake has decreased and then applies 828 the answers received from the individual to a second dietary filter. When the second dietary filter is activated (e.g., when the answer indicates that the individual has reduced food intake after receiving their last supply of the germline sodium-glucose co-transporter 2 inhibitor pharmaceutical composition), the device generates (821-8) a record of the adverse event (e.g., aggregated in an adverse event data store with records of adverse events from multiple users) and initiates (811-3) an override procedure (e.g., generates a record indicating that the user must confirm that they have discussed their use of the germline sodium-glucose co-transporter 2 inhibitor medicament with a healthcare professional).

The device performs an identification process that prompts the individual to provide information indicating whether they presented a pancreatic question and then applies (830) the answer received from the individual to a second pancreatic disease filter. When the second pancreatic disorder filter is activated (e.g., when the answer indicates that the individual has a pancreatic problem after receiving their last supply of the geiletin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition), the device generates (821-9) a record of the adverse event (e.g., aggregated in an adverse event data store with records of adverse events from multiple users) and initiates (811-4) an override procedure (e.g., generates a record indicating that the user must confirm that he has discussed use of the geiletin sodium-glucose co-transporter 2 inhibitor medicament with a healthcare professional).

The device performs an authentication process, prompts the individual to indicate their alcohol consumption status and then applies (832) the answer received from the individual to a second alcohol consumption filter. When the second alcohol-consuming filter is activated (e.g., when the answer indicates that the individual begins to abuse alcohol), the device generates (821-10) a record of the adverse event (e.g., aggregated in an adverse event data store with records of adverse events from multiple users) and initiates (811-5) an override procedure (e.g., generates a record indicating that the user must confirm that they have discussed use of the gyragliflozin sodium-glucose co-transporter 2 inhibitor medicament with a healthcare professional).

The device performs an identification process, prompts the individual to provide information indicating whether they have experienced a yeast infection and then applies (834) the answer received from the individual to a yeast infection filter. When the yeast infection filter is activated (e.g., when the answer indicates that the individual experienced a yeast infection after receiving their last supply of the germline sodium-glucose co-transporter 2 inhibitor pharmaceutical composition), the device generates (821-11) a record of the adverse event (e.g., aggregated in an adverse event data store with records of adverse events from multiple users) and initiates (811-6) an override procedure (e.g., generates a record indicating that the user must confirm that they have discussed use of the germline sodium-glucose co-transporter 2 inhibitor medicament with a healthcare professional).

The device performs an identification process, prompts the individual to provide information indicating whether they are hypoglycemic and then applies (836) the answers received from the individual to a hypoglycemic symptoms filter. When the hypoglycemic symptoms filter is activated (e.g., when the answer indicates that the individual has experienced hypoglycemia after receiving its last supply of the gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition), the device generates (821-12) a record of the adverse event (e.g., aggregated in an adverse event data store with records of adverse events from multiple users) and initiates (811-7) an override procedure (e.g., generates a record indicating that the user must confirm that he has discussed use of the gerzin sodium-glucose co-transporter 2 inhibitor medicament with a healthcare professional).

The device performs an authentication process, prompts the individual to indicate whether they are experiencing physical stress and then applies (838) the answer received from the individual to a physical stress filter. When the body pressure filter is activated (e.g., when the answer indicates that the individual is experiencing body pressure, such as fever, trauma, or infection), the device terminates (803) the identification process, optionally with a recommendation occurring to the individual to discuss use of the agent that is an inhibitor of the geist sodium-glucose co-transporter 2.

When the body pressure filter is not activated, the device performs an identification process, prompting the subject to indicate whether it is using diabetes medicine and then applies (840) the answer received from the subject to the diabetes medicine filter. When the diabetes drug filter is activated (e.g., when the answer indicates that the subject is using diabetes drug), the device terminates (803) the identification process, optionally with a recommendation to the subject to develop a drug that is a member of the medical professional's discussion of using the geist sodium-glucose co-transporter 2 inhibitor.

The device performs an identification process that determines (842) whether an override procedure has been triggered (e.g., by initiation of any of a second liver disease filter, a second surgery filter, a second diet filter, a second pancreatic disease filter, a second alcohol consumption filter, a yeast infection filter, or a hypoglycemic symptoms filter). If the override procedure is triggered, the device prompts (817) the user to confirm that he is in discussion with the medical professional regarding the use of the gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition (e.g., in view of potential risk factors triggering the second liver disease filter, the second surgical filter, the second dietary filter, the second pancreatic disease filter, the second alcohol consumption filter, the yeast infection filter, and/or the hypoglycemic symptoms filter) and the medical professional recommends the use of the gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition. If the user's answer indicates that they have not been discussed with a medical professional or that the medical professional does not advise to use the gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition, the device terminates (803) the procedure and optionally sends the individual a recommendation to consult the medical professional.

If the override procedure is not triggered or the override procedure is triggered and the individual's answer (817) indicates that the medical professional advises him to use the gyragliflozin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition (e.g., in view of potential risk factors triggering the override procedure), then the device proceeds with a re-authentication procedure, prompting (844) the individual to confirm his answer. If the user confirms his answer, the device sends (846) a drug fact label for the gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition and prompts the user to read the drug fact label. If the individual confirms that he has read the drug fact label, the device proceeds to authorize the purchase of a gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition.

In one aspect, the present disclosure provides methods, software and computer systems for identifying a human subject eligible for over-the-counter delivery of a gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition for lowering blood glucose, e.g., thereby treating type 2 diabetes and/or maintaining sub-diabetic blood glucose levels. In one embodiment, a computer system (e.g., computer system 250 in FIG. 2) includes instructions for conducting a survey of an individual (e.g., including survey questions 208 and 212 presented by evaluation module 252 in FIG. 2) to obtain information about the individual necessary to run against at least two series of filters (e.g., filters 216 and 222 in first filter category 214-1 and second filter category 220-1, respectively, in FIG. 2). The computer system also includes instructions for executing the findings against the filter. When the individual's findings identify contraindications for OTC gyricon sodium-glucose co-transporter 2 inhibitors, filter 216 in first series of filters 214 prevents authorization to provide OTC gyricon sodium-glucose co-transporter 2 inhibitors. When the individual's findings identify a risk factor for the OTC gyragliflozin sodium-glucose co-transporter 2 inhibitor, filter 222 in second series of filters 220 generates an alert 226. In some embodiments, the alert 226 includes a prompt that requires the individual to confirm that they have discussed risk factors with a physician to proceed with the identification of an inhibitor of OTC gyragliflozin sodium-glucose co-transporter 2.

In one aspect, the present disclosure provides methods, software and computer systems for re-qualifying a human subject for over-the-counter delivery of a pharmaceutical composition of geijiezin sodium-glucose co-transporter 2 inhibitor for use in lowering blood glucose, e.g., thereby treating type 2 diabetes and/or maintaining sub-diabetic blood glucose levels. In one embodiment, a computer system (e.g., computer system 250 of fig. 2) includes instructions for conducting a survey of an individual (e.g., given by re-evaluation module 254 of fig. 2) to obtain information about the individual necessary for at least two series of filter runs. The computer system also includes instructions for executing the findings against the filter. When the individual's findings identify contraindications for OTC gyricon sodium-glucose co-transporter 2 inhibitors, filter 216 in the third series of filters 214-2 prevents authorized delivery of OTC gyricon sodium-glucose co-transporter 2 inhibitors. When the individual's findings identify a risk factor for the OTC gyragliflozin sodium-glucose co-transporter 2 inhibitor, filter 222 in the fourth series of filters 220-2 generates an alert 226. In some embodiments, the alert 226 includes a prompt that requires the individual to confirm that they have discussed risk factors with a physician to proceed with the identification of an inhibitor of OTC gyragliflozin sodium-glucose co-transporter 2.

In one aspect, the present disclosure provides a computer system for identifying a human subject eligible for over-the-counter delivery of a gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition for reducing blood glucose, e.g., thereby treating type 2 diabetes and/or maintaining sub-diabetic blood glucose levels. The computer system comprises one or more processors and memory, the memory comprising non-transitory instructions that when executed by the one or more processors perform a method for qualifying a human individual for over-the-counter delivery of a gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition. The method includes conducting a first survey of the individual, thereby obtaining a first plurality of survey results necessary for the operation of a first plurality of filters of a first category and a second plurality of filters of a second category. Next, the method comprises running all or a portion of the first plurality of findings for a first plurality of filters of a first category, wherein when a respective filter of the first plurality of filters is activated, the individual is deemed to be ineligible for delivery of the gerlabel sodium-glucose co-transporter 2 inhibitor pharmaceutical composition and the method terminates without delivering the gerlabel sodium-glucose co-transporter 2 inhibitor pharmaceutical composition to the individual. Next, the method includes running all or a portion of the first plurality of findings for a second plurality of filters of a second category, wherein when a respective filter of the second plurality of filters is activated, an alert is provided to the individual corresponding to the respective filter. The method also includes obtaining confirmation from the individual of the alert issued to the individual by any of the second plurality of filters. The method further includes performing a fulfillment process when a filter of the first plurality of filters is not activated and the individual acknowledges each alert associated with each activated filter of the second plurality of filters. The fulfillment process includes: the method includes storing in an individual profile an indication of an initial order for a gemiflozin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition, communicating to the individual an over-the-counter drug fact label for the gemiflozin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition, and authorizing provision of the gemiflozin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition to the individual after the individual confirms that the over-the-counter drug fact label has been received and read. In some embodiments, the authorization includes a pharmacy associated with the individual.

In some embodiments, the first plurality of findings indicates a plurality of findings selected from the findings listed in table 1. In one embodiment, the first plurality of survey results indicates: whether the individual is one of the following: (i) pregnancy, (ii) lactation, or (iii) scheduled pregnancy; a type 1 diabetes status of the individual; ketoacidosis status of the subject; renal status of the subject; the age of the individual; the blood glucose level of the individual; whether an individual has liver problems; whether the individual has had urinary problems; the surgical status of the individual; the dietary status of the individual; whether an individual has had pancreatic problems; the alcohol consumption status of the individual; and whether the subject is using diabetes drugs.

In some embodiments, the first plurality of filters comprises a plurality of filters selected from the filters listed in table 2. In one embodiment, the first plurality of filters includes a first pregnancy filter, type 1 diabetes, a ketoacidosis filter, a first nephropathy filter, an age filter, and a first blood glucose filter.

In some embodiments, the second plurality of filters comprises a plurality of filters selected from the filters listed in table 3. In one embodiment, the second plurality of filters includes a first liver disease filter, a first urinary problem filter, a first surgical filter, a first diet filter, a first pancreatic disease filter, a first alcohol consumption filter, and a first diabetes drug filter.

In some embodiments, the first and second plurality of filters comprise filters selected from the filters listed in table 7. In some embodiments, the first plurality of filters of the first category includes a first subset of the filters listed in table 7, e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, or all 18 of the filters listed in table 7, and the second plurality of filters of the first category includes a second subset of the filters listed in table 7 that is different from the first subset of the filters, e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, or all 18 of the filters listed in table 7. In some embodiments, each filter of the first sub-plurality of filters is different from each filter of the second sub-plurality of filters (e.g., neither the first sub-plurality nor the second sub-plurality of filters includes the filters listed in table 7). In some embodiments, a system for identifying an individual as eligible for delivery of an over-the-counter gyricon sodium-glucose co-transporter 2 inhibitor pharmaceutical composition comprises instructions for applying only one plurality of filters, e.g., only filters of a single class of filters. In some embodiments, when the method, system, or software applies a single plurality of filters, the plurality of filters comprises a plurality of filters selected from the filters listed in table 7, e.g., at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, or all 18 of the filters listed in table 7. In some embodiments, when the filter listed in table 7 corresponds to the filter listed in table 2 or table 3, the threshold level sufficient to activate the respective filter listed in table 2 or table 3 is sufficient to activate the filter listed in table 7, as described in detail above.

TABLE 7 example filters for contraindications and risk factors associated with identifying an individual's eligibility to receive an over-the-counter supply of a Gelidine sodium-glucose co-transporter 2 inhibitor pharmaceutical composition

In one embodiment, the first and second plurality of filters comprise filters selected from the filters listed in table 8. In some embodiments, the first plurality of filters of the first category comprises a first sub-plurality of filters listed in table 8, e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16 of the filters listed in table 8, and the second plurality of filters of the first category comprises a second sub-plurality of filters listed in table 8 that is different from the first sub-plurality of filters, e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16 of the filters listed in table 8. In some embodiments, each filter of the first sub-plurality of filters is different from each filter of the second sub-plurality of filters (e.g., neither the first sub-plurality nor the second sub-plurality of filters includes the filters listed in table 8). In some embodiments, a system for identifying an individual as eligible for delivery of an over-the-counter gyricon sodium-glucose co-transporter 2 inhibitor medicament includes instructions for applying only one of a plurality of filters, e.g., only filters of a single class of filters. In some embodiments, when the method, system, or software applies a single plurality of filters, the plurality of filters comprises a plurality of filters selected from the filters listed in table 8, e.g., at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16 of the filters listed in table 8. In some embodiments, when the filter listed in table 8 corresponds to the filter listed in table 2 or table 3, the threshold level sufficient to activate the respective filter listed in table 2 or table 3 is sufficient to activate the filter listed in table 8, as described in detail above. In some embodiments, the first plurality of filters of the first category includes some or all of the filters listed in table 8. In some embodiments, the second plurality of filters of the second category includes some or all of the filters listed in table 8.

In one embodiment, the present disclosure provides a computer system for identifying a human subject eligible for delivery of an over-the-counter gyricon sodium-glucose co-transporter 2 inhibitor pharmaceutical composition for lowering blood pressure. The computer system includes one or more processors and memory containing non-transitory instructions that, when executed by the one or more processors, perform a method for identifying a human subject as eligible for delivery of an over-the-counter girlistine sodium-glucose co-transporter 2 inhibitor pharmaceutical composition for lowering blood pressure. The method includes conducting a first survey of the individual, thereby obtaining a first plurality of survey results, wherein the first plurality of survey results comprises a plurality of survey results sufficient to run for each of a first plurality of filters of a first category and a second plurality of filters of a second category, as indicated in table 8. The method further comprises running all or a portion of the first plurality of findings for a first plurality of filters of a first category, wherein the individual is deemed to be ineligible for delivery of the gerhaving sodium-glucose co-transporter 2 inhibitor pharmaceutical composition and the method terminates without delivery of the gerhaving sodium-glucose co-transporter 2 inhibitor pharmaceutical composition to the individual when a respective filter of the first plurality of filters is activated, wherein the first plurality of filters comprises a plurality of filters selected from the filters listed in table 8. The method also includes running all or a portion of the first plurality of findings for a second plurality of filters of a second category, wherein when a respective filter of the second plurality of filters is activated, an alert is provided to the individual corresponding to the respective filter, and wherein the second plurality of filters includes a plurality of filters selected from the filters listed in table 8. Next, the method includes obtaining confirmation from the individual of the alert issued to the individual by any of the second plurality of filters. Next, the method includes performing a fulfillment process under the following conditions: (i) a filter of the first plurality of filters is not activated and (ii) the individual acknowledges each alert associated with each activated filter of the second plurality of filters, wherein the fulfillment process comprises: the method includes storing in an individual profile an indication of an initial order for a gemiflozin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition, communicating to the individual an over-the-counter drug fact label for the gemiflozin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition, and authorizing provision of the gemiflozin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition to the individual after the individual confirms that the over-the-counter drug fact label has been received and read, wherein the authorization includes a pharmacy associated with the individual.

TABLE 8 example filters for contraindications and risk factors associated with identifying an individual's eligibility to receive an over-the-counter supply of a Gelidine sodium-glucose co-transporter 2 inhibitor pharmaceutical composition

In some embodiments, the renal disease filter is activated when the first plurality of findings indicate that the individual has moderate to severe renal dysfunction. In some embodiments, moderate to severe renal insufficiency is characterized by persistent (e.g., three consecutive months) eGFR test results <60 ml/min/1.73 square meters (by MDRD) and/or persistent CrCl levels less than 60 ml/min (by Cockcroft-goldt analysis).

In some embodiments, the diuretic filter is activated when the first plurality of findings indicate that the individual has a history of dehydration, e.g., has a higher risk of hypovolemia, or is using diuretic therapy, e.g., loop diuretics (loop diuretics).

In one embodiment, the first and second plurality of filters comprise filters selected from the filters listed in table 9. In some embodiments, the first plurality of filters of the first category comprises a first sub-plurality of filters listed in table 9, e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, or 17 of the filters listed in table 9, and the second plurality of filters of the first category comprises a second sub-plurality of filters listed in table 9 that is different from the first sub-plurality of filters, e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, or 17 of the filters listed in table 9. In some embodiments, each filter of the first sub-plurality of filters is different from each filter of the second sub-plurality of filters (e.g., neither the first sub-plurality nor the second sub-plurality of filters includes the filters listed in table 9). In some embodiments, a system for identifying an individual as eligible for delivery of an over-the-counter gyricon sodium-glucose co-transporter 2 inhibitor medicament includes instructions for applying only one of a plurality of filters, e.g., only filters of a single class of filters. In some embodiments, when the method, system, or software applies a single plurality of filters, the plurality of filters comprises a plurality of filters selected from the filters listed in table 9, for example, at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, or 17 of the filters listed in table 9. In some embodiments, when the filter listed in table 9 corresponds to the filter listed in table 2 or table 3, the threshold level sufficient to activate the respective filter listed in table 2 or table 3 is sufficient to activate the filter listed in table 9, as described in detail above. In some embodiments, the first plurality of filters of the first category includes some or all of the filters listed in table 9. In some embodiments, the second plurality of filters of the second category includes some or all of the filters listed in table 9.

In one embodiment, the present disclosure provides a computer system for identifying a human subject eligible for delivery of an over-the-counter gyricon sodium-glucose co-transporter 2 inhibitor pharmaceutical composition for lowering blood pressure. The computer system includes one or more processors and memory containing non-transitory instructions that, when executed by the one or more processors, perform a method for identifying a human subject as eligible for delivery of an over-the-counter girlistine sodium-glucose co-transporter 2 inhibitor pharmaceutical composition for lowering blood pressure. The method includes conducting a first survey of the individual, thereby obtaining a first plurality of survey results, wherein the first plurality of survey results comprises a plurality of survey results sufficient to run for each of a first plurality of filters of a first category and a second plurality of filters of a second category, as indicated in table 9. The method further comprises running all or a portion of the first plurality of findings for a first plurality of filters of a first category, wherein the individual is deemed to be ineligible for delivery of the gerhaving sodium-glucose co-transporter 2 inhibitor pharmaceutical composition and the method terminates without delivery of the gerhaving sodium-glucose co-transporter 2 inhibitor pharmaceutical composition to the individual when a respective filter of the first plurality of filters is activated, wherein the first plurality of filters comprises a plurality of filters selected from the filters listed in table 9. The method also includes running all or a portion of the first plurality of findings for a second plurality of filters of a second category, wherein when a respective filter of the second plurality of filters is activated, an alert is provided to the individual corresponding to the respective filter, and wherein the second plurality of filters includes a plurality of filters selected from the filters listed in table 9. Next, the method includes obtaining confirmation from the individual of the alert issued to the individual by any of the second plurality of filters. Next, the method includes performing a fulfillment process under the following conditions: (i) a filter of the first plurality of filters is not activated and (ii) the individual acknowledges each alert associated with each activated filter of the second plurality of filters, wherein the fulfillment process comprises: the method includes storing in an individual profile an indication of an initial order for a gemiflozin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition, communicating to the individual an over-the-counter drug fact label for the gemiflozin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition, and authorizing provision of the gemiflozin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition to the individual after the individual confirms that the over-the-counter drug fact label has been received and read, wherein the authorization includes a pharmacy associated with the individual.

TABLE 9 example filters for contraindications and risk factors associated with identifying an individual's eligibility to receive an over-the-counter supply of a gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition

In some embodiments, the blood pressure filter is activated when the first plurality of findings indicate that the individual has hypotension or is using a hypertensive medication. In some embodiments, the blood pressure filter is also activated when the first plurality of findings indicate that the individual has a heart disease.

In some embodiments, the cream allergy filter is activated when the first plurality of findings indicate that the individual is allergic to cream.

In one embodiment, the first and second plurality of filters comprise filters selected from the filters listed in table 10. In some embodiments, the first plurality of filters of the first category comprises a first sub-plurality of filters listed in table 10, e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16 of the filters listed in table 10, and the second plurality of filters of the first category comprises a second sub-plurality of filters listed in table 10 that is different from the first sub-plurality of filters, e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16 of the filters listed in table 10. In some embodiments, each filter of the first sub-plurality of filters is different from each filter of the second sub-plurality of filters (e.g., neither the first sub-plurality nor the second sub-plurality of filters includes the filters listed in table 10). In some embodiments, a system for identifying an individual as eligible for delivery of an over-the-counter gyricon sodium-glucose co-transporter 2 inhibitor medicament includes instructions for applying only one of a plurality of filters, e.g., only filters of a single class of filters. In some embodiments, when the method, system, or software applies a single plurality of filters, the plurality of filters comprises a plurality of filters selected from the filters listed in table 10, e.g., at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16 of the filters listed in table 10. In some embodiments, when the filter listed in table 10 corresponds to the filter listed in table 2 or table 3, the threshold level sufficient to activate the respective filter listed in table 2 or table 3 is sufficient to activate the filter listed in table 10, as described in detail above. In some embodiments, the first plurality of filters of the first category includes some or all of the filters listed in table 10. In some embodiments, the second plurality of filters of the second category includes some or all of the filters listed in table 10.

In one embodiment, the present disclosure provides a computer system for identifying a human subject eligible for delivery of an over-the-counter gyricon sodium-glucose co-transporter 2 inhibitor pharmaceutical composition for lowering blood pressure. The computer system includes one or more processors and memory containing non-transitory instructions that, when executed by the one or more processors, perform a method for identifying a human subject as eligible for delivery of an over-the-counter girlistine sodium-glucose co-transporter 2 inhibitor pharmaceutical composition for lowering blood pressure. The method includes conducting a first survey of the individual, thereby obtaining a first plurality of survey results, wherein the first plurality of survey results comprises a plurality of survey results sufficient to run for each of a first plurality of filters of a first category and a second plurality of filters of a second category, as indicated in table 10. The method further comprises running all or a portion of the first plurality of findings for a first plurality of filters of a first category, wherein the individual is deemed to be ineligible for delivery of the gerhaving sodium-glucose co-transporter 2 inhibitor pharmaceutical composition and the method terminates without delivery of the gerhaving sodium-glucose co-transporter 2 inhibitor pharmaceutical composition to the individual when a respective filter of the first plurality of filters is activated, wherein the first plurality of filters comprises a plurality of filters selected from the filters listed in table 10. The method also includes running all or a portion of the first plurality of findings for a second plurality of filters of a second category, wherein when a respective filter of the second plurality of filters is activated, an alert is provided to the individual corresponding to the respective filter, and wherein the second plurality of filters includes a plurality of filters selected from the filters listed in table 10. Next, the method includes obtaining confirmation from the individual of the alert issued to the individual by any of the second plurality of filters. Next, the method includes performing a fulfillment process under the following conditions: (i) a filter of the first plurality of filters is not activated and (ii) the individual acknowledges each alert associated with each activated filter of the second plurality of filters, wherein the fulfillment process comprises: the method includes storing in an individual profile an indication of an initial order for a gemiflozin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition, communicating to the individual an over-the-counter drug fact label for the gemiflozin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition, and authorizing provision of the gemiflozin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition to the individual after the individual confirms that the over-the-counter drug fact label has been received and read, wherein the authorization includes a pharmacy associated with the individual.

TABLE 10 example filters for contraindications and risk factors associated with identifying an individual's eligibility to receive an over-the-counter supply of a gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition

In some embodiments, the heart disease filter is activated when the first plurality of findings indicates that the individual has a severe history of heart disease or has experienced a stroke.

In some embodiments, the diuretic filter is activated when the first plurality of findings indicate that the individual has a history of dehydration, e.g., has a higher risk of hypovolemia, or is using diuretic therapy, e.g., loop henry diuretics.

In one embodiment, the first and second plurality of filters comprise filters selected from the filters listed in table 11. In some embodiments, the first category of the first plurality of filters comprises a first sub-plurality of filters listed in table 11, e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or 13 of the filters listed in table 11, and the first category of the second plurality of filters comprises a second sub-plurality of filters listed in table 11 that is different from the first sub-plurality of filters, e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or 13 of the filters listed in table 11. In some embodiments, each filter of the first sub-plurality of filters is different from each filter of the second sub-plurality of filters (e.g., neither the first sub-plurality nor the second sub-plurality of filters includes the filters listed in table 11). In some embodiments, a system for identifying an individual as eligible for delivery of an over-the-counter gyricon sodium-glucose co-transporter 2 inhibitor medicament includes instructions for applying only one of a plurality of filters, e.g., only filters of a single class of filters. In some embodiments, when the method, system, or software applies a single plurality of filters, the plurality of filters comprises a plurality of filters selected from the filters listed in table 11, e.g., at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or 13 of the filters listed in table 11. In some embodiments, when the filter listed in table 11 corresponds to the filter listed in table 2 or table 3, the threshold level sufficient to activate the respective filter listed in table 2 or table 3 is sufficient to activate the filter listed in table 11, as described in detail above. In some embodiments, the first plurality of filters of the first category includes some or all of the filters listed in table 11. In some embodiments, the second plurality of filters of the second category includes some or all of the filters listed in table 11.

In one embodiment, the present disclosure provides a computer system for identifying a human subject eligible for delivery of an over-the-counter gyricon sodium-glucose co-transporter 2 inhibitor pharmaceutical composition for lowering blood pressure. The computer system includes one or more processors and memory containing non-transitory instructions that, when executed by the one or more processors, perform a method for identifying a human subject as eligible for delivery of an over-the-counter girlistine sodium-glucose co-transporter 2 inhibitor pharmaceutical composition for lowering blood pressure. The method includes conducting a first survey of the individual, thereby obtaining a first plurality of survey results, wherein the first plurality of survey results comprises a plurality of survey results sufficient to run for each of a first plurality of filters of a first category and a second plurality of filters of a second category, as indicated in table 11. The method further comprises running all or a portion of the first plurality of findings for a first plurality of filters of a first category, wherein the individual is deemed to be ineligible for delivery of the gerhaving sodium-glucose co-transporter 2 inhibitor pharmaceutical composition and the method terminates without delivery of the gerhaving sodium-glucose co-transporter 2 inhibitor pharmaceutical composition to the individual when a respective filter of the first plurality of filters is activated, wherein the first plurality of filters comprises a plurality of filters selected from the filters listed in table 11. The method also includes running all or a portion of the first plurality of findings for a second plurality of filters of a second category, wherein when a respective filter of the second plurality of filters is activated, an alert is provided to the individual corresponding to the respective filter, and wherein the second plurality of filters includes a plurality of filters selected from the filters listed in table 11. Next, the method includes obtaining confirmation from the individual of the alert issued to the individual by any of the second plurality of filters. Next, the method includes performing a fulfillment process under the following conditions: (i) a filter of the first plurality of filters is not activated and (ii) the individual acknowledges each alert associated with each activated filter of the second plurality of filters, wherein the fulfillment process comprises: the method includes storing in an individual profile an indication of an initial order for a gemiflozin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition, communicating to the individual an over-the-counter drug fact label for the gemiflozin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition, and authorizing provision of the gemiflozin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition to the individual after the individual confirms that the over-the-counter drug fact label has been received and read, wherein the authorization includes a pharmacy associated with the individual.

TABLE 11 example filters for contraindications and risk factors associated with identifying an individual's eligibility to receive an over-the-counter supply of a gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition

In one aspect, the present disclosure provides methods, software and computer systems for identifying human subjects eligible for reordering over-the-counter delivery of a pharmaceutical composition of gegliflozin sodium-glucose co-transporter 2 inhibitor for lowering blood glucose, e.g., thereby treating type 2 diabetes and/or maintaining sub-diabetic blood glucose levels. In one embodiment, the computer system includes instructions that, in response to receiving a reorder request for a gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition from an individual, perform a re-fulfillment procedure comprising performing a second survey of the individual, thereby obtaining a second plurality of survey results necessary to run for a third plurality of filters of the first category and a fourth plurality of filters of the second category. Next, the method includes running all or a portion of the second plurality of findings for a third plurality of filters of the first category, wherein when a respective filter of the third plurality of filters is activated, the individual is deemed to be ineligible for delivery of the gerlabel sodium-glucose co-transporter 2 inhibitor pharmaceutical composition and the method terminates without delivering the gerlabel sodium-glucose co-transporter 2 inhibitor pharmaceutical composition to the individual. Next, the method includes running all or a portion of the second plurality of findings for a fourth plurality of filters of the second category, wherein when a respective filter of the fourth plurality of filters is activated, an alert is provided to the individual corresponding to the respective filter. The method further includes obtaining confirmation from the individual of the alert issued to the individual by any of the fourth plurality of filters. The method further includes performing a redemption process when a filter of the third plurality of filters is not activated and the individual acknowledges each alert associated with each activated filter of the fourth plurality of filters. The fulfillment process includes: storing in the profile of the individual an indication to reorder a gelistine sodium-glucose co-transporter 2 inhibitor pharmaceutical composition, communicating to the individual an over-the-counter drug fact label for the gelistine sodium-glucose co-transporter 2 inhibitor pharmaceutical composition, and authorizing provision of the gelistine sodium-glucose co-transporter 2 inhibitor pharmaceutical composition to the individual after confirming that the individual has received and read the over-the-counter drug fact label. In some embodiments, the third series of filters includes one or more of the filters listed in table 5.

In some embodiments, the third plurality of filters includes a second pregnancy filter, a ketoacidosis filter, a renal problem filter, a second urinary problem filter, a body pressure filter, and a second diabetic drug filter.

In some embodiments, the fourth series of filters includes one or more of the filters listed in table 6. In some embodiments, the fourth plurality of filters includes a second surgical filter, a second dietary filter, a second pancreatic disease filter, a second alcohol consumption filter, a yeast infection filter, and a hypoglycemic symptoms filter.

In some embodiments, the third and fourth plurality of filters comprise filters selected from the filters listed in table 12. In some embodiments, the third plurality of filters of the first category includes a third subset of the plurality of filters listed in table 12, e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or all 20 of the plurality of filters listed in table 12, and the fourth plurality of filters of the first category includes a fourth subset of the plurality of filters listed in table 12 that is different from the third subset of the plurality of filters, e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or all 20 of the plurality of filters listed in table 12. In some embodiments, each filter of the third sub-plurality of filters is different from each filter of the fourth sub-plurality of filters (e.g., neither the first sub-plurality nor the second sub-plurality of filters includes the filters listed in table 12). In some embodiments, a system for identifying an individual as eligible for delivery of an over-the-counter gyricon sodium-glucose co-transporter 2 inhibitor pharmaceutical composition comprises instructions for applying only one plurality of filters, e.g., only filters of a single class of filters. In some embodiments, when the method, system, or software applies a single plurality of filters, the plurality of filters comprises a plurality of filters selected from the filters listed in table 12, e.g., at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or all 20 of the filters listed in table 12. In some embodiments, when the filter listed in table 12 corresponds to a filter listed in table 2, table 3, table 5, or table 6, the threshold level sufficient to activate the respective filter listed in table 2, table 3, table 5, or table 6 is sufficient to activate the filter listed in table 12, as described in detail above.

TABLE 12 example filters for contraindications and risk factors associated with identifying an individual's eligibility to receive an over-the-counter supply of a gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition

In one aspect, the present disclosure provides a computer system for identifying a human subject eligible for over-the-counter delivery of a gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition for reducing blood glucose, the computer system comprising one or more processors and a memory, the memory comprising non-transitory instructions that when executed by the one or more processors perform a method comprising: a) conducting a first survey of an individual, thereby obtaining a first plurality of survey results, wherein the first plurality of survey results comprises: whether the individual is one of the following: (i) pregnancy, (ii) lactation, or (iii) scheduled pregnancy; a type 1 diabetes status of the individual; ketoacidosis status of the subject; renal status of the subject; the age of the individual; the blood glucose level of the individual; whether an individual has liver problems; whether the individual has had urinary problems; the surgical status of the individual; the dietary status of the individual; whether an individual has had pancreatic problems; the alcohol consumption status of the individual; and whether the subject is using diabetes drugs; b) running all or a portion of the first plurality of findings against a first plurality of filters of a first category, wherein when a respective filter of the first plurality of filters is activated, the individual is deemed to be ineligible for delivery of a gerhaving sodium-glucose co-transporter 2 inhibitor pharmaceutical composition and the method terminates without delivering the gerhaving sodium-glucose co-transporter 2 inhibitor pharmaceutical composition to the individual, wherein the first plurality of filters comprises: a first pregnancy filter activated at least when the first plurality of findings indicate that the individual is pregnant or that the individual is nursing; a type 1 diabetes filter that is activated at least when the first plurality of findings indicate that the individual has type 1 diabetes; a ketoacidosis filter activated at least when the first plurality of findings indicate that the individual has ketoacidosis; a first kidney disease filter activated at least when the first plurality of findings indicate that the individual has kidney disease; an age filter; and a first blood glucose filter activated at least when the first plurality of findings indicate that the individual's blood glucose levels satisfy the following conditions: (i) below a first baseline blood glucose level, or (ii) above a maximum blood glucose level; c) running all or a portion of the first plurality of findings against a second plurality of filters of a second category, wherein when a respective filter of the second plurality of filters is activated, an alert is provided to the individual corresponding to the respective filter, and wherein the second plurality of filters comprises: a first liver disease filter that is activated at least when the first plurality of findings indicate that the individual has liver problems; a first urological problem filter activated at least when the first plurality of findings indicate that the individual has a history of urological problems; a first surgical filter activated at least when the first plurality of findings indicate that the individual is planning to perform a surgery; a first diet filter activated at least when the first plurality of findings indicate a decrease in food intake of the individual; a first pancreatic disease filter activated at least when the first plurality of findings indicate that the individual has a pancreatic problem; a first alcohol consuming filter; and a first diabetes drug filter activated at least when the first plurality of findings indicate that the subject is using diabetes drug; d) obtaining confirmation from the individual of the alert sent to the individual by any of the second plurality of filters; e) performing a fulfillment process when (i) a filter of the first plurality of filters is not activated and (ii) the individual acknowledges each alert associated with each activated filter of the second plurality of filters, wherein the fulfillment process comprises: the method includes storing in an individual profile an indication of an initial order for a gemiflozin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition, communicating to the individual an over-the-counter drug fact label for the gemiflozin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition, and authorizing provision of the gemiflozin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition to the individual after the individual confirms that the over-the-counter drug fact label has been received and read.

In some embodiments of the above disclosed aspects, the geriflozin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition has the following structure:

wherein: r¹、R²And R^2aIndependently hydrogen, OH, OR⁵Alkyl, CF₃、OCHF₂、OCF₃、SR⁵ⁱOr halogen, or R¹、R²And R^2aMay together form a cyclic five-, six-or seven-membered carbocyclic or heterocyclic ring which may contain from 1 to 4 heteroatoms in the ring, which heteroatoms are N, O, S, SO and/or SO₂；R₃And R₄Independently hydrogen, OH, OR^5aO aryl, OCH₂Aryl, alkyl, cycloalkyl, CF₃、-OCHF₂、-OCF₃Halogen, -CN, -CO₂R^5b、-CO₂H、COR^6b、-CH(OH)R^6c、-CH(OR^5h)R^6d、-CONR⁶R^6a、-NHCOR^5c、-NHSO₂R^5d、-NHSO₂Aryl, -SR^5e、-SOR^5f、-SO₂R^5g、-SO₂Aryl or a five-, six-or seven-membered heterocyclic ring which may contain 1 to 4 heteroatoms in the ring, which heteroatoms are N, O, S, SO and/or SO₂Or R is³And R⁴Together with the carbon to which they are attached form a cyclic five-, six-or seven-membered carbocyclic or heterocyclic ring which may contain from 1 to 4 heteroatoms in the ring, which heteroatoms are N, O, S, SO and/or SO₂；R⁵、R^5a、R^5b、R^5c、R^5d、R^5e、R^5f、R^5g、R^5hAnd R⁵ⁱIndependently is an alkyl group; r⁶、R^6a、R^6b、R^6cAnd R^6dIndependently is hydrogen, alkyl, aryl, alkylaryl or cycloalkyl, or R⁶And R^6aTogether with the nitrogen to which they are attached form a cyclic five-, six-or seven-membered heterocyclic ring which may contain from 1 to 4 heteroatoms in the ring, which heteroatoms are N, O, S, SO and/or SO ₂(ii) a A is O, S, NH or (CH)₂)_nWherein n is 0-3, or a pharmaceutically acceptable salt, stereoisomer, or prodrug ester thereof; with the proviso that when A is (CH)₂)_nWherein n is 0, 1, 2 or 3 or A is O and R¹、R²And R^2aAt least one of which is OH OR OR⁵Then R¹、R²And R^2aIs CF₃、OCF₃Or OCHF₂And/or R³And R⁴Is CF₃、-OCHF₂、-OCF₃、-CN、-CO₂R^5b、CH(OR^5h)R^6d、CH(OH)R^6c、COR^6b、-NHCOR^5c、-NHSO₂R^5d、-NHSO₂Aryl, -SR^5e、-SOR^5f、-SO₂R^5gor-SO₂And (4) an aryl group.

In some embodiments of the above disclosed aspects, the geragliflozin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition is dapagliflozin or a pharmaceutically acceptable salt thereof.

In some embodiments of aspects disclosed above, the gegliflozin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition is dapagliflozin propylene glycol.

In some embodiments of the above disclosed aspects, the individual is authorized to be provided with a dose of the gelistine sodium-glucose co-transporter inhibitor pharmaceutical composition of 5 milligrams to 10 milligrams per day after the individual confirms that the over-the-counter drug fact label has been received and read.

In some embodiments of the above disclosed aspects, the individual is authorized to be provided with a dose of 5 milligrams per day of the gerzin sodium-glucose co-transporter inhibitor pharmaceutical composition after the individual confirms that the over-the-counter drug fact label has been received and read.

In some embodiments of the above disclosed aspects, the geriflozin sodium-glucose co-transporter inhibitor pharmaceutical composition is selected from the group consisting of: empagliflozin, canagliflozin, and eggliflozin.

In some embodiments of the above disclosed aspects, the gerliptin sodium-glucose co-transporter inhibitor pharmaceutical composition is empagliflozin and is administered to the individual at a dose of 2.5 milligrams to 50 milligrams per day.

In some embodiments of the above disclosed aspects, the individual is authorized to be provided with a dose of empagliflozin selected from the group of 5 mg, 10 mg, 20 mg, and/or 25 mg per day after the individual confirms that the over-the-counter medication fact label has been received and read.

In some embodiments of the above disclosed aspects, the geist sodium-glucose co-transporter inhibitor pharmaceutical composition is canagliflozin and is administered to the individual at a dose of 50 milligrams to 600 milligrams per day.

In some embodiments of the above disclosed aspects, the individual is authorized to be provided with a dose of canagliflozin selected from the group of 100 milligrams, 200 milligrams, and/or 300 milligrams per day after the individual confirms that the over-the-counter medication fact label has been received and read.

In some embodiments of the above disclosed aspects, the geragliflozin sodium-glucose co-transporter inhibitor pharmaceutical composition is egagliflozin and is administered to the individual a dose of 1 mg to 30 mg per day.

In some embodiments of the above disclosed aspects, the individual is authorized to be provided with a dose of eggliflozin selected from the group of 2.5 milligrams, 5 milligrams, and/or 15 milligrams per day after the individual confirms that the over-the-counter medication fact label has been received and read.

In some embodiments of the above disclosed aspects, the first pregnancy filter is further activated when the first plurality of findings indicate that the individual is planning a pregnancy within a predetermined time period.

In some embodiments of the above disclosed aspects, the age filter is activated when the first plurality of findings indicates that the individual is less than eighteen years of age.

In some embodiments of the above disclosed aspects, the first baseline blood glucose level used in the first blood glucose filter is 6.5% glycated hemoglobin.

In some embodiments of the above disclosed aspects, the maximum blood glucose level used in the first blood glucose filter is 8% glycated hemoglobin.

In some embodiments of the above disclosed aspects, the first urinary problem filter is activated when the first plurality of findings indicate that the individual has a history of urinary tract infection or a urinary problem.

In some embodiments of the above disclosed aspects, the first dietary filter is activated when the first plurality of findings indicate that the individual's food intake is decreasing due to disease, surgery, or recent dietary changes.

In some embodiments of the above disclosed aspects, the first alcohol consumption filter is activated when the first plurality of findings indicate that the individual consumes at least the predetermined number of alcoholic beverages, on average, over the predetermined time period.

In some embodiments of the above-disclosed aspects, the first plurality of findings further comprises whether the individual is allergic to a gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition, and the first plurality of filters comprises an adverse reaction filter that is activated when the first plurality of findings indicates that the individual is allergic to a gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition.

In some embodiments of aspects disclosed above, the first plurality of findings further comprises whether the individual has had bladder cancer, and the first plurality of filters comprises a first bladder cancer filter that is activated when the first plurality of findings indicates that the individual has bladder cancer.

In some embodiments of the above disclosed aspects, the alert corresponding to the respective filter of the second plurality of filters comprises a risk factor prompting the individual to indicate whether the individual has discussed the activated respective filter of the second plurality of filters with a healthcare professional; and obtaining confirmation from the individual when the individual indicates that the individual has discussed the potential risk factors for the activated respective filter of the second plurality of filters with a healthcare professional.

In some embodiments of the above disclosed aspects, the fulfillment process further comprises: a medication dispense associated with the individual is stored in the individual profile.

In some embodiments of the above disclosed aspects, the fulfillment process further comprises: coordinating the transport of a gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition to a physical location associated with an individual.

In some embodiments of the above disclosed aspects, the method further comprises: f) in response to receiving a request from an individual to reorder a gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition, performing a re-fulfillment procedure comprising: (i) conducting a second survey of the individual, thereby obtaining a second plurality of survey results, wherein the second plurality of survey results comprises information indicative of: whether the individual is one of the following: (i) pregnant, (ii) lactating, or (iii) an individual who is scheduled to become pregnant; whether the subject has developed ketoacidosis after receiving its last supply of the pharmaceutical composition of geilizin sodium-glucose co-transporter 2 inhibitor; whether an individual has a renal problem after receiving their last supply of a pharmaceutical composition of a geilizin sodium-glucose co-transporter 2 inhibitor; whether an individual has a urinary problem after receiving their last supply of a pharmaceutical composition of a geletam sodium-glucose co-transporter 2 inhibitor; whether an individual has a liver problem after receiving their last supply of a pharmaceutical composition of geletam sodium-glucose co-transporter 2 inhibitor; the surgical status of the individual; the dietary status of the individual; whether an individual has a pancreatic problem after receiving their last supply of a pharmaceutical composition of geletam sodium-glucose co-transporter 2 inhibitor; the alcohol consumption status of the individual; whether the individual has experienced a yeast infection after receiving its last supply of a pharmaceutical composition of geletam sodium-glucose co-transporter 2 inhibitor; whether an individual has developed hypoglycemia after receiving its last supply of a pharmaceutical composition of a geilizin sodium-glucose co-transporter 2 inhibitor; whether the individual is experiencing physical stress; and whether the subject is using diabetes drugs; (i i) running all or a portion of the second plurality of findings against a third plurality of filters of the first category, wherein when a respective filter of the third plurality of filters is activated, the individual is deemed to be ineligible for obtaining a gerlabel sodium-glucose co-transporter 2 inhibitor pharmaceutical composition and the re-fulfillment process is terminated without delivering the gerlabel sodium-glucose co-transporter 2 inhibitor pharmaceutical composition to the individual, wherein the third plurality of filters comprises: a second pregnancy filter activated at least when the second plurality of findings indicate that the individual is pregnant or that the individual is nursing; a ketoacidosis symptom filter activated at least when the second plurality of findings indicate that the individual has developed ketoacidosis after receiving its last supply of the geist sodium-glucose co-transporter 2 inhibitor pharmaceutical composition; a renal problem filter that is activated at least when a second plurality of findings indicate that the individual has a renal problem following receipt of their last supply of a pharmaceutical composition of a geist sodium-glucose co-transporter 2 inhibitor; a second urinary problem filter that is activated at least when a second plurality of findings indicate that the individual developed a urinary tract infection after receiving its last supply of the pharmaceutical composition of geqizin sodium-glucose co-transporter 2 inhibitor; a physical stress filter that is activated at least when the second plurality of findings indicate that the individual is experiencing physical stress; and a second diabetes drug filter activated at least when the second plurality of findings indicate that the subject is using diabetes drug; (iii) running all or a portion of a second plurality of survey results against a fourth plurality of filters of a second category, wherein when a respective filter of the fourth plurality of filters is activated, an alert is provided to the individual corresponding to the respective filter, and wherein the fourth plurality of filters comprises: a second liver disease filter initiated at least when a second plurality of findings indicate that the individual has a liver problem following receipt of their last supply of a pharmaceutical composition of geist sodium-glucose co-transporter 2 inhibitor; a second surgical filter activated at least when the second plurality of findings indicate that the individual is planning to perform a surgery; a second dietary filter that is activated at least when a second plurality of findings indicate that the individual has decreased food intake after receiving their last supply of the sodium-glucose co-transporter 2 inhibitor pharmaceutical composition; a second pancreatic disease filter that is activated at least when a second plurality of findings indicate that the individual has a pancreatic problem after receiving its last supply of the gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition; a second alcohol consuming filter; a yeast infection filter that is activated at least when a second plurality of findings indicate that an individual experienced a yeast infection after receiving its last supply of a gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition; and a hypoglycemic symptoms filter activated at least when the second plurality of findings indicate that the individual develops hypoglycemia after receiving its last supply of the pharmaceutical composition of geqijing sodium-glucose co-transporter 2 inhibitor; (iv) obtaining confirmation from the individual of the alert sent to the individual by any of the fourth plurality of filters; and (v) performing a redeployment process under the following conditions: (i) the redemption process not terminating due to the activation of a filter of the third plurality of filters and (ii) the individual confirming each alert associated with a filter of the third plurality of filters that was activated and associated with the alert, wherein the redemption process further comprises: storing in the profile of the individual an indication to reorder a gelistine sodium-glucose co-transporter 2 inhibitor pharmaceutical composition, communicating to the individual an over-the-counter drug fact label for the gelistine sodium-glucose co-transporter 2 inhibitor pharmaceutical composition, and authorizing the individual to reorder a supply of the gelistine sodium-glucose co-transporter 2 inhibitor pharmaceutical composition after confirming that the individual has received and read the over-the-counter drug fact label.

In some embodiments of the above disclosed aspects, the second pregnancy filter is further activated when the second plurality of findings indicate that the individual is scheduled to be pregnant within the predetermined time period.

In some embodiments of the above disclosed aspects, the symptom of ketoacidosis capable of initiating a ketoacidosis filter is selected from the group consisting of: increased ketones in the blood of the subject, increased ketones in the urine of the subject, nausea, fatigue, vomiting, dyspnea, and abdominal pain.

In some embodiments of the above disclosed aspects, the symptom of the renal problem capable of activating the renal problem symptom filter is selected from the group consisting of: decreased food intake, decreased water intake, vomiting, diarrhea, dehydration, and being diagnosed with kidney disease in an individual.

In some embodiments of the above disclosed aspects, the symptom of the urinary problem capable of activating the urinary problem filter is selected from the group consisting of: burning sensation during urination, increased urge to urinate, pelvic pain, hematuria, fever, back pain, nausea and vomiting.

In some embodiments of the above disclosed aspects, the second alcohol consumption filter is activated when the second plurality of findings indicate that the individual consumes at least the predetermined number of alcoholic beverages, on average, over the predetermined time period.

In some embodiments of the above disclosed aspects, the symptom of yeast infection capable of initiating a yeast infection filter is selected from the group consisting of: penile yeast infection, vaginal yeast infection, sore throat, increased urge to urinate, increased urine volume, and increased urge to urinate at night.

In some embodiments of the above disclosed aspects, the symptom of hypoglycemia capable of activating the hypoglycemic symptoms filter is selected from the group consisting of: shivering, sweating, accelerated heartbeat, altered vision, increased hunger, headache and mood changes.

In some embodiments of the above disclosed aspects, the body pressure capable of activating the body pressure filter is selected from the group consisting of: fever, recent trauma, infection, and recent surgery.

In some embodiments of the above-disclosed aspects, the second plurality of findings further comprises whether the individual experienced dehydration symptoms after receiving its last supply of the germlining sodium-glucose co-transporter 2 inhibitor pharmaceutical composition, and the fourth plurality of filters further comprises a dehydration filter that is activated at least when the second plurality of findings indicate that the individual experienced dehydration symptoms selected from the group consisting of: dizziness, fainting, dizziness, and asthenia.

In some embodiments of the above disclosed aspects, the second plurality of findings further comprises the subject's bladder cancer status and the third plurality of filters further comprises a second bladder cancer filter that is initiated at least when the second plurality of findings indicates that the subject has developed bladder cancer after receiving its last supply of the geqin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition.

In some embodiments of the above disclosed aspects, the redeployment procedure further comprises obtaining the glycemic state of the individual in a second plurality of findings when the individual profile of the individual does not include the current glycemic state of the individual; and including a second blood glucose filter in the third plurality of filters of the first category that is activated at least when the second plurality of findings indicate that the blood glucose level of the individual is at least the second baseline blood glucose level.

In some embodiments of the above disclosed aspects, the fulfillment program further comprises: obtaining a glycemic state of the individual in a second plurality of findings; and including a second blood glucose filter in the third plurality of filters of the first category that is activated at least when the second plurality of findings indicate that the blood glucose level of the individual is at least the second baseline blood glucose level.

In some embodiments of the above disclosed aspects, the second baseline blood glucose level used in the second blood glucose filter is 7% glycated hemoglobin.

In some embodiments of the above disclosed aspects, the lowering of blood glucose is for the treatment or prevention of type 2 diabetes.

In some embodiments of the above disclosed aspects, the geragliflozin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition comprises canagliflozin; the first plurality of findings further comprises one or more findings selected from the group consisting of: a history of heart failure in the subject, a history of resection in the subject, a history of leg neuropathy in the subject, a history of diabetic foot ulcers in the subject, and a history of hyperkalemia in the subject; and the first plurality of filters and/or the second plurality of filters further comprises one or more filters selected from the group consisting of: a heart failure filter that is triggered at least when the first plurality of findings indicate that the individual has a history of heart failure; an ablation filter that is triggered at least when the first plurality of findings indicate that the individual has undergone a body-part ablation; a leg neuropathy filter triggered at least when the first plurality of findings indicate that the individual has leg neuropathy; a diabetic foot ulcer filter triggered at least when the first plurality of findings indicate that the individual has a diabetic foot ulcer; and a hyperkalemia filter that is triggered at least when the first plurality of findings indicate that the individual has hyperkalemia.

In some embodiments of the above disclosed aspects, the geragliflozin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition comprises egagliflozin; the first plurality of findings further comprises one or more findings selected from the group consisting of: a history of resection of the subject, a history of leg neuropathy of the subject, and a history of diabetic foot ulcers of the subject; and the first plurality of filters and/or the second plurality of filters further comprises one or more filters selected from the group consisting of: an ablation filter that is triggered at least when the first plurality of findings indicate that the individual has undergone a body-part ablation; a leg neuropathy filter triggered at least when the first plurality of findings indicate that the individual has leg neuropathy; and a diabetic foot ulcer filter that is triggered at least when the first plurality of findings indicate that the individual has a diabetic foot ulcer.

In some embodiments, the present disclosure provides methods of lowering blood pressure using a pharmaceutical composition of an over-the-counter gliflozin sodium-glucose co-transporter 2 inhibitor. The method includes providing, by a computer system having a processor programmed to conduct a first survey, a first survey to obtain a first set of information from a human, wherein the first set of information includes information about the human that is related to potential risk factors and contraindications for a gerlabel sodium-glucose co-transporter 2 inhibitor pharmaceutical composition, as described herein. The method also includes applying, by a computer system having a processor programmed to perform an algorithm, the algorithm to the first set of information. The algorithm runs all or a portion of the first set of information against a first plurality of filters, wherein a human is deemed to be ineligible for treatment with an over-the-counter gemiflozin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition for lowering blood pressure when a respective filter of the first plurality of filters is activated, and the method terminates without authorizing provision of the gemiflozin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition to the human, wherein the first plurality of filters includes filters associated with contraindications for the gemiflozin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition as described herein. The algorithm also runs all or a portion of the first set of information for a second plurality of filters, wherein when a respective filter of the second plurality of filters is activated, a warning is provided to a human corresponding to the respective filter, and wherein the second plurality of filters includes filters associated with risk factors for a gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition as described herein. The algorithm also obtains confirmation from the human of the risk factors associated with each alert issued to the human by any of the second plurality of filters. In some embodiments, confirming comprises confirming that the human has discussed the risk factor with a physician. The algorithm proceeds to perform the fulfillment process when (a) a filter of the first plurality of filters is not activated and (b) a human confirms each alert associated with each activated filter of the second plurality of filters. The fulfillment process includes storing in the profile of the individual an indication of an initial order for a germline sodium-glucose co-transporter 2 inhibitor pharmaceutical composition, communicating to the human an over-the-counter drug fact label for the germline sodium-glucose co-transporter 2 inhibitor pharmaceutical composition, and authorizing provision of the germline sodium-glucose co-transporter 2 inhibitor pharmaceutical composition to the human after the individual confirms that the over-the-counter drug fact label has been received and read, wherein the authorization includes a pharmacy associated with the individual. In some embodiments, the method further comprises treating the human to lower blood pressure in the human after the authorizing providing, for example, by providing a gerlabel sodium-glucose co-transporter 2 inhibitor pharmaceutical composition to the human and/or by administering a gerlabel sodium-glucose co-transporter 2 inhibitor pharmaceutical composition to the human to lower blood pressure.

Examples of the invention

Example 1: a computer system configured to identify an individual eligible for over-the-counter delivery of a dapagliflozin pharmaceutical composition for treating diabetes (e.g., by lowering blood glucose). The computer system includes instructions for conducting a survey of an individual. Utilizing the survey to obtain one or more of the following results: whether the individual is pregnant, nursing, or an individual who is scheduled to become pregnant; a type 1 diabetes status of the individual; ketoacidosis status of the subject; renal status of the subject; the age of the individual; the blood glucose level of the individual; whether an individual has liver problems; whether the individual has had urinary problems; the surgical status of the individual; the dietary status of the individual; whether an individual has had pancreatic problems; the alcohol consumption status of the individual; whether the subject is using diabetes drugs; and whether the individual has ever suffered from bladder cancer.

The computer system runs the results of the survey against a first series of filters, each associated with a first filter category. The first filter category is configured to prevent authorization for OTC delivery of OTC dapagliflozin when the findings of the individual identify contraindications for dapagliflozin. In some embodiments, the first series of filters includes one or more of: a first pregnancy filter, a type 1 diabetes filter, a ketoacidosis filter, a first kidney disease filter, an age filter, a first blood glucose filter, and a first bladder cancer filter. The first pregnancy filter is configured to ensure that the individual is not pregnant, nursing or planning a pregnancy. The type 1 diabetes filter is configured to ensure that the individual does not have type 1 diabetes. The ketoacidosis filter is configured to ensure that the individual does not suffer from ketoacidosis. The first kidney disease filter is configured to ensure that the individual does not have kidney disease. The age filter is configured to ensure that the age of the individual is greater than or equal to eighteen years. The first blood glucose filter is configured to ensure that the subject's blood glucose level is above a first baseline blood glucose level (e.g., 6.5% glycated hemoglobin) or below a maximum blood glucose level (e.g., 8% glycated hemoglobin). Further, the first bladder cancer filter is configured to ensure that the individual does not have bladder cancer.

The computer system runs the findings against a second series of filters that each generate an alert when the findings of the individual identify a risk factor for OTC dapagliflozin. In some embodiments, the second series of filters includes a first liver disease filter, a first urinary problem filter, a first surgical filter, a first diet filter, a first pancreatic disease filter, a first alcohol consumption filter, and a first diabetes drug filter. The first liver disease filter is configured to ensure that the individual has not experienced liver problems. The first urinary problem filter is configured to ensure that the individual does not have a history of urinary problems or urinary tract infections or urination problems. The first surgical filter is configured to ensure that the individual is not planning to perform a surgery. The first diet filter is configured to ensure that the food intake of the individual is not reduced due to illness, surgery, or recent dietary changes. The first pancreatic disease filter is configured to ensure that the individual does not have pancreatic problems. The first alcohol-consuming filter is configured to ensure that the individual does not consume more than a predetermined number of alcoholic beverages on average within a predetermined period of time. The first diabetes drug filter is configured to ensure that the subject is not using diabetes drug.

The computer system then prompts the individual to confirm or deny that the alerts have been discussed with a medical professional (e.g., his physician or healthcare professional). The computer system then proceeds through the fulfillment process only when the first series of filters is not activated and the individual confirms that it has discussed each alert issued with respect to the second series of filters being activated.

The computer system stores an indication of the initial order of OTC amlodipine (amlodipine) in the profile of the individual and communicates to the individual an over-the-counter drug fact label for the dapagliflozin pharmaceutical composition. After the individual confirms that it has received and read the over-the-counter drug fact label, the computer system authorizes the provision of the OTC dapagliflozin pharmaceutical composition to the individual.

In some embodiments, the computer system comprises instructions for conducting another survey of the individual in response to a reorder request for dapagliflozin pharmaceutical composition. This survey is utilized to obtain one or more of the following results: whether the individual is pregnant, nursing, or scheduled to become pregnant; whether the individual has experienced symptoms of ketoacidosis after receiving its last supply of dapagliflozin pharmaceutical composition; whether the individual has experienced symptoms of kidney problems after receiving their last supply of dapagliflozin pharmaceutical composition; whether the individual has experienced symptoms of urinary problems after receiving their last supply of dapagliflozin pharmaceutical composition; whether the individual has experienced a liver problem after receiving their last supply of dapagliflozin pharmaceutical composition; the surgical status of the individual; the dietary status of the individual; whether the individual has experienced a pancreatic problem after receiving their last supply of dapagliflozin pharmaceutical composition; the alcohol consumption status of the individual; whether the individual has experienced a yeast infection after receiving its last supply of dapagliflozin pharmaceutical composition; whether the individual has experienced symptoms of hypoglycemia after receiving its last supply of dapagliflozin pharmaceutical composition; whether the individual is experiencing physical stress; and whether the subject is using diabetes drugs.

The computer system runs the results of the survey against a third series of filters, each associated with a first filter category. In some embodiments, the third series of filters comprises one or more of: a second pregnancy filter, a ketoacidosis symptom filter, a kidney problem filter, a second urinary problem filter, a body pressure filter, and a second diabetes drug filter. This second pregnancy filter is configured to ensure that the individual is not pregnant, nursing, or scheduled to become pregnant within a predetermined time period. The ketoacidosis filter is configured to ensure that the individual has not experienced symptoms of ketoacidosis after receiving their last dapagliflozin supply. Symptoms of ketoacidosis that can initiate the ketoacidosis symptom filter include increased ketone in the blood of the individual, increased ketone in the urine of the individual, nausea, fatigue, vomiting, dyspnea, and abdominal pain. The renal problem filter is configured to ensure that an individual has not experienced symptoms of a renal problem after receiving their last dapagliflozin supply. Symptoms of a renal problem that can activate the renal problem symptom filter include a decrease in food intake by the individual, a decrease in water intake by the individual, vomiting, diarrhea, dehydration, and the individual being diagnosed with a renal disease. The second urinary problem filter is configured to ensure that the individual has not experienced symptoms of a urinary tract infection after receiving their last dapagliflozin supply. Symptoms of a urinary problem that can activate the urinary problem filter include burning sensation upon urination, increased urge to urinate, pelvic pain, hematuria, fever, back pain, nausea, and vomiting. The body pressure filter is configured to ensure that the individual is not experiencing body pressure. Physical stresses that can activate the body pressure filter include fever, recent trauma, infection, and recent surgery. The second diabetes filter is configured to ensure that the subject is not using diabetes medication.

The computer system runs the survey results against a fourth series of filters that each generate an alert when the individual's survey results identify a risk factor for OTC amlodipine. In some embodiments, the fourth series of filters comprises a second liver disease filter, a second surgery filter, a second diet filter, a second pancreatic disease filter, a second alcohol consumption filter, a yeast infection filter, and a hypoglycemia symptom filter. The second liver disease filter is configured to be activated at least when the findings indicate that the individual exhibits symptoms of liver disease after receiving the last supply of dapagliflozin pharmaceutical composition. The second surgical filter is configured to ensure that the individual is not scheduled to perform surgery. The second dietary filter is configured to ensure that the individual does not have a reduction in food intake after receiving their last supply of dapagliflozin pharmaceutical composition. The second pancreatic disease filter is configured to ensure that the individual has no pancreatic problems after receiving their last supply of dapagliflozin pharmaceutical composition. The second alcohol-consuming filter is configured to ensure that the individual does not, on average, consume more than a predetermined number of beverages within a predetermined time. The yeast infection filter is configured to ensure that the individual has not experienced symptoms of a yeast infection after receiving its last supply of dapagliflozin pharmaceutical composition. Yeast infections that can initiate yeast infection filters include yeast infections of the penis, yeast infections of the vagina, sore throat, increased urge to urinate, increased urine volume, and increased urge to urinate at night. The hypoglycemic symptoms filter is configured to ensure that the individual has not experienced symptoms of hypoglycemia after receiving its last supply of dapagliflozin pharmaceutical composition. Symptoms of hypoglycemia that can activate the hypoglycemic symptoms filter include shivering, sweating, increased heartbeat, altered vision, increased hunger, headaches, and mood changes.

The computer system then prompts the individual to confirm or deny that the alerts have been discussed with a medical professional (e.g., his physician or healthcare professional). The computer system then proceeds to the redemption process only when the third series of filters is not activated and the individual confirms that he has discussed each alert issued with respect to the activated fourth series of filters.

The computer system stores an indication of the reordering of OTC amlodipine in the individual profile and communicates an over-the-counter drug fact label for the amlodipine pharmaceutical composition to the individual. After the individual confirms that it has received and read the over-the-counter drug fact label, the computer system authorizes the provision of the OTC amlodipine pharmaceutical composition to the individual.

Example 2: a computer system configured to identify an individual as eligible for over-the-counter delivery of a canagliflozin pharmaceutical composition for treating diabetes (e.g., by lowering blood glucose). The computer system includes instructions for conducting a survey of an individual. Utilizing the survey to obtain one or more of the following results: whether the individual is pregnant, nursing, or an individual who is scheduled to become pregnant; a type 1 diabetes status of the individual; ketoacidosis status of the subject; renal status of the subject; the age of the individual; the blood glucose level of the individual; whether an individual has liver problems; whether the individual has had urinary problems; the surgical status of the individual; the dietary status of the individual; whether an individual has had pancreatic problems; the alcohol consumption status of the individual; whether the subject is using diabetes drugs; a history of heart failure in the subject; a history of resection of the subject; a history of leg neuropathy in the subject; a history of diabetic foot ulcers in the subject; and a history of hyperkalemia in the subject.

The computer system runs the results of the survey against a first series of filters, each associated with a first filter category. The first filter category is configured to prevent authorization for OTC cardagliflozin OTC delivery when an individual's findings identify a contraindication for cardagliflozin. In some embodiments, the first series of filters includes one or more of: a first pregnancy filter, a type 1 diabetes filter, a ketoacidosis filter, a first nephropathy filter, an age filter, a first blood glucose filter, a heart failure filter, an amputation filter, a leg neuropathy filter, a diabetic foot ulcer filter, and a hyperkalemia filter. The first pregnancy filter is configured to ensure that the individual is not pregnant, nursing or planning a pregnancy. The type 1 diabetes filter is configured to ensure that the individual does not have type 1 diabetes. The ketoacidosis filter is configured to ensure that the individual does not suffer from ketoacidosis. The first kidney disease filter is configured to ensure that the individual does not have kidney disease. The age filter is configured to ensure that the age of the individual is greater than or equal to eighteen years. The first blood glucose filter is configured to ensure that the subject's blood glucose level is above a first baseline blood glucose level (e.g., 6.5% glycated hemoglobin) or below a maximum blood glucose level (e.g., 8% glycated hemoglobin). The heart failure filter is configured to ensure that the individual does not have a history of heart failure. The resection filter is configured to ensure that the individual has not undergone any body part resection. The leg neuropathy filter is configured to ensure that the individual does not have leg neuropathy. The diabetic foot ulcer filter is configured to ensure that the individual does not have a diabetic foot ulcer. In addition, the hyperkalemia filter is configured to ensure that the individual does not have hyperkalemia.

The computer system runs the findings against a second series of filters that each generate an alert when the findings of the individual identify a risk factor for OTC canagliflozin. In some embodiments, the second series of filters comprises a first liver disease filter, a first urinary problem filter, a first surgical filter, a first diet filter, a first pancreatic disease filter, a first alcohol consumption filter, a first diabetic drug filter, a history of heart failure in the subject, a history of resection in the subject, a history of leg neuropathy in the subject, a history of diabetic foot ulcers in the subject, and a history of hyperkalemia in the subject. The first liver disease filter is configured to ensure that the individual has not experienced liver problems. The first urinary problem filter is configured to ensure that the individual does not have a history of urinary problems or urinary tract infections or urination problems. The first surgical filter is configured to ensure that the individual is not planning to perform a surgery. The first diet filter is configured to ensure that the food intake of the individual is not reduced due to illness, surgery, or recent dietary changes. The first pancreatic disease filter is configured to ensure that the individual does not have pancreatic problems. The first alcohol-consuming filter is configured to ensure that the individual does not consume more than a predetermined number of alcoholic beverages on average within a predetermined period of time. The first diabetes drug filter is configured to ensure that the subject is not using diabetes drug. The heart failure filter is configured to ensure that the individual does not have a history of heart failure. The resection filter is configured to ensure that the individual has not undergone any body part resection. The leg neuropathy filter is configured to ensure that the individual does not have leg neuropathy. The diabetic foot ulcer filter is configured to ensure that the individual does not have a diabetic foot ulcer. In addition, the hyperkalemia filter is configured to ensure that the individual does not have hyperkalemia.

The computer system stores an indication of an initial order of OTC canagliflozin in an individual profile and communicates an over-the-counter drug fact label for the canagliflozin pharmaceutical composition to the individual. After the individual confirms that he or she has received and read the over-the-counter drug fact label, the computer system authorizes the provision of the OTC canagliflozin pharmaceutical composition to the individual.

In some embodiments, the computer system comprises instructions for conducting another survey of the individual in response to a reorder request for canagliflozin pharmaceutical composition. This survey is utilized to obtain one or more of the following results: whether the individual is pregnant, nursing, or scheduled to become pregnant; whether the individual has experienced symptoms of ketoacidosis after receiving its last supply of dapagliflozin pharmaceutical composition; whether the individual has experienced symptoms of kidney problems after receiving their last supply of the canagliflozin pharmaceutical composition; whether the individual has experienced symptoms of urinary problems after receiving their last supply of the canagliflozin pharmaceutical composition; whether the individual has experienced a liver problem after receiving their last supply of canagliflozin pharmaceutical composition; the surgical status of the individual; the dietary status of the individual; whether the individual has experienced a pancreatic problem after receiving their last supply of canagliflozin pharmaceutical composition; the alcohol consumption status of the individual; whether the individual has experienced a yeast infection after receiving its last supply of the canagliflozin pharmaceutical composition; whether the individual has experienced symptoms of hypoglycemia after receiving their last supply of canagliflozin pharmaceutical composition; whether the individual is experiencing physical stress; and whether the subject is using diabetes drugs.

The computer system runs the findings against a fourth series of filters that each generate an alert when the findings of the individual identify a risk factor for OTC canagliflozin. In some embodiments, the fourth series of filters comprises a second liver disease filter, a second surgery filter, a second diet filter, a second pancreatic disease filter, a second alcohol consumption filter, a yeast infection filter, and a hypoglycemia symptom filter. The second liver disease filter is configured to ensure that the individual does not develop symptoms of liver disease after receiving their last supply of canagliflozin pharmaceutical composition. The second surgical filter is configured to ensure that the individual is not scheduled to perform surgery. The second dietary filter is configured to ensure that the individual does not have a reduction in food intake after receiving their last supply of canagliflozin pharmaceutical composition. The second pancreatic disease filter is configured to ensure that the individual has no pancreatic problems after receiving their last supply of the canagliflozin pharmaceutical composition. The second alcohol-consuming filter is configured to ensure that the individual does not, on average, consume more than a predetermined number of beverages within a predetermined time. The yeast infection filter is configured to ensure that the individual has not experienced symptoms of yeast infection after receiving its last supply of canagliflozin pharmaceutical composition. Yeast infections that can initiate yeast infection filters include yeast infections of the penis, yeast infections of the vagina, sore throat, increased urge to urinate, increased urine volume, and increased urge to urinate at night. The hypoglycemic symptoms filter is configured to ensure that the individual has not experienced symptoms of hypoglycemia after receiving its last supply of the canagliflozin pharmaceutical composition. Symptoms of hypoglycemia that can activate the hypoglycemic symptoms filter include shivering, sweating, increased heartbeat, altered vision, increased hunger, headaches, and mood changes.

The computer system stores an indication of the reordering of OTC canagliflozin in the individual profile and communicates an over-the-counter drug fact label for the canagliflozin pharmaceutical composition to the individual. After the individual confirms that he or she has received and read the over-the-counter drug fact label, the computer system authorizes the provision of the OTC canagliflozin pharmaceutical composition to the individual.

Example 3: a computer system configured to identify an individual eligible for over-the-counter delivery of an eggliflozin pharmaceutical composition for treating diabetes (e.g., by lowering blood glucose). The computer system includes instructions for conducting a survey of an individual. Utilizing the survey to obtain one or more of the following results: whether the individual is pregnant, nursing, or an individual who is scheduled to become pregnant; a type 1 diabetes status of the individual; ketoacidosis status of the subject; renal status of the subject; the age of the individual; the blood glucose level of the individual; whether an individual has liver problems; whether the individual has had urinary problems; the surgical status of the individual; the dietary status of the individual; whether an individual has had pancreatic problems; the alcohol consumption status of the individual; whether the subject is using diabetes drugs; a history of resection of the subject; a history of leg neuropathy in the subject; and a history of diabetic foot ulcers in the subject.

The computer system runs the results of the survey against a first series of filters, each associated with a first filter category. The first filter class is configured to prevent authorization to perform OTC delivery of OTC eggliflozin when the individual's findings identify contraindications for eggliflozin. In some embodiments, the first series of filters includes one or more of: a first pregnancy filter, a type 1 diabetes filter, a ketoacidosis filter, a first nephropathy filter, an age filter, a first blood glucose filter, an amputation filter, a leg neuropathy filter, and a diabetic foot ulcer filter. The first pregnancy filter is configured to ensure that the individual is not pregnant, nursing or planning a pregnancy. The type 1 diabetes filter is configured to ensure that the individual does not have type 1 diabetes. The ketoacidosis filter is configured to ensure that the individual does not suffer from ketoacidosis. The first kidney disease filter is configured to ensure that the individual does not have kidney disease. The age filter is configured to ensure that the age of the individual is greater than or equal to eighteen years. The first blood glucose filter is configured to ensure that the subject's blood glucose level is above a first baseline blood glucose level (e.g., 6.5% glycated hemoglobin) or below a maximum blood glucose level (e.g., 8% glycated hemoglobin). The resection filter is configured to ensure that the individual has not undergone any body part resection. The leg neuropathy filter is configured to ensure that the individual does not have leg neuropathy.

The computer system runs the findings against a second series of filters that each generate an alert when the findings of the individual identify a risk factor for OTC eggliflozin. In some embodiments, the second series of filters includes a first liver disease filter, a first urinary problem filter, a first surgical filter, a first diet filter, a first pancreatic disease filter, a first alcohol consumption filter, a first diabetic drug filter, a subject's resection history, a subject's leg neuropathy history, and a subject's history of diabetic foot ulcers. The first liver disease filter is configured to ensure that the individual has not experienced liver problems. The first urinary problem filter is configured to ensure that the individual does not have a history of urinary problems or urinary tract infections or urination problems. The first surgical filter is configured to ensure that the individual is not planning to perform a surgery. The first diet filter is configured to ensure that the food intake of the individual is not reduced due to illness, surgery, or recent dietary changes. The first pancreatic disease filter is configured to ensure that the individual does not have pancreatic problems. The first alcohol-consuming filter is configured to ensure that the individual does not consume more than a predetermined number of alcoholic beverages on average within a predetermined period of time. The first diabetes drug filter is configured to ensure that the subject is not using diabetes drug. The resection filter is configured to ensure that the individual has not undergone any body part resection. The leg neuropathy filter is configured to ensure that the individual does not have leg neuropathy. The diabetic foot ulcer filter is configured to ensure that the individual does not have a diabetic foot ulcer.

The computer system stores an indication of the initial order of OTC eggliflozin in the profile of the individual and communicates an over-the-counter drug fact label for the eggliflozin pharmaceutical composition to the individual. After the individual confirms that it has received and read the over-the-counter drug fact label, the computer system authorizes the provision of the OTC emamectin pharmaceutical composition to the individual.

In some embodiments, the computer system includes instructions for conducting another survey of the individual in response to a reorder request for the eggliflozin pharmaceutical composition. This survey is utilized to obtain one or more of the following results: whether the individual is pregnant, nursing, or scheduled to become pregnant; whether the individual has experienced symptoms of ketoacidosis after receiving its last supply of dapagliflozin pharmaceutical composition; whether the individual has experienced symptoms of kidney problems after receiving their last supply of the pharmaceutical composition of eggliflozin; whether the individual has experienced symptoms of urinary problems after receiving their last supply of the eggliflozin pharmaceutical composition; whether the individual has experienced a liver problem after receiving their last supply of the eggliflozin pharmaceutical composition; the surgical status of the individual; the dietary status of the individual; whether the individual has experienced a pancreatic problem after receiving their last supply of the eggliflozin pharmaceutical composition; the alcohol consumption status of the individual; whether the individual has experienced a yeast infection after receiving its last supply of the eggliflozin pharmaceutical composition; whether the individual has experienced symptoms of hypoglycemia after receiving their last supply of canagliflozin pharmaceutical composition; whether the individual is experiencing physical stress; and whether the subject is using diabetes drugs.

The computer system runs the results of the survey against a third series of filters, each associated with a first filter category. In some embodiments, the third series of filters comprises one or more of: a second pregnancy filter, a ketoacidosis symptom filter, a kidney problem filter, a second urinary problem filter, a body pressure filter, and a second diabetes drug filter. This second pregnancy filter is configured to ensure that the individual is not pregnant, nursing, or scheduled to become pregnant within a predetermined time period. The ketoacidosis filter is configured to ensure that the individual has not experienced symptoms of ketoacidosis after receiving their last dapagliflozin supply. Symptoms of ketoacidosis that can initiate the ketoacidosis symptom filter include increased ketone in the blood of the individual, increased ketone in the urine of the individual, nausea, fatigue, vomiting, dyspnea, and abdominal pain. The renal problem filter is configured to ensure that an individual has not experienced symptoms of a renal problem after receiving their last dapagliflozin supply. Symptoms of a renal problem that can activate the renal problem symptom filter include a decrease in food intake by the individual, a decrease in water intake by the individual, vomiting, diarrhea, dehydration, and the individual being diagnosed with a renal disease. The second urinary problem filter is configured to ensure that the individual has not experienced symptoms of a urinary tract infection after receiving their last dapagliflozin supply. Symptoms of a urinary problem that can activate the urinary problem filter include burning sensation upon urination, increased urge to urinate, pelvic pain, hematuria, fever, back pain, nausea, and vomiting. The body pressure filter is configured to ensure that the individual is not experiencing body pressure. Physical stresses that can activate the body pressure filter include fever, recent trauma, infection, and recent surgery. The second diabetes filter is configured to ensure that the subject is not using diabetes medication. The computer system runs the findings against a fourth series of filters that each generate an alert when the findings of the individual identify a risk factor for OTC eggliflozin. In some embodiments, the fourth series of filters comprises a second liver disease filter, a second surgery filter, a second diet filter, a second pancreatic disease filter, a second alcohol consumption filter, a yeast infection filter, and a hypoglycemia symptom filter. The second liver disease filter is configured to ensure that the individual does not experience symptoms of liver disease after receiving their last supply of the eggliflozin pharmaceutical composition. The second surgical filter is configured to ensure that the individual is not scheduled to perform surgery. The second dietary filter is configured to ensure that the individual does not have a reduction in food intake after receiving their last supply of the emamectin pharmaceutical composition. The second pancreatic disease filter is configured to ensure that the individual has no pancreatic problems after receiving their last supply of the eggliflozin pharmaceutical composition. The second alcohol-consuming filter is configured to ensure that the individual does not, on average, consume more than a predetermined number of beverages within a predetermined time. The yeast infection filter is configured to ensure that the individual has not experienced symptoms of a yeast infection after receiving its last supply of the eggliflozin pharmaceutical composition. Yeast infections that can initiate yeast infection filters include yeast infections of the penis, yeast infections of the vagina, sore throat, increased urge to urinate, increased urine volume, and increased urge to urinate at night. The hypoglycemic symptoms filter is configured to ensure that the individual has not experienced symptoms of hypoglycemia after receiving its last supply of the egagliflozin pharmaceutical composition. Symptoms of hypoglycemia that can activate the hypoglycemic symptoms filter include shivering, sweating, increased heartbeat, altered vision, increased hunger, headaches, and mood changes. The computer system then prompts the individual to confirm or deny that the alerts have been discussed with a medical professional (e.g., his physician or healthcare professional). The computer system then proceeds to the redemption process only when the third series of filters is not activated and the individual confirms that he has discussed each alert issued with respect to the activated fourth series of filters.

The computer system stores an indication of the reordering of OTC eggliflozin in the individual profile and communicates an over-the-counter drug fact label for the eggliflozin pharmaceutical composition to the individual. After the individual confirms that it has received and read the over-the-counter drug fact label, the computer system authorizes the provision of the OTC emamectin pharmaceutical composition to the individual.

Example 4: a computer system configured to identify an individual as eligible for over-the-counter delivery of empagliflozin pharmaceutical composition for treating diabetes (e.g., by lowering blood glucose). The computer system includes instructions for conducting a survey of an individual. Utilizing the survey to obtain one or more of the following results: whether the individual is pregnant, nursing, or an individual who is scheduled to become pregnant; a type 1 diabetes status of the individual; ketoacidosis status of the subject; renal status of the subject; the age of the individual; the blood glucose level of the individual; whether an individual has liver problems; whether the individual has had urinary problems; the surgical status of the individual; the dietary status of the individual; whether an individual has had pancreatic problems; the alcohol consumption status of the individual; and whether the subject is using diabetes drugs.

The computer system runs the results of the survey against a first series of filters, each associated with a first filter category. The first filter class is configured to prevent authorization to perform OTC delivery of OTC eprazinam when the findings of the individual identify contraindications for eprazinam. In some embodiments, the first series of filters includes one or more of: a first pregnancy filter, a type 1 diabetes filter, a ketoacidosis filter, a first nephropathy filter, an age filter, and a first blood glucose filter. The first pregnancy filter is configured to ensure that the individual is not pregnant, nursing or planning a pregnancy. The type 1 diabetes filter is configured to ensure that the individual does not have type 1 diabetes. The ketoacidosis filter is configured to ensure that the individual does not suffer from ketoacidosis. The first kidney disease filter is configured to ensure that the individual does not have kidney disease. The age filter is configured to ensure that the age of the individual is greater than or equal to eighteen years. The first blood glucose filter is configured to ensure that the subject's blood glucose level is above a first baseline blood glucose level (e.g., 6.5% glycated hemoglobin) or below a maximum blood glucose level (e.g., 8% glycated hemoglobin).

The computer system runs the findings against a second series of filters that each generate an alert when the individual's findings identify a risk factor for OTC empagliflozin. In some embodiments, the second series of filters includes a first liver disease filter, a first urinary problem filter, a first surgical filter, a first diet filter, a first pancreatic disease filter, a first alcohol consumption filter, and a first diabetes drug filter. The first liver disease filter is configured to ensure that the individual has not experienced liver problems. The first urinary problem filter is configured to ensure that the individual does not have a history of urinary problems or urinary tract infections or urination problems. The first surgical filter is configured to ensure that the individual is not planning to perform a surgery. The first diet filter is configured to ensure that the food intake of the individual is not reduced due to illness, surgery, or recent dietary changes. The first pancreatic disease filter is configured to ensure that the individual does not have pancreatic problems. The first alcohol-consuming filter is configured to ensure that the individual does not consume more than a predetermined number of alcoholic beverages on average within a predetermined period of time. The first diabetes drug filter is configured to ensure that the subject is not using diabetes drug.

The computer system stores an indication of the initial ordering of OTC amlodipine in the profile of the individual and communicates an over-the-counter drug fact label for empagliflozin pharmaceutical composition to the individual. After the individual confirms that it has received and read the over-the-counter drug fact label, the computer system authorizes the provision of the OTC empagliflozin pharmaceutical composition to the individual.

In some embodiments, the computer system includes instructions for conducting another survey of the individual in response to a reorder request for empagliflozin pharmaceutical composition. This survey is utilized to obtain one or more of the following results: whether the individual is pregnant, nursing, or scheduled to become pregnant; whether the individual has experienced symptoms of ketoacidosis after receiving its last supply of empagliflozin pharmaceutical composition; whether the individual has experienced symptoms of kidney problems after receiving their last supply of empagliflozin pharmaceutical composition; whether the individual has experienced symptoms of urinary problems after receiving their last supply of empagliflozin pharmaceutical composition; whether the individual has experienced a liver problem after receiving their last supply of empagliflozin pharmaceutical composition; the surgical status of the individual; the dietary status of the individual; whether the individual has experienced a pancreatic problem after receiving their last supply of empagliflozin pharmaceutical composition; the alcohol consumption status of the individual; whether the individual has experienced a yeast infection after receiving its last supply of empagliflozin pharmaceutical composition; whether the individual has experienced symptoms of hypoglycemia after receiving its last supply of empagliflozin pharmaceutical composition; whether the individual is experiencing physical stress; and whether the subject is using diabetes drugs.

The computer system runs the results of the survey against a third series of filters, each associated with a first filter category. In some embodiments, the third series of filters comprises one or more of: a second pregnancy filter, a ketoacidosis symptom filter, a kidney problem filter, a second urinary problem filter, a body pressure filter, and a second diabetes drug filter. This second pregnancy filter is configured to ensure that the individual is not pregnant, nursing, or scheduled to become pregnant within a predetermined time period. The ketoacidosis filter is configured to ensure that the individual has not experienced symptoms of ketoacidosis after receiving their last empagliflozin supply. Symptoms of ketoacidosis that can initiate the ketoacidosis symptom filter include increased ketone in the blood of the individual, increased ketone in the urine of the individual, nausea, fatigue, vomiting, dyspnea, and abdominal pain. The renal problem filter is configured to ensure that the individual has not experienced symptoms of a renal problem after receiving their last empagliflozin supply. Symptoms of a renal problem that can activate the renal problem symptom filter include a decrease in food intake by the individual, a decrease in water intake by the individual, vomiting, diarrhea, dehydration, and the individual being diagnosed with a renal disease. The second urinary problem filter is configured to ensure that the individual has not experienced symptoms of a urinary tract infection after receiving their last empagliflozin supply. Symptoms of a urinary problem that can activate the urinary problem filter include burning sensation upon urination, increased urge to urinate, pelvic pain, hematuria, fever, back pain, nausea, and vomiting. The body pressure filter is configured to ensure that the individual is not experiencing body pressure. Physical stresses that can activate the body pressure filter include fever, recent trauma, infection, and recent surgery. The second diabetes filter is configured to ensure that the subject is not using diabetes medication.

The computer system runs the survey results against a fourth series of filters that each generate an alert when the individual's survey results identify a risk factor for OTC amlodipine. In some embodiments, the fourth series of filters comprises a second liver disease filter, a second surgery filter, a second diet filter, a second pancreatic disease filter, a second alcohol consumption filter, a yeast infection filter, and a hypoglycemia symptom filter. The second liver disease filter is configured to be activated at least when the findings indicate that the individual exhibits symptoms of liver disease after receiving the last supply of empagliflozin pharmaceutical composition. The second surgical filter is configured to ensure that the individual is not scheduled to perform surgery. The second dietary filter is configured to ensure that the subject does not have a reduction in food intake after receiving their last supply of empagliflozin pharmaceutical composition. The second pancreatic disease filter is configured to ensure that the individual has no pancreatic problems after receiving their last supply of empagliflozin pharmaceutical composition. The second alcohol-consuming filter is configured to ensure that the individual does not, on average, consume more than a predetermined number of beverages within a predetermined time. The yeast infection filter is configured to ensure that the individual has not experienced symptoms of yeast infection after receiving its last supply of empagliflozin pharmaceutical composition. Yeast infections that can initiate yeast infection filters include yeast infections of the penis, yeast infections of the vagina, sore throat, increased urge to urinate, increased urine volume, and increased urge to urinate at night. The hypoglycemic symptoms filter is configured to ensure that the individual has not experienced symptoms of hypoglycemia after receiving their last supply of empagliflozin pharmaceutical composition. Symptoms of hypoglycemia that can activate the hypoglycemic symptoms filter include shivering, sweating, increased heartbeat, altered vision, increased hunger, headaches, and mood changes.

The computer system stores an indication of the reordering of OTC empagliflozin in the profile of the individual and communicates an over-the-counter drug fact label for empagliflozin pharmaceutical composition to the individual. After the individual confirms that it has received and read the over-the-counter drug fact label, the computer system authorizes the provision of the OTC empagliflozin pharmaceutical composition to the individual.

Cited documents and alternative embodiments

All references cited herein are incorporated herein by reference in their entirety and for all purposes to the same extent as if each individual publication or patent application was specifically or individually indicated to be incorporated by reference in its entirety for all purposes.

The present invention may be embodied in the form of a computer program product comprising a computer program mechanism embedded in a non-transitory computer readable storage medium. For example, the computer program product may contain program modules shown in any combination of fig. 1, 2 and 3 and/or described in fig. 4 or 5. These program modules may be stored on a CD-ROM, DVD, magnetic disk storage product, USB key, or any other non-transitory computer readable data or program storage product.

Many modifications and variations of this invention can be made without departing from its spirit and scope, as will be apparent to those skilled in the art. The specific embodiments described herein are provided by way of example only. The embodiments were chosen and described in order to best explain the principles of the invention and its practical applications, to thereby enable others skilled in the art to best utilize the invention and various embodiments with various modifications as are suited to the particular use contemplated. The invention is to be limited only by the terms of the appended claims, along with the full scope of equivalents to which such claims are entitled.

Claims

1. A computer system for identifying a human subject eligible for over-the-counter delivery of a gerzin Sodium (gliflozin Sodium) -glucose co-transporter 2 inhibitor pharmaceutical composition for reducing blood glucose, the computer system comprising one or more processors and a memory, the memory comprising non-transitory instructions that when executed by the one or more processors perform a method comprising:

a) conducting a first survey of the individual, thereby obtaining a first plurality of survey results, wherein the first plurality of survey results comprises:

Whether the individual is an individual that satisfies the following condition: (i) pregnancy, (ii) lactation, or (iii) planned pregnancy,

the type 1 diabetes mellitus state of the subject,

a ketoacidosis status of the subject,

the renal disease status of the subject,

the age of the individual is such that,

(ii) the blood glucose level of the individual,

whether the individual has a problem with the liver,

whether the individual has had a urinary problem or not,

the surgical status of the individual is determined,

the dietary status of the individual is such that,

whether the individual had a pancreatic problem,

the alcohol consumption status of the subject, and

whether the subject is using diabetes drugs;

b) running all or a portion of the first plurality of survey results against a first plurality of filters of a first category, wherein when a respective filter of the first plurality of filters is activated, the individual is deemed to be ineligible for delivery of the gemiflozin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition and the method terminates without delivering the gemiflozin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition to the individual, wherein the first plurality of filters comprises:

a first pregnancy filter activated at least when the first plurality of findings indicate that the individual is pregnant or the individual is nursing,

A type 1 diabetes filter that is activated at least when the first plurality of findings indicate that the individual has type 1 diabetes,

a ketoacidosis filter activated at least when the first plurality of findings indicate that the individual has ketoacidosis,

a first kidney disease filter activated at least when the first plurality of findings indicate that the individual has kidney disease,

an age filter, and

a first blood glucose filter activated at least when the first plurality of findings indicate that the individual's blood glucose level satisfies any one of the following conditions: (i) below a first baseline blood glucose level, or (ii) above a maximum blood glucose level;

c) running all or a portion of the first plurality of survey results against a second plurality of filters of a second category, wherein when a respective filter of the second plurality of filters is activated, an alert is provided to the individual corresponding to the respective filter, and wherein the second plurality of filters includes:

a first liver disease filter activated at least when the first plurality of findings indicate that the individual has liver problems,

a first urinary problem filter activated at least when the first plurality of findings indicate that the individual has a history of urinary problems,

A first surgical filter activated at least when the first plurality of findings indicate that the individual is planning to perform a surgery,

a first diet filter activated at least when the first plurality of findings indicate a decrease in food intake of the individual,

a first pancreatic disease filter activated at least when the first plurality of findings indicate that the individual has a pancreatic problem,

a first alcohol consuming filter, and

a first diabetes drug filter activated at least when said first plurality of findings indicate that said subject is using diabetes drug;

d) obtaining confirmation from the individual of the alert issued to the individual by any of the second plurality of filters;

e) performing a fulfillment process when (i) a filter of the first plurality of filters is not activated and (ii) the individual acknowledges each alert associated with each activated filter of the second plurality of filters, wherein the fulfillment process comprises:

storing an indication of an initial order for the gelliflozin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition in an individual profile,

an over-the-counter drug fact label that communicates to the individual the pharmaceutical composition of the gegliflozin sodium-glucose co-transporter 2 inhibitor, an

Authorizing provision of the gerlabel sodium-glucose co-transporter 2 inhibitor pharmaceutical composition to the individual after the individual confirms that the over-the-counter medication fact label has been received and read.

2. The computer system of claim 1, wherein the geriflozin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition has the structure:

wherein

R¹、R²And R^2aIndependently hydrogen, OH, OR⁵Alkyl, CF₃、OCHF₂、OCF₃、SR⁵ⁱOr halogen, or R¹、R²And R^2aTwo of which together with the carbon to which they are attached may form a cyclic five, six orA seven membered carbocyclic or heterocyclic ring which may contain 1 to 4 heteroatoms in the ring, which heteroatoms are N, O, S, SO and/or SO₂；

R₃And R₄Independently hydrogen, OH, OR^5aO aryl, OCH₂Aryl, alkyl, cycloalkyl, CF₃、-OCHF₂、-OCF₃Halogen, -CN, -CO₂R^5b、-CO₂H、COR^6b、-CH(OH)R^6c、-CH(OR^5h)R^6d、-CONR⁶R^6a、-NHCOR^5c、-NHSO₂R^5d、-NHSO₂Aryl, -SR^5e、-SOR^5f、-SO₂R^5g、-SO₂Aryl or a five-, six-or seven-membered heterocyclic ring which may contain 1 to 4 heteroatoms in the ring, which heteroatoms are N, O, S, SO and/or SO₂Or R is³And R⁴Together with the carbon to which they are attached form a cyclic five-, six-or seven-membered carbocyclic or heterocyclic ring which may contain from 1 to 4 heteroatoms in the ring, which heteroatoms are N, O, S, SO and/or SO ₂；

with the proviso that when A is (CH)₂)_nWherein n is 0, 1, 2 or 3 or A is O and R¹、R²And R^2aAt least one of which is OH orOR⁵Then R¹、R²And R^2aIs CF₃、OCF₃Or OCHF₂And/or R³And R⁴Is CF₃、-OCHF₂、-OCF₃、-CN、-CO₂R^5b、CH(OR^5h)R^6d、CH(OH)R^6c、COR^6b、-NHCOR^5c、-NHSO₂R^5d、-NHSO₂Aryl, -SR^5e、-SOR^5f、-SO₂R^5gor-SO₂And (4) an aryl group.

3. The computer system of claim 1, wherein the geragliflozin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition comprises dapagliflozin (dapagliflozin) or a pharmaceutically acceptable salt thereof.

4. The computer system of claim 1, wherein the geragliflozin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition is dapagliflozin propylene glycol.

5. The computer system of any one of claims 2 to 4, wherein the individual is authorized to be provided with a dose of the gelliflozin sodium-glucose co-transporter inhibitor pharmaceutical composition of from 5 milligrams to 10 milligrams per day after the individual confirms that the over-the-counter medication fact label has been received and read.

6. The computer system of any one of claims 2 to 4, wherein the individual is authorized to be provided with a dose of 5 milligrams per day of the gelliflozin sodium-glucose co-transporter inhibitor pharmaceutical composition after the individual confirms that the over-the-counter medication fact label has been received and read.

7. The computer system of claim 1, wherein the geriflozin sodium-glucose co-transporter inhibitor pharmaceutical composition is selected from the group consisting of: empagliflozin (empagliflozin), canagliflozin (canagliflozin), and ertugliflozin (ertugliflozin).

8. The computer system of any of claims 1-7, wherein the first pregnancy filter is further activated when the first plurality of findings indicate that the individual is scheduled to be pregnant within a predetermined time period.

9. The computer system of any of claims 1-8, wherein the age filter is activated when the first plurality of findings indicate that the individual is less than eighteen years of age.

10. The computer system of any one of claims 1-9, wherein the first baseline blood glucose level used in the first blood glucose filter is 6.5% glycated hemoglobin.

11. The computer system of any one of claims 1-10, wherein the maximum blood glucose level used in the first blood glucose filter is 8% glycated hemoglobin.

12. The computer system of any one of claims 1 to 11, wherein the first urinary problem filter is activated when the first plurality of findings indicate that the individual has a history of urinary tract infection or a urinary problem.

13. The computer system of any of claims 1-12, wherein the first dietary filter is activated when the first plurality of findings indicate that the individual's food intake has decreased due to disease, surgery, or recent dietary changes.

14. The computer system of any of claims 1-13, wherein the first alcohol-consuming filter is activated when the first plurality of findings indicate that the individual consumes at least a predetermined number of alcoholic beverages, on average, over a predetermined period of time.

15. The computer system of any of claims 1-14, wherein:

the first plurality of findings further comprises whether the individual is allergic to the geist sodium-glucose co-transporter 2 inhibitor pharmaceutical composition, and

The first plurality of filters comprises an adverse reaction filter that is initiated when the first plurality of findings indicate that the individual is allergic to the geqizin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition.

16. The computer system of any of claims 1-15, wherein:

the first plurality of findings further comprises whether the individual has had bladder cancer, and

the first plurality of filters includes a first bladder cancer filter that is activated when the first plurality of findings indicate that the individual has bladder cancer.

17. The computer system of any of claims 1-16, wherein:

the alert corresponding to a respective filter of the second plurality of filters includes a potential risk factor prompting the individual to indicate whether they have discussed the respective filter of the second plurality of filters that was activated with a healthcare professional; and

obtaining confirmation from the individual when the individual indicates that the individual has discussed the potential risk factors for the activated respective filter of the second plurality of filters with a healthcare professional.

18. The computer system of any of claims 1-17, wherein the fulfillment process further comprises:

Storing a medication dispense associated with the individual in the individual profile.

19. The computer system of any of claims 1-18, wherein the fulfillment process further comprises:

coordinating the transport of the gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition to a physical location associated with the individual.

20. The computer system of any of claims 1-19, wherein the method further comprises:

f) in response to receiving a re-order request from the individual for the geriflozin sodium-glucose co-transporter 2 inhibitor blocker pharmaceutical composition, performing a re-fulfillment procedure comprising:

(i) conducting a second survey of the individual, thereby obtaining a second plurality of survey results, wherein the second plurality of survey results comprises information indicative of:

whether the subject has developed ketoacidosis after receiving its last supply of the gegliflozin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition,

whether or not the subject has a renal problem after receiving their last supply of the pharmaceutical composition of gelistine sodium-glucose co-transporter 2 inhibitor,

Whether the individual has a urinary problem after receiving their last supply of the gegliflozin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition,

whether the individual has a liver problem after receiving their last supply of the gelistine sodium-glucose co-transporter 2 inhibitor pharmaceutical composition,

the surgical status of the individual is determined,

the dietary status of the individual is such that,

whether the individual has a pancreatic problem after receiving their last supply of the gegliflozin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition,

the alcohol consumption status of the individual is,

whether the individual has experienced a yeast infection after receiving its last supply of the gelistine sodium-glucose co-transporter 2 inhibitor pharmaceutical composition,

whether the individual has developed hypoglycemia after receiving its last supply of the geqizin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition,

whether the individual is experiencing physical stress, and

whether the subject is using diabetes drugs;

(ii) running all or a portion of the second plurality of findings against a third plurality of filters of the first category, wherein the individual is deemed to be ineligible for obtaining the geridozin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition and the fulfillment process is terminated without delivering the geridozin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition to the individual when a respective filter of the third plurality of filters is activated, wherein the third plurality of filters comprises:

A second pregnancy filter activated at least when the second plurality of findings indicate that the individual is pregnant or the individual is nursing,

a ketoacidosis symptom filter activated at least when the second plurality of findings indicate that the individual has developed ketoacidosis after receiving its last supply of the geist sodium-glucose co-transporter 2 inhibitor pharmaceutical composition,

a renal problem filter activated at least when the second plurality of findings indicate that the individual has a renal problem following receipt of its last supply of the sodium-glucose co-transporter 2 inhibitor pharmaceutical composition,

a second urinary problem filter that is activated at least when the second plurality of findings indicate that the individual is experiencing a urinary tract infection following receipt of its last supply of the geist sodium-glucose co-transporter 2 inhibitor pharmaceutical composition,

a physical stress filter that is activated at least when the second plurality of findings indicate that the individual is experiencing physical stress, and

a second diabetes drug filter that is activated at least when said second plurality of findings indicate that said subject is using diabetes drug;

(iii) Running all or a portion of the second plurality of survey results against a fourth plurality of filters of the second category, wherein when a respective filter of the fourth plurality of filters is activated, an alert is provided to the individual corresponding to the respective filter, and wherein the fourth plurality of filters includes:

a second liver disease filter that is activated at least when the second plurality of findings indicate that the individual has a liver problem following receipt of their last supply of the geist sodium-glucose co-transporter 2 inhibitor pharmaceutical composition,

a second surgical filter activated at least when the second plurality of findings indicate that the individual is planning to perform surgery,

a second dietary filter activated at least when the second plurality of findings indicate that the individual has decreased food intake following receipt of their last supply of the sodium-glucose co-transporter 2 inhibitor pharmaceutical composition,

a second pancreatic disease filter that is activated at least when the second plurality of findings indicate that the individual has a pancreatic problem following receipt of its last supply of the geist sodium-glucose co-transporter 2 inhibitor pharmaceutical composition,

A second alcohol-consuming filter, which is a second alcohol-consuming filter,

a yeast infection filter that is activated at least when the second plurality of findings indicate that the individual experienced a yeast infection after receiving its last supply of the gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition, an

A hypoglycemic symptoms filter activated at least when the second plurality of findings indicate that the individual develops hypoglycemia after receiving its last supply of the geqizin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition;

(iv) obtaining confirmation from the individual of the alert issued to the individual by any filter of the fourth plurality of filters; and

(v) conducting the redemption process when (i) the redemption process is not terminated by the activation of a filter of the third plurality of filters and (ii) each alert associated with each activated filter of the third plurality of filters is acknowledged by the individual, wherein the redemption process further comprises:

storing in the individual profile an indication of a reorder of the gerliptin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition,

The over-the-counter drug fact label communicating to the individual the pharmaceutical composition of the gegliflozin sodium-glucose co-transporter 2 inhibitor, and

authorizing the individual to reorder a supply of the gerlabel sodium-glucose co-transporter 2 inhibitor pharmaceutical composition upon confirmation by the individual that the over-the-counter medication fact label has been received and read.

21. The computer system of claim 20, wherein the second pregnancy filter is further activated when the second plurality of findings indicate that the individual is scheduled to be pregnant within a predetermined time period.

22. The computer system of claim 20 or 21, wherein the symptom of ketoacidosis capable of initiating the ketoacidosis filter is selected from the group consisting of: increased ketone in the blood of the subject, increased ketone in the urine of the subject, nausea, fatigue, vomiting, dyspnea, and abdominal pain.

23. The computer system of any one of claims 20 to 22, wherein the symptom of a renal problem capable of actuating the renal problem symptom filter is selected from the group consisting of: a decrease in food intake by the subject, a decrease in water intake by the subject, vomiting, diarrhea, dehydration, and being diagnosed with kidney disease.

24. The computer system of any one of claims 20 to 23, wherein the symptom of the urinary problem capable of activating the urinary problem filter is selected from the group consisting of: burning sensation during urination, increased urge to urinate, pelvic pain, hematuria, fever, back pain, nausea and vomiting.

25. The computer system of any of claims 20-24, wherein the second alcohol-consuming filter is activated when the second plurality of findings indicate that the individual consumes at least a predetermined number of alcoholic beverages, on average, over a predetermined period of time.

26. The computer system of any one of claims 20 to 25, wherein a symptom of a yeast infection capable of initiating the yeast infection filter is selected from the group consisting of: penile yeast infection, vaginal yeast infection, sore throat, increased urge to urinate, increased urine volume, and increased urge to urinate at night.

27. The computer system of any one of claims 20 to 26, wherein a symptom of hypoglycemia that can activate the hypoglycemic symptoms filter is selected from the group consisting of: shivering, sweating, accelerated heartbeat, altered vision, increased hunger, headache and mood changes.

28. The computer system of any of claims 20-27, wherein the body pressure capable of activating the body pressure filter is selected from the group consisting of: fever, recent trauma, infection, and recent surgery.

29. The computer system of any of claims 20 to 28, wherein:

the second plurality of findings further comprises whether the individual experienced dehydration symptoms after receiving their last supply of the geist sodium-glucose co-transporter 2 inhibitor pharmaceutical composition, and

the fourth plurality of filters further comprises a dehydration filter that is activated at least when the second plurality of findings indicate that the individual experienced dehydration symptoms selected from the group consisting of: dizziness, fainting, dizziness, and asthenia.

30. The computer system of any of claims 20 to 29, wherein:

the second plurality of findings further comprises a bladder cancer status of the individual, and

the third plurality of filters further comprises a second bladder cancer filter that is activated at least when the second plurality of findings indicate that the individual has developed bladder cancer after receiving their last supply of the gemiflozin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition.

31. The computer system of any of claims 20-30, wherein the re-fulfillment program further comprises, when the individual profile of the individual does not include the current glycemic state of the individual:

obtaining a glycemic state of the individual in the second plurality of findings; and

including a second blood glucose filter in the third plurality of filters of the first category that is activated at least when the second plurality of findings indicate that the subject's blood glucose level is at least a second baseline blood glucose level.

32. The computer system of any of claims 20-30, wherein the re-fulfillment program further comprises:

33. The computer system of claim 31 or 32, wherein the second baseline blood glucose level used in the second blood glucose filter is 7% glycated hemoglobin.

34. The computer system of any one of claims 1 to 33, wherein reducing blood glucose is for the treatment or prevention of type 2 diabetes.

35. The computer system of any one of claims 1 to 34, wherein:

the pharmaceutical composition of the giragliflozin sodium-glucose co-transporter 2 inhibitor is canagliflozin;

the first plurality of findings further comprises one or more findings selected from the group consisting of:

a history of heart failure in said individual,

the history of the resection of the subject,

(ii) a history of leg neuropathy in the subject,

a history of diabetic foot ulcers in said subject, and

a history of hyperkalemia in the subject; and

the first plurality of filters and/or the second plurality of filters further comprise one or more filters selected from the group consisting of:

a heart failure filter that is triggered at least when the first plurality of findings indicate that the individual has a history of heart failure;

an ablation filter triggered at least when the first plurality of findings indicate that the individual has undergone a body-part ablation;

a leg neuropathy filter triggered at least when the first plurality of findings indicate that the individual has leg neuropathy;

A diabetic foot ulcer filter that is triggered at least when the first plurality of findings indicate that the individual has a diabetic foot ulcer; and

a hyperkalemia filter that is triggered at least when the first plurality of findings indicate that the individual has hyperkalemia.

36. The computer system of any one of claims 1 to 34, wherein:

the pharmaceutical composition of the giriflozin sodium-glucose co-transporter 2 inhibitor is eggliflozin;

the history of the resection of the subject,

a history of leg neuropathy in said subject, an

A history of diabetic foot ulcers in the subject; and

a leg neuropathy filter triggered at least when the first plurality of findings indicate that the individual has leg neuropathy; and

A diabetic foot ulcer filter that is triggered at least when the first plurality of findings indicate that the individual has a diabetic foot ulcer.

37. A method for reducing blood glucose in an individual in need thereof, the method comprising:

administering to an individual having a pharmaceutical composition of gegliflozin sodium-glucose co-transporter 2 inhibitor obtained in an over-the-counter manner.

38. The method of claim 37, wherein the gerzin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition comprises (2S,3R,4R,5S,6R) -2- [ 4-chloro-3- [ (4-ethoxyphenyl) methyl ] phenyl ] -6- (hydroxymethyl) dioxane-3, 4, 5-triol or a pharmaceutically acceptable salt thereof as an active ingredient.

39. The method of claim 37, wherein the geriflozin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition comprises an active ingredient having the structure:

wherein

R¹、R²And R^2aIndependently hydrogen, OH, OR⁵Alkyl, CF₃、OCHF₂、OCF₃、SR⁵ⁱOr halogen, or R¹、R²And R^2aMay together form a cyclic five-, six-or seven-membered carbocyclic or heterocyclic ring which may contain from 1 to 4 heteroatoms in the ring, which heteroatoms are N, O, S, SO and/or SO ₂；

R₃And R₄Independently hydrogen, OH, OR^5aO aryl, OCH₂Aryl, alkyl, cycloalkyl, CF₃、-OCHF₂、-OCF₃Halogen, -CN, -CO₂R^5b、-CO₂H、COR^6b、-CH(OH)R^6c、-CH(OR^5h)R^6d、-CONR⁶R^6a、-NHCOR^5c、-NHSO₂R^5d、-NHSO₂Aryl, -SR^5e、-SOR^5f、-SO₂R^5g、-SO₂Aryl or a five-, six-or seven-membered heterocyclic ring which may contain 1 to 4 heteroatoms in the ring, which heteroatoms are N, O, S, SO and/or SO₂Or R is³And R⁴Together with the carbon to which they are attached form a cyclic five, six orA seven membered carbocyclic or heterocyclic ring which may contain 1 to 4 heteroatoms in the ring, which heteroatoms are N, O, S, SO and/or SO₂；

with the proviso that when A is (CH)₂)_nWherein n is 0, 1, 2 or 3 or A is O and R¹、R²And R^2aAt least one of which is OH OR OR⁵Then R¹、R²And R^2aIs CF₃、OCF₃Or OCHF₂And/or R³And R⁴Is CF₃、-OCHF₂、-OCF₃、-CN、-CO₂R^5b、CH(OR^5h)R^6d、CH(OH)R^6c、COR^6b、-NHCOR^5c、-NHSO₂R^5d、-NHSO₂Aryl, -SR ^5e、-SOR^5f、-SO₂R^5gor-SO₂And (4) an aryl group.

40. The method of claim 37, wherein the geragliflozin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition comprises, as an active ingredient, dapagliflozin or a pharmaceutically acceptable salt thereof.

41. The method of claim 37, wherein the pharmaceutical composition of a gegliflozin sodium-glucose co-transporter 2 inhibitor is dapagliflozin propylene glycol as an active ingredient.

42. The method of any one of claims 38 to 41, wherein 2.5 milligrams to 10 milligrams of the active ingredient is administered to the individual per day.

43. The method of claim 37, wherein as an active ingredient, the geriflozin sodium-glucose co-transporter 2 inhibitor pharmaceutical composition is selected from the group consisting of: empagliflozin, canagliflozin, angagliflozin, or a pharmaceutically acceptable salt thereof.

44. The method of claim 43, wherein 100 mg to 300 mg of canagliflozin is administered to the individual per day.

45. The method of claim 43, wherein 5 mg to 25 mg empagliflozin is administered to the subject per day.

46. The method of claim 43, wherein 2.5 mg to 15 mg of Eagliflozin is administered to the subject per day.